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SUMMARY 
 
Transarterial Chemoembolization (TACE) has become a leading therapy in patients suffering 
from intermediate to advanced hepatocellular carcinoma (HCC), the fifth most common 
cancer making it a major heath issue worldwide.  TACE is a non-surgical transarterial 
therapy that involves injection of embolizing particles and chemotherapeutic agents directly 
to the tumour site.  Once administrated though the hepatic artery, the particles block the 
blood flow to the tumour starving it of oxygen while also allowing targeted delivery of the 
anti-cancer drugs.  Several therapies have proven to increase survival in people suffering 
from HCC where drug eluting beads (DEBs) have become a frequently used method.  DEBs 
allow anti-cancer drugs to be loaded onto preformed beads where they are held tightly though 
electrostatic interactions between the drug and beads allowing high loadings and controlled 
release to be achieved.  Despite their success, DEBs are limited to drugs that interact with the 
embolizing material’s functional groups.  Also, the embolizing beads must be calibrated to a 
patient’s blood vessel size where smaller sized beads will display faster release rates than 
larger beads, potentially resulting in high toxicity peaks for some patients.  In order to 
overcome these disadvantages, a Particle-in-Particle (PIP) system is proposed which will be 
produced of two main components, a drug delivery component and an embolizing 
component.  Small microparticles (1 – 3 µm) are to be manufactured to suit a specific drug 
with high drug loadings and the ability to control the release rate, where they will function as 
the drug delivery component of the PIP system.  These microparticles are then to be 
encapsulated into larger microparticles (100 – 1000 µm) which will act as the embolizing 
component of the PIP system.   
Initially experiments exploring materials that were capable of controlling the release rate of 
small molecular weight hydrophilic drugs were investigated using verapamil hydrochloride as 
2 
 
the model drug.  Various water soluble polymers that effectively encapsulated the compound 
were explored however, they were incapable of controlling the drug release of the drug.  By 
incorporation of an inorganic material into an organic polymer, stronger gels were produced 
that dramatically decreased the release rate of the hydrophilic compound compared to the 
single organic polymer.  Drug loadings and release rates could be tailored from days to weeks 
by adjustment of the concentration of organic polymer and inorganic material.  
This organic-inorganic blend was processed into drug delivery microparticles where the 
effects of the processing parameters in the water in oil (w-o) emulsion and spray drying 
methods were investigated.  In the w-o emulsion method, effects of polymer concentration, 
mixing speed, surfactant concentration and crosslinker concentration were assessed by light 
microscopy and laser diffraction where various microparticle sizes could be obtained by 
adjustment of the processing parameters.  Production of spherical particles was seen to be 
highly dependent on the formation of a stable emulsion with sufficient surfactant and high 
crosslinking concentrations, and particle size was seen to be dependent on polymer 
concentration and mixing speed.  Despite spherical particles being formed, the o-w emulsion 
method failed to encapsulate any of the hydrophilic compound.  Spray drying was 
investigated as an alternate method since it is known to yield high entrapment efficiencies.  
The effects of polymer concentration, inlet temperature and feed flow rate were investigated 
by SEM and laser diffraction.  Again, adjustment of the parameters allowed particle size to be 
adjusted where the feed flow rate and polymer concentration were found to highly effect 
particle size.  Effects of polymer concentration and drug concentration on drug loading and 
release rate were also analysed by UV spectroscopy where alteration of the parameters 
allowed varied loadings and release rates to be achieved.   
Production of the embolizing particle system was investigated using the w-o emulsion and 
nozzle vibrating methods.  In the w-o emulsion method,  effects of mixing speed on particle 
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size was analysed with light microscopy and laser diffraction where smaller spheres were 
produced with increased mixing speeds.  Once optimum embolizing particles were produced, 
the drug delivery particles were loaded yielding the PIP system, where the effects of drug 
delivery particle loading were investigated by UV spectroscopy.  This PIP system displayed 
similar release rates to the un-encapsulated drug delivery particles due to the embolizing 
materials high porosity.  This allowed PIP systems of various sizes to poses similar release 
rates indicating that the effect of particle size on drug release rate had been decoupled, 
overcoming a pitfall with current TACE therapies.  The system could also be used for a 
variety of other drugs by tailor making the inner drug delivery particles to a desired 
compound.  A microencapsulation method that has seen limited attention in the literature 
based on nozzle vibrating technology was also investigated.   In this method, the effects of 
nozzle vibration, electrode voltage and nozzle size were analysed by light microscopy and 
laser diffraction where spherical particles with narrow distributions within the TACE range 
could be produced under mild processing methods.  Despite this method being highly 
attractive for TACE, the drug delivery particles previously produced were too large and 
aggregated to pass though the nozzle.  An alternate to the PIP system was investigated where 
the organic/inorganic drug delivery blend investigated was processed using the 
microencapsulation device to produce a drug delivery system for the controlled release of the 
hydrophilic drug where effects of polymer concentration and nozzle size on drug loading and 
release rate was investigated.  This microencapsulation device along with the organic-
inorganic blend investigated gave an interesting approach to the development of a 
microparticle system for controlled release of hydrophilic drugs, that was well suited for 
TACE and other drug delivery applications.      
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CHAPTER 1 
INTRODUCTION TO HEPATOCELLULAR CARCINOMA 
 
1.1 Introduction   
 
Hepatocellular carcinoma (HCC) is ranked as the 5
th
 most common cancer world-wide with 
approximately 750,000 new cases arising each year making it a major health issue worldwide 
(Parkin et al 2001).  Most HCC cases end in fatality which has ranked it as the 3
rd
 leading 
cause of cancer related death (Ferlay et al 2008).  Hot spots around the globe are Asia, 
Africa, Europe and North America where the western regions have seen an increase due to 
the spread of the hepatitis C virus (HCV), alcoholism, obesity and poor lifestyle choices (El-
Serag 2011). The introduction to this thesis highlights the main causes of HCC along with 
how the condition can be monitored and treated.  Emphasis is given to transarterial 
chemoembolization (TACE), a non-surgical palliative treatment for intermediate HCC where 
current therapies are reviewed and a new concept of a particle-in-particle (PIP) system is 
proposed as a new treatment method.   
1.2 Causes and risk factors in HCC 
 
Many HCC conditions initially develop from carriers of the hepatitis B virus (HBV), HCV 
and conditions that arise from poor lifestyle habits such as alcoholism and obesity. Causes 
also vary from global locations around the world (Table 1.1) (Sherman 2010). In Asia and 
Africa carriers of HBV can be at high risk of developing HCC whereas in Europe and North 
America carriers of HCV and alcoholics can have a potentially high rate of developing the 
disease (Alazawi et al 2010, Sherman 2010).  Men are known to be at higher risk of 
developing HCC opposed to women, especially those that have a high body mass index 
(Calle et al 2003).  Carriers of HBV or HCV that also abuse alcohol are known to have an 
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even higher risk of developing HCC (Donato et al 2008).  Unlike other cancers, HCC can 
possess two simultaneous conditions, the tumour and an underlying scaring known as 
cirrhosis, which can make HCC a difficult condition to monitor and treat.  Cirrhosis can be 
caused by the same factors that cause HCC (HCV/alcoholism etc) and up to 80 % of HCC 
conditions begin from a cirrhotic liver.  If left untreated the scared liver can result in liver 
failure and then progress into the more serious HCC condition resulting in a number of 
tumours developing on top of the scarred tissue.     
Region HBV HCV Alcohol Other 
Europe 10-15 % 60-70 % 20 % 10 % 
North America 20 % 50 % 20 % < 10 % 
Asia and Africa 70 % 20 % 10 % < 10 % 
Table 1.1 – Global causes of HCC (Sherman 2010) 
 
1.3 Surveillance and diagnosis of HCC 
 
Surveillance of HCC has shown to reduce the fatality rate.  By screening patients known to 
be at high risk (carriers of HBV/HCV and people with a family history of the disease) the 
condition can be monitored and action taken with the potential to catch the condition in its 
early stage, allowing patients to live a disease free life (Crosswell et al 2010). A study in 
China where patients were monitored against un-monitored patients saw survival rates at 1, 3 
and 5 years was 66 %, 53 % and 46 % for the monitored patients against 31 %, 7 % and 0 % 
for the un-monitored patients (Zhang et al 2004).  Like other cancers, early detection is the 
best method for long term survival, however only 30 % of HCC cases are caught at the early 
stages since no cancer related symptoms become recognisable until the intermediate/late 
stages have developed (Lencioni 2012).  Organisations such as the American Association for 
the Study of Liver Disease and the European Association for the Study of the Liver have 
published guidelines to help clinicians monitor and diagnosis HCC (Figure 1.1).  Patients that 
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are carriers of HBV, HCV or have developed cirrhosis are considered high risk patents where 
screening is recommended once every 6 months (Bruix et al 2005).  Methods of screening 
include ultrasonography, assessment of the level of alpha fetoprotein (AFP), computed 
tomography and magnetic resonance imaging (MRI) where ultrasound is the preferred 
method and AFP is the most widely used serological test (Singal et al 2009).  Nodules less 
than 2 cm are often hard to discover making the diagnosis difficult, whereas nodules greater 
than 2 cm allow a diagnosis to be made (Parikh et al 2007).  Combination of ultrasound with 
AFP is known to be more effective in finding nodules however the cost of the procedure is 
increased when AFP levels greater than 400 ng/mL show indications of the presence of HCC.  
Nodules less than 1 cm have a 50 % chance of being malignant however ultrasound every 6 
months is recommended to monitor the condition and take the required action if the condition 
progresses to increase survival (Parikh et al 2007).   
 
 
 
 
 
 
 
 
 
16 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 – HCC surveillance guidelines 
 
 
Cirrhotic patients: 
Ultrasound (US) every 6 
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No Nodule  
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typical vascular pattern 
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or typical vascular 
pattern on two imaging 
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Typical vascular 
pattern on two 
imaging 
methods 
Surveillance (US) 
every 3 – 4 months 
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Increasing 
in size 
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Proceed as 
size per 
nodule 
Surveillance 
(US) every 6 
months 
 HCC 
Liver 
Biopsy HCC 
 Diagnostic  Non-diagnostic 
 HCC Surveillance (US) 
every 3 – 4 
months 
17 
 
1.4 Staging of HCC 
 
Several staging systems have been established in order to determine the severity of the HCC 
condition where the Barcelona Cancer of the Liver Clinic system (BCLC) has become the 
most frequently used method.  An algorithm (Figure 1.2) is used where the most effective 
treatment is picked.  The BCLC system splits HCC into the early, intermediate and advanced 
stages where various treatments can be chosen depending on the HCC stage.  The early stage 
shows good liver reserve, excellent performance status along with a limited tumour burden 
where this stage is open to possible curative treatments with high survival rates.  The 
intermediate stage shows moderate liver reserve, excellent performance status with multi 
nodular tumours where non curative methods are chosen, where TACE is the treatment of 
choice. Finally, the advance stage shows moderate liver reserve, vascular invasion, extra 
hepatic spread and a venerable performance.  TACE can be offered at this late stage where it 
has seen limited success in improving patient survival, however at this stage the HCC is often 
beyond achieving effective treatment from the current therapies, therefore the best possible 
care is given (Parikh et al 2008).   
Before a treatment method can be picked, the function of the liver is assessed and a stage is 
assigned depending on the status of the condition by the child pugh scoring system.  During 
this assessment, parameters including the levels of bilirubin and albumin, prothrombin time, 
encephalopathy and presence of ascites are assessed where points are calculated to give the 
child pugh score of A-C (Table 1.2 and 1.3).  Stage A shows good function allowing curative 
treatment methods to chosen, stage B shows a vulnerable performance status where TACE is 
commonly chosen and C shows poor function where transplantation is offered to specially 
selected patients (Forner et al 2010 and Parikh et al 2008).  Also the degree of vascular 
invasion and extra hepatic spread must also be evaluated before treatments methods can be 
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picked.  For example, small tumours can meet the criteria for transplantation, however if the 
condition has spread outside of the liver, the limited number of organs would likely rule these 
patients out for a transplant since it would have a higher reoccurrence rate, therefore other 
therapies such as TACE will be offered  (Parikh et al 2008).   
In terms of possible curative treatments, transplantation, resection and ablation are possible 
treatments which have strict criteria that are assessed and will be describe in further detail in 
the next section. Curative treatments are only open to patients with early stage HCC which 
accounts to only 30 % of all cases since no cancer related symptoms are seen until the 
intermediate stage is reached and the screening process for small tumours previously 
discussed is a challenging process.  In intermediate HCC, palliative treatment methods such 
as TACE is frequently offered which accounts for approximately 50% of HCC cases. 
Chemical Parameters 1 point 2 points 3 points 
Encephalopathy none 1 - 2 3-4 
Ascites none slight Moderate 
Albumin (g/dL) > 3.5 2.8 – 3.5 < 3.5 
Prothrombin time 
prolonged (sec) 
1-4 4-6 > 6 
Bilirubin (mg/dL) 1-2 2 - 3 > 3 
Table 1.2 – Pointing system for determining the child pugh score 
 
Child Pugh Score Liver function Total points 
A Good  5-6 
B Moderate  7-8 
C Poor  10-15 
Table 1.3 – The child pugh score staging system 
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Figure 1.2 – Treatment algorithm in determining the most effective treatment for HCC 
 
1.5 Curative treatments for HCC 
 
As discussed, before a treatment method for HCC is chosen, the condition must be assessed 
so that the most effective treatment for the patient can be applied.   Potential curative 
treatments include transplantation, resection and ablation.  Non-curative methods have shown 
to increase patient survival where methods such as TACE are used in approximately 50 % of 
HCC cases. 
1.5.1 Resection 
 
Resection is a surgical procedure that involves removal of a section of the liver and is the 
treatment of choice in patients with HCC that do not display cirrhosis, which can make the 
procedure more challenging and dangerous for the patient (Belghiti et al 2000).  In cases 
where the underlying cirrhosis is present, patients are carefully selected to avoid 
HCC 
Child 
Pugh 
Score 
Tumour 
Number 
Tumour 
Diameter 
Treatment 
Method  
A/B C 
1 2/3 4+ 1-3 4+ 
≤ 3 Cm > 3 Cm ≤ 3 Cm 
Resection 
Ablation Transplant  Palliative Care  Embolization  
Resection 
Ablation 
Resection 
Embolization 
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complications such as liver failure or increased risk of death.  Patients in the child pugh class 
A (single tumour, good liver reserve and good performance status) are the main class to 
undergo resection since their livers will still show good function. However, patients in Class 
B (multiple nodules and moderate liver reserve) are not entirely ruled out for resection 
although the reoccurrence rates can be relatively high.  These patients are carefully selected 
based on the survival and reoccurrence rates compared to other therapies such as ablation and 
embolization.  The reoccurrence rate at 2 and 5 years is 50 % and 70 % after resection 
(Imamura et al 2003).  In cases where the cancer reoccurs, transplantation can be offered 
when the procedure has failed.  This method allows an efficient use of the limited number of 
organs available for transplantation (Maluccio et al 2012).      
1.5.2 Ablation 
 
Ablation is another potentially curative treatment that induces tumour necrosis for early stage 
HCC in tumours ranging from 2-3 cm with similar survival rates to resection.  In tumours 
greater than 3 cm ablation is less effective, however, the method can be combined with 
embolization to improve response rates (Yan et al 2008).  The two types of ablation are 
thermal and chemical ablation.   Thermal ablation applies radiofrequency by a needle that is 
inserted into the tumour tissue causing tumour necrosis. Advantages of radiofrequency are 
that it is a non-surgical method with low complication rates, low cost and the procedure can 
be repeated (Willet et al 2012).  In terms of the tumour size, tumours greater than 5 cm are 
considered too big for ablation.  Also the method is limited to a maximum of 3 tumours (Lam 
et al 2008).  Complications of the radiofrequency procedure can include pain and 
haemorrhage.  Chemical ablation involves an injection of 95 % ethanol to the tumour which 
is a low cost procedure with a low chance of complications.    Disadvantages include the need 
for repeat procedures and an inability to achieve complete necrosis in large tumours which 
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has led to radiofrequency being a favourable therapy (Livraghi et al 1999).  Thermal albation 
gives better control and survival over the ethanol injection however its side effects are more 
frequent.  Both ablation therapies are effective since the tumour is a soft tissue surrounded by 
a hard cirrhotic liver which insulates the tumour tissue.  Also the hard cirrhotic liver prevents 
the alcohol from leaking out of the tumours tissue once administrated (Shiina et al 2012).  5 
year survival in patients with child pugh score A is at 50 – 75% (Willet et al 2012) and like 
resection, transplantation can be offered if ablation fails making efficient use of organs.   
1.5.3 Transplantation  
 
Transplantation is the most effective procedure with the potential to cure both the cancer and 
the underling cirrhosis.  Due to the shortage of organs, criteria have been stabilised where the 
Milan criteria is the most frequently used.  The criteria state that a patient with a single 
tumour measuring less than 5 cm or 3 tumours measuring 3 cm or less are eligible for 
transplantation.  5 year survival has a rate of 75 % with a reoccurrence of less than 15 % 
(Mazzaferro et al 1996).   Due to the limited number of organs patients are often referred to a 
waiting list which will often see a high drop-out rate due to patient death or tumour 
progression no longer making the treatment possible (Lolvet et al 1999).  Bridging therapies 
such as ablation and embolization have been frequently used for patients awaiting 
transplantation to prevent tumour progression and has shown success (Graziadei et al 2003).   
1.6 TACE 
 
As discussed, most HCC cases arise in the intermediate to advanced stages where potential 
curative treatments are no longer possible.  TACE is a palliative non-surgical arterial based 
technique applied to intermediate to advanced HCC where it is used in more than 50 % of 
HCC conditions (Lencioni 2012).  When HCC arises, the tumour receives the majority of its 
blood supply by the hepatic artery.    TACE therapies take advantage of this feature by using 
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it as a delivery route allowing targeted drug delivery directly to the tumour site.   Anti-cancer 
agents are delivered to treat the tumour along with embolizing particles which block the 
blood flow to the tumour starving it of oxygen, preventing tumour growth and also 
preventing wash out of the drugs.   
1.6.1 Conventional TACE 
The conventional TACE procedure involves injection of chemotherapeutic agents which are 
emulsified with Lipidol, an oily medium composed of long-chained ethyl esters derived from 
poppy seed oil which increases the solution viscosity aiding delivery and imaging.  
Doxorubicin is a frequently used single drug and doxorubicin, cisplatin and mitomycin C is a 
frequently used cocktail in the conventional TACE procedure (Osaga et al 2012).  The drug 
solutions and emulsion are prepared and blended in the clinic prior to treatment then 
administrated to the patient via a micro catheter.  Following the administration of the anti-
cancer agents, embolizing particles are then administrated where gelatin or polyvinyl alcohol 
(PVA) particles are common choices (Table 1.4).  Gelatin particles are cheap and 
biodegradable and are available in the size range of 40 – 60 µm (Makuuchi et al 1985), 
however the size and morphology of these particles are irregular with wide size distributions 
which can result in aggregation (Osaga et al 2009).  PVA particles are available in a larger 
size range of 50 – 1200 µm, however these particle also display irregular shapes and are also 
non-degradable.  Disadvantages of the conventional TACE method include high reoccurrence 
rates following treatment, no control over the drug release rate, potential for high 
concentrations of drug to enter the system circulation and the need for two injections. 
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Category Device Composition 
Conventional 
particles 
Gelport 
PVA 
Porous gelatin 
Non spherical PVA 
Bland beads Emosphere 
Bead Block 
Contour SE 
Embozene 
Trisacryl polymer embedded with gelatin 
Spherical PVA 
Spherical PVA 
Polyphosphazene-coated PMMA 
Drug eluting 
beads 
DC/LC bead 
Quadrasphere/Hepasphere 
PVA modified with sulfonate sodium salt 
Super absorbent polymer 
Table 1.4 – Embolic devices used in TACE 
To overcome the aggregation issues with non-spherical gelatin and PVA particles, spherical 
particles with smooth hydrophilic surfaces have become the standard choice of embolizing 
agents for TACE (Figure 1.3).  They avoid aggregation and can be easily passed through a 
microcatheter and allow easier targeted delivery to the tumour sight by choosing the optimum 
particle size (Osaga et al 2012).       
 
Figure 1.3 – Spherical embolizing particles for TACE (Osaga et al 2012) 
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Several beads have been developed specifically for bland embolization, where HCC is treated 
purely by the embolizing particles with no anti-cancer agents allowing no chemotherapeutic 
related side-effects to arise after the treatment has been applied.  Emosphere is a brand of 
embolizing beads produced from trisacryl gelatin and are available in the size range of 40 – 
120, 100 – 300, 300 – 500, 500 – 700, 700 – 900 and 900 – 1200 µm (Osaga et al 2012).  In 
most cases, a single bead can block a vessel, effectively embolizing the tumour (Laurent et al 
2004).  Contor and Bead Block are other devices that have come to market available in the 
size ranges of 100 – 300, 300 – 500, 500 – 700, 700 – 900 and 900 – 1200 µm and the beads 
have less resistance in the blood vessels than Emosphere beads (Osaga et al 2012 and Laurent 
et al 2006).  Another bead Emozene is a polyphosphazene coated polymethymethacyrlate 
bead.  The particle size is available in a narrower size range of 40, 75, 100, 250, 400, 500, 
700, 900, 1100 and 1300 µm.  Each size has a specific colour to allow visibility and allow the 
bead size to be easily distinguished.  The coating of polyphosphazene on the bead acts as an 
anti-inflammatory for when long periods of exposer to the embolic material is needed to 
reduce patient discomfort (Stampfl et al 2011).  
1.6.2 Drug eluting beads 
The major disadvantage of conventional TACE is its inability to control drug release and 
target drug delivery directly to the tumour with limited tumour response.  Since the 1990s this 
pitfall of conventional TACE have been overcome where drug eluting beads (DEBs) have 
become a favourable choice in patients suffering from intermediate HCC.  During the TACE 
procedure, a drug solution is added to blank DEBs where a typical loading of doxorubicin can 
reach a maximum loading of 37 mg/mL in 20 minutes (Figure 1.4) (Liapi et al 2007).  The 
beads are then administrated to the patient via a micro catheter which takes approximately 1.5 
hours (Liapi et al 2007).  The DEBs are calibrated between 100 – 1000 µm allowing targeted 
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delivery to the tumour where the procedure can be completed in a single injection compared 
to two injections that are required for conventional TACE.     DEBs also allow high loadings 
and controlled release of the therapeutic compound over time, a particular important feature 
for anti-cancer drugs which can display narrow therapeutic windows.   
Two brand of beads based on PVA are available, the DC bead (in Europe) and the LC bead 
(in the US).  The DC bead is a PVA based bead that has been modified with sulfonate groups 
that gives the bead a strong negative charge (Osaga et al 2012).  This allows positively 
charged drugs such as doxorubicin to be loaded onto the preformed beads and the ability to 
release the drug slowly over a period of days to weeks depending on the size of the bead 
(Liapi et al 2007).  The size ranges of the DC beads that are available are 100 – 300, 300 – 
500, 500- 700 and 700 – 900 µm.  Indication of the loading can be confirmed since the dry 
beads undergo a colour change from blue to red once the doxorubicin is loaded.   
 
 
 
Figure 1.4 – Loading of anti-cancer drugs to DEBs.  The drug solution is added to the dry beads where drug 
molecules bind to the embolic device.  DEBs typically display a negative charge and can load positively charged 
drugs such as doxorubicin with high loadings and controlled release capabilities.  
Another two brands of DEBs are Hepasphere and Quadrasphere which are produced form 
vinyl alcohol and sodium acrylate copolymer.  During the TACE procedure, the dry beads are 
added to a drug solution in saline and expand up to four times their dry bead size, which are 
available from 50 – 100, 100 – 150 and 150 – 200 µm.  Like the DC bead they are also 
negatively charged and can load the positively charged doxorubicin in 20 minutes where 
50 mg of the drug can be loaded on to 25 mg of dry beads then be released in a controlled 
DOX 
   20 min 
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state overtime.  Negative or neutrally charged drugs can also be loaded into the beads, 
however in-vitro studies have shown the drug release rate to be rather fast where all of the 
drug is released within a 24 hour period (Maeda et al 2010).   
DEBs have shown to greatly improve survival with improved tumour response compared to 
conventional TACE.  The major disadvantage of DEBs is that when controlled release of the 
therapeutic is required, the DEBs are limited to positively charged drugs, since the strong 
interactions between the drug and material allow the controlled rate to be achieved.  Also, 
DEBs are specifically calibrated to a patient’s blood vessel size.  Patients with varying blood 
vessel widths will require different sized particles resulting in various release rates where the 
smaller sized DC beads release doxorubicin within 24 hours and the larger DC beads control 
the release rate over 14 days (Maeda et al 2010).  This is a particular disadvantage since 
patients with narrow blood vessels with require more treatments and can potentially be 
exposed to peaks in drug toxicity resulting in unwanted side-effects.  Finally, DEBs fall short 
if multiple drugs are to be administrated since the drug is loaded to pre-formed beads and the 
beads have a limited loading capacity.   
1.7 Proposal of a new microparticle drug delivery system for TACE 
 
As discussed, many current therapies have proven to cure/reduce tumour burden for patients 
that suffer from HCC.  Specifically for TACE, the DEBs have emerged as a dominant 
therapy in the treatment of intermediate HCC, where the DC bead has been a major player for 
the delivery of doxorubicin, a commonly used drug to treat HCC.  However, the DEBs have 
several setbacks that limit the use to specific drugs and patients with various blood vessel 
widths will receive the drug at different rates.   
A new delivery system is proposed in an attempt to overcome the limitation to one class of 
drugs and also to decouple the effect of particle size on drug release rate, allowing a single 
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release profile to be available to all patients.  This new system will be composed of 
microparticles encapsulated into larger microparticles yielding a particle-in-particle (PIP) 
system (Figure 1.5).  The PIP system will have two key functions that current TACE 
therapies lack.  The first function of the PIP system is a drug delivery/chemotherapy 
component, composed of small microparticles approximately 1 – 3 µm in diameter for 
delivery of the drug.  The second function of the PIP system is the embolization component, 
composed of larger spherical microparticles with porous structures in the 100 – 1000 µm size 
range allowing effective embolization and targeted delivery to the tumour site.  The small 
drug delivery particles are to be designed to encapsulate a desired drug with high drug 
loadings and controlled release characteristics, allowing multi drugs to be encapsulated into 
the PIP system.  A key feature of the embolizing particles is a particle with a high porosity 
allowing PIPs of various sizes to display the same release pattern and also where the 
encapsulated drug delivery particles show no interaction with the embolizing material which 
could potentially result various drug release patterns.  This will allow patients with various 
blood vessels widths to receive similar release rates for a wide range of drugs which will stay 
in the same therapeutic window range, a function that current DEBs for TACE lack.  The 
embolic particles are also to be produced from a biocompatible and biodegradable polymer so 
that the particles degrade overtime avoiding accumulation in the blood vessels, since many 
treatments may be needed over the patents life span.   
It is to this authors knowledge that there is currently no other particle based drug delivery 
system capable of decoupling the effect of particle size on drug release rate for TACE or in 
any other drug delivery application.  Also it is believed that there are no other current PIP 
systems designed to encapsulate a specific or multiple drugs for TACE.  Therefore this new 
PIP system will have great potential to not only deliver current drugs used for TACE but also 
any new drugs that are could prove to be more effective with all the benefits that the current 
28 
 
DEBs display.  The ability for the PIPs to display identical release rates can also reduce the 
peaks in drug toxicity reducing side effects along with the number of treatments thereby 
improving patient quality of life.  
Since these particles are to be delivered by the parental route, formation of a sterile product is 
critical where some methods of manufacturing could possibly allow a sterilization step to be 
avoided.  Like with the DEBs these PIPs would be stored in the dry state allowing greater 
stability during storage and preventing the drug leaking out over time.  They would then be 
suspended in saline and administrated to the patient via a micro catheter in the clinic under 
local anaesthetic. Like some of the embolization devices discussed, the PIPs will display 
smooth spherical surface, with narrow size ranges allowing the PIPs to be administrated with 
ease, and allow targeted delivery directly to the tumour site.  Use of Lipidol as used in 
conventional TACE could also aid delivery and imaging of the beads post treatment.  Finally, 
current DEBs available are mainly non resorbable systems.  Materials investigated in this 
work will be mainly from natural biodegradable polymers.  Since patients suffering from 
intermediate HCC may need multiple treatments over their life span, the PIPs produced in 
this work must be able to breakdown and be removed from the body once the delivery of the 
drug has been completed.  
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Figure 1.5 – The proposed PIP system composed of microparticles encapsulated into microparticles.  The inner 
drug delivery particles are to be tailored to a desired drug with high drug loadings and controlled release 
capabilities.  These drug delivery particles are then encapsulated into larger microparticles which will act as the 
embolic device allowing embolization of the tumour and targeted delivery to the tumour site.     
The body of this thesis explores various aspects of polymer science and particle production 
processes that have been reported within the field of drug delivery.  More specifically the 
following chapters explore; 
 Possible materials capable of controlled release where small molecular weight 
hydrophilic drugs with chemistry similar to doxorubicin are to be delivered.   
 Particle production processes for particles that display high drug loadings and 
controlled release of the encapsulated drug.     
 Materials and methods that allow porous embolic particles (100 – 1000 µm) to be 
produced. 
 Particle production processes that allow the drug delivery particles to be uniformly 
distributed within the embolizing particles 
 Production methods of PIPs that allow the effect of particle size to be decoupled from 
drug release rate.    
Drug delivery particles 
to encapsulate a desired 
drug (1 – 3 µm) 
Embolic particle 
containing the drug 
delivery particles (100 – 
1000 µm) 
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CHAPTER 2 
POLYMERS IN DRUG DELIVERY 
 
2.1 Introduction  
 
Polymer Science is an area that has seen extensive research within the food, cosmetics and 
pharmaceutical industries.   For pharmaceutical applications, polymers have been a favoured 
choice as drug delivery systems since they are biocompatible and biodegradable.  Release 
from such systems is by diffusion of drug molecules from a polymer matrix into an external 
volume of media, or by degradation of the polymer as it enters a particular environment.  
Polymers can be produced from natural sources such as plants and animals or be synthetically 
man made (Kunal et al 2009).  Natural polymers such as alginate, chitosan and gelatin 
generally have more complex structures than synthetic polymers, and their properties can 
vary greatly depending on the source from which they are produced (Enderle et al 2005).  
They are a class that are open to a wide range of functional groups and chemical 
characteristics making them an interesting choice as drug delivery vehicles.  Natural 
polymers also carry hydrophilic characteristics along with low costs making them an 
attractive choice for encapsulation of hydrophilic drugs allowing the water soluble 
compounds to be well mixed and processed into a solid matrix with the drug uniformly 
distributed.  The disadvantage of natural polymers is a risk of microbial contamination from 
the animal or plant source (Kunal et al 2009).  Synthetic (also argued as semi-synthetic) 
polymers such as polylactic acid (PLA), polycaprolactone (PCL) and poly (lactic-co-glycolic 
acid) (PGLA) can be tailor made to suit a specific application and batches of the produced 
material can have more like for like chemical characteristics compared to natural polymers.  
They can also be easier to process than natural polymers since they often do not require 
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crosslinking to form a drug delivery system.   However, they carry a higher cost and often 
require the use of environmentally unfriendly solvents such as dichloromethane when 
fabricating them into drug delivery systems.   
2.1.1 Hydrogels in drug delivery applications 
 
In modern drug delivery technology development scientists look to improve upon existing 
drug delivery methods by developing sustained release systems that control the rate a drug 
enters the blood stream (Brannon-Peppas 1997).  This method of drug delivery can avoid 
overdosing, reduce the required dose of drug and decrease the number of unwanted side 
effects.  Many of these controlled drug delivery systems are composed from hydrogels.  
Hydrogels consist of three dimensional polymer networks that retain large volumes of water.  
Hydrogels make attractive delivery systems since they can be made of the similar building 
blocks that mimic living tissue and can therefore display lower toxicity and a better 
biocompatibility than other materials (Gupta et al 2002).  Hydrogels are produced by 
crosslinking functional groups along the polymer backbone which increase the rigidity and 
density of the network which can be a physical or chemical process (Hoffmann 2002). 
Physical crosslinking processes involve a change in the polymers physical state though 
methods such as temperature changes and UV/gamma radiation producing the three 
dimensional gel network (Moffat and Mara 2004, Taleb 2008).  Chemical crosslinking 
requires addition of a chemical agent to the polymer solution that induces hydrogel formation 
(Moffat and Mara 2004, Taleb 2008).  Chemical crosslinking is generally an easier process to 
control over physical crosslinking since the experimental parameters such as polymer 
concentration, crosslinking agent concentration and crosslinking time can be adjusted to fit a 
desired requirement (Peppas 1987, Kashyap et al 2005).  Also, chemical crosslinking can be 
completed by two methods known as zero length and non-zero length crosslinking.  Zero 
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length crosslinking involves binding two different polymer chains of opposite charge though 
interaction of oppositely charged functional groups.  For example the negative carboxylic 
acid groups in alginate can bind to the positive amine groups in chitosan to form the gel.  
Non-zero length crosslinking involves binding the functional groups in a single polymer to 
form a gel, for example crosslinking of alginates carboxylic acids groups with calcium ions 
(Petite et al 1994, Kao et al 2004).   
When designing a drug delivery system, the choice of material is often dependent on the drug 
to be encapsulated.  The polymer and manufacturing method used must allow the chemical 
nature of the drug to be preserved, for example when encapsulating sensitive drugs such as 
proteins, use of materials that require harsh solvents or high temperatures may not be ideal.  
The physical properties of the drug must also be addressed.  If a hydrophilic drug is to be 
encapsulated, methods such as the oil in water emulsion will not be ideal as a large quantity 
of the drug can be lost to the water based continuous phase, resulting in low drug loadings.    
Some materials are chosen to allow electrostatic interactions between the polymer and drug 
allowing a drug delivery system to hold the drug more effectively, resulting in higher 
encapsulation efficiencies and controlled release rates.  Bonferoni et al (2007) produced a 
particulate system from the positively charged polysaccharide chitosan to encapsulate 
salicylic acid, a negatively charged drug where the interactions between polymer and drug 
allowed controlled release to be achieved.  Mahesh et al (2007) produced a drug delivery 
system composed of alginate and an anionic surfactant Aerosol OT by a double emulsion 
method.  The anionic surfactant introduced stronger functional groups to interact with a range 
of positively charged drugs including doxorubicin and verapamil hydrochloride that were 
released over a 30 day period with high drug loadings and encapsulation efficiencies.   
The choice of drug investigated this thesis will be given to small molecular weight 
hydrophilic drugs, since their encapsulation into microparticles for controlled release has seen 
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limited attention in the literature where they are known to display rapid release rates due to 
their water loving nature.   Many anti-cancer drugs possess a positive charge, particularly the 
commonly used doxorubicin, which belongs to the class of drugs are explored in this thesis.  
Water soluble polymers make an attractive choice of materials for the entrapment of 
hydrophilic compounds since they are open to a wide variety of functional groups that can 
interact with the drug molecule, and since both dissolve well in water, the drug can be well 
mixed and encapsulated throughout a solid particle matrix once processed.  Natural polymers 
that display a negative charge are the class of materials investigated since they can allow 
interaction with the positive charge of the drug molecule which can potentially allow high 
loadings and a sustained release rate to be achieved.  This can be particularly challenging for 
hydrogel based systems encapsulating hydrophilic drugs since the gels are known to swell 
rapidly in water where the encapsulated contents can be instantly released.  Therefore strong 
interactions between the material and drug will be of great importance in order for the 
hydrogel system to effectively retain the drug making it capable of controlled release.  
Several of these commonly used water soluble polymers are discussed along with some of 
their current uses as microparticle based drug delivery vehicles.   
2.2 Alginate  
 
Alginate (Figure 2.1a) is an anionic linear polysaccharide derived from brown seaweed that 
consists of D mannuronic acid (known as the M unit) and L guluronic acid (known as the G 
unit) units along the polymer backbone, where these units are arranged in a random 
distribution (GG, MM, MG, GM) depending on the alginate  source (Draget et al 1996).  One 
characteristic that makes alginate an attractive material in drug delivery is its ability to form 
instant gels upon addition to solutions of divalent ions such as calcium chloride.  The gel 
forms though crosslinking of the G unit carboxyl groups and the calcium ions which has 
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become known as the egg box configuration, which is a mild process making it an attractive 
method for the encapsulation of sensitive drug molecules (Ostberg et al 1994) (Figure 2.1b).  
The G and M units vary in alginate sources and the ratio of the M/G units is known to 
influence the gel strength.   Alginate containing a high G content produces strong but brittle 
gels while alginate with a high M content forms weaker flexible gels (Kakita et al 2008).  In 
drug delivery applications alginate with a high G content is desirable since the stronger gel 
will have more potential to produce a denser polymer network once crosslinked, potentially 
allowing a sustained release rate to be achieved.  Along with the M/G ratio, the solution 
concentration and molecular weight can produce gels with variable drug release properties 
where gels produced from solutions of high molecular weight and high concentrations can 
yield strong gels however the solutions will be highly viscous making them difficult to 
process (Lee et al 2011).  Calcium ions can induce alginate gelation by two methods.  The 
first is an external gelation method.  When alginate solutions come into contact with calcium 
chloride solutions, gelation occurs from the exterior of the hydrogel where the alginate 
carboxyl groups are crosslinked with the calcium ions.  Gelation can also be induced from the 
interior of the gel where calcium carbonate solutions are mixed in with the alginate solution.  
By addition of glacial acetic acid, calcium ions are released from the alginate/calcium 
carbonate blend where the gel is from the interior.  Factors effecting gel strength are the 
concentration of alginate and crosslinking solution and crosslinking time (Kunal et al 2009).   
 
Figure 2.1a – Chemical structure of Alginate (Mahesh et al 2007) 
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Figure 2.1b – Egg box configuration for Alginate gelation (Mahesh et al 2007) 
Various methods have been investigated for alginate gelation.  One of the commonly used 
methods is by the syringe droplet method where solutions of alginate are added to a bath of 
calcium chloride where the alginate forms instant gel beads upon entry into the crosslinking 
solution.  This particle production method generates large beads greater than 1 mm in 
diameter, which can be considered too large for some drug delivery applications.  The size of 
the beads can be to a some degree controlled by use of a needle with a narrow diameter, 
however this limits the choice of alginate to low concentration/molecular weight/viscosity 
solutions as solutions too viscous would not pass though the needle.    On the other hand, due 
to the beads greater diameter and therefore lower surface area, the method allows hydrogels 
with greater controlled release capabilities to be produced.  Alginate has also been formed 
into micro sized drug delivery systems by use of water in oil emulsions.  When processing by 
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an emulsion method, an alginate solution mixed with a drug to be encapsulated is emulsified 
in an oil and suitable surfactant.  Micro sized droplets are produced which can be crosslinked 
into solid particles by gradually adding a solution of calcium chloride to the emulsion.  By 
varying mixing speed, alginate concentration and the surfactant concentration, the size of the 
droplets can be tailored from micro to nano sized droplets.  Another attractive technique for 
microparticle production method is by use of nozzle vibrating technology where a vibration is 
applied to a flowing polymer jet which breaks to the jet down into droplets of a uniform size 
once passed through a nozzle or needle allowing particles or beads of a more uniform size to 
be produced.  These techniques will be discussed in further detail in later chapters of this 
thesis.    
Encapsulation of small molecular weight hydrophilic drugs in alginate hydrogels in the 
literature is limited due to the polymers high porosity and rapid swelling characteristics.    
Alginate has been used for the encapsulation of poorly/slightly water soluble drugs where 
Soni et al (2010) produced alginate microparticles by a water-in-oil emulsion method where 
the alginate particles sustained the release of theophylline over 8 hours from particles with a 
Dv50 of approximately 10 µm.  Alginate has also been used to encapsulate proteins and large 
molecules due to its mild gel formation process which avoids use of solvents and conditions 
that can potentially denature the protein to be encapsulated.  Mobus et al (2012) spray dried 
zinc crosslinked alginate microsphere to encapsulate insulin for delivery to the lungs.  The 
particles had a Dv50 of 4 µm and controlled the rate of the large molecule over 48 hours.  To 
extend controlled release capabilities of some drug delivery systems, alginate has been used 
in conjunction with positively charged polymers such as chitosan as a coating technique 
known as a layer-by-layer approach, where the additional layers can potentially make the 
diffusion process of a drug more challenging (Liu et al 2013).   
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Publications for controlled release of small molecular weight hydrophilic drugs using alginate 
as a carrier particle are limited.  Several publications have discussed addition of materials that 
enhance interactions between the drug and carrier particles and produce stronger gels with 
reduced porosity.  Mahesh et al (2007) combined alginate with the anionic surfactant 
Aerosol OT which contains sulfonate groups (function groups responsible for making the DC 
bead capable of controlled release) to prolong the release rate of several positively charged 
drugs, including verapamil hydrochloride and doxorubicin.  The addition of the sulfonated 
agent sustained the drug release over a 30 day period.  The drug loadings of several 
negatively charged drugs were also investigated where the loadings were less than that of the 
positively charged drugs however no drug release studies were performed with the negatively 
charged compounds.   
2.3 Pectin 
 
Pectin (Figure 2.2) is a linear polysaccharide obtained from the walls of most plants such as 
citrus fruit and apples. Its polymer chain consists of repeating 1 – 4 linked D-galacturonic 
acid units which contain carboxyl groups along the backbone in the form of smooth and hairy 
regions giving the molecule a negative charge (Luishu et al 2003).  Like alginate, pectin 
forms instant gels in the presence of calcium ions though the egg box configuration, making 
it attractive for drug delivery applications.  The galacturonic groups in pectin are partly 
esterified with methyl groups which can vary in pectin types and influence the properties of 
the polymer where this characteristic is known as the degree of esterification (DE).  Pectin 
with a DE below 50 % is classed as low DE pectin and pectin with a DE above 50 % is 
classed as high DE pectin (Luishu et al 2003).  High DE pectin has less carboxyl groups 
available in the polymer backbone and giving it a lower water permeability than low DE 
pectin making it an ideal coating agent where it has been used in oral dosage forms to reduce 
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water permeability (Wong et al 2002).   As for drug delivery matrixes pectin with a low DE 
is an ideal choice since they have a greater number of carboxyl groups available for 
interaction with calcium ions, allowing denser gels to be produced.  As with alginate factors 
influencing gel strength are the concentration of polymer used, crosslinking time and 
concentration and polymer molecular weight (Wong et al 2002).   
 
Figure 2.2 – Chemical structure of Pectin (Luishu et al 2003) 
 
Pectin has been used to produce gels by similar methods as discussed with alginate.  Pectins 
main applications have been as a drug carrier for delivering drugs to the colon by the oral 
route since it is degraded by the colonic micro-flora (Wong et al 2002).  Vaidya et al (2009) 
produced a pectin based microparticle system containing metronidazole where the pectin 
particles were coated with Eudragit S100, a pH responsive polymer that protects the 
encapsulated drug along the upper gastrointestinal tract until it reaches the colon site allowing 
the full load of drug to be released.  The drug was displayed a controlled release using in-
vitro testing in conditions simulating the colon over 18 hours.   
2.4 Carrageenan  
Carrageenan (Figure 2.3a) is a family of sulfonated linear polysaccharides that are derived 
from red marine algae where its use has been used as a thickener in the food industry.  Their 
linear primary structure is based on alternating 1,3 linked D galactose and 1,4 linked 
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D galactose which are linked with 1,3 and 1,4 glycosidic linkages, with varying degrees of 
sulfation (Mayur et al 2004).  They are a family of polymers that depending on the number of 
sulfonate groups in the polymer backbone, form gels with strong or elastic characteristics.  In 
the heated state the polymer exists as a random distribution of coils.  Upon cooling, the 
polymer chains arrange into double helical junction zones (Figure 2.3b) that become closer as 
the temperature decreases resulting in gel formation (Mayur et al 2004).  Addition of cations, 
potassium for kappa carrageenan and calcium for iota carrageenan give a more ordered 
structure, reinforcing the gel (Mayur et al 2004).  Three types of carrageenan are commonly 
used in industry, kappa, iota and lambda carrageenan.  Kappa carrageenan contains one 
sulfonate group in the backbone and forms strong gels that can be reinforced with potassium 
ions.  Iota carrageenan has two sulphate groups in the backbone and forms soft elastic gels at 
lower temperatures than kappa carrageenan.  Lambda carrageenan has three sulphate groups 
in the backbone which cannot form a gel where it is used as a thickener in the food industry 
(Mayur et al 2004).   
 
Figure 2.3a – Chemical structure of kappa, iota and lambda carrageenan (Janna et al 2011) 
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Figure 2.3b – Gel formation of thermoresponsive polymers.  In the heated state the polymer chains are in a 
randomised coil formation.  Upon cooling the chains form double helix junctions leading to the gel formation 
(Mayur et al 2004). 
In drug delivery applications, kappa carrageenan is known to be an ideal choice since it forms 
strong gels.  However, production of micro sized particle systems has seen limited attention, 
since the material needs temperatures up to 90 °C in order to form a processable solution 
which will degrade some drugs during the encapsulation process.  Also, common particle 
production methods such as emulsions and spray drying will require these high temperatures 
for vast amounts of time limiting their use to fabricate microparticle systems.  Most delivery 
systems discussed in the literature produce large gel beads produced by the syringe droplet 
method where hot solutions of the polymer/drug blend are added to cold solutions of 
potassium chloride.  Sipahigil et al (2001) produced large kappa carrageenan beads 
encapsulating verapamil hydrochloride given beads containing 3 % w/v carrageenan and 1 % 
w/v drug.  The large beads sustained the release of the hydrophilic compound over 5 hours in 
phosphate buffered saline (pH 7.4) where the beads had entrapment efficiencies up to 70 %.   
Carrageenan was chosen since it possesses sulfonate groups in the polymer backbone which 
are the functional groups in the DC bead that make it capable of controlling the release rate of 
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doxorubicin.  The strong interaction between the verapamil and carrageenan could potentially 
give the drug delivery system high loadings and controlled release characteristics.   
2.5 Gellan 
  
Gellan (Figure 2.4) is an anionic linear polysaccharide that is fermented from the microbe 
Pseudomonas elodea.  It is made up of repeating units of one L rhamnose, one D glucuronic 
acid and two D glucose units (Hasheminya et al 2003).  Like carrageenan, gellan is also a 
thermo responsive polymer where gels are formed upon cooling followed by crosslinking 
with calcium ions due to the presence of carboxyl groups along the polymer backbone.  
Gellan has two main forms with high or low acyl content, which has a strong influence on the 
materials gelling characteristics.  Low acyl gellan dissolves in water at temperatures around 
90 °C and can be processed into hydrogels that form strong gels in the presence of calcium 
ions, therefore making it ideal for drug delivery applications (Liang et al 2006).  The high 
acyl form of gellan forms weaker gels because of the bulky acetyl and glyceryl groups which 
prevent close association between gellan polymer chains in the double helical formation 
making it less ideal as a drug delivery system for controlled release (Liang et al 2006). 
 
 
Figure 2.4 – Chemical structure of Gellan (Janna et al 2011) 
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Gellan like carrageenan has also been processed into large gel beads by the syringe droplet 
method by dropping hot solutions into hot solutions of calcium chloride.  Verma et al (2011) 
encapsulated rifabutin, a low water soluble drug into the large beads where the drug was 
released over a 4 hour period.   
2.6 Inorganic materials in drug delivery 
 
Despite the field of drug delivery being a polymer dominated area of research, inorganic 
based delivery systems have also become a growing area of interest in the field.  Inorganic 
systems have several advantages over organic polymers.  Firstly, they have slower 
degradation rates and do not swell to the extent of polymer based systems upon contact with 
an aqueous environment (Lovino et al 2005).  These characteristics of inorganic delivery 
systems can make them a more beneficial choice for controlled release where other systems 
fall short due to the rapid swelling and degradation rate.    Also inorganics can have a greater 
biocompatibility over some polymers (particularly synthetics) which can break down into 
acidic compounds during degradation, which often result in irritation of tissue.  (Lui et al 
2006).  The disadvantage to inorganic drug delivery systems is that they can remain in the 
body for long periods of time or permanently due to their slow degradation time.       
Several reviews have demonstrated the significance of inorganics in drug delivery.  Wang et 
al (2010) produced a carboxyl methyl chitosan/calcium carbonate nanoparticle hybrid by an 
ionic gelation method where preformed particles were loaded with doxorubicin and showed 
controlled release characteristics over a 30 day period.  Also, Assifaoui et al (2012) produced 
calcium pectinate hydrogel beads by the syringe droplet method where the beads were then 
coated with silica by a sol-gel process.  The coated beads reduced swelling and the drug 
release rate of theophylline compared to the pure gel beads.  Finally Birdi et al (2012) 
produced an alginate/sodium silicate hybrid bead by the syringe droplet method where the 
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presence of the sodium silicate dramatically decreased the beads degradation rates to the pure 
alginate beads; however no drug release studies were investigated.  Since a drug delivery 
system capable of controlled release is required, encapsulating drugs into an inorganic matrix 
can have the potential to produce a system where the diffusion of the drug is more 
challenging therefore improving its controlled release capability.  The sodium silicate used in 
the study by Birdi was also investigated as a material to bind into the alginate hydrogels 
crosslinking mechanism since it greatly reduced the beads degradation, where it was believed 
it could have potential to improve the systems capabilities for controlled release.   
2.7 Verapamil Hydrochloride  
 
The model drug used in this thesis was verapamil hydrochloride, a small molecular weight 
negatively charged basic drug (Figure 2.5), since it displays similar chemical characteristics 
to doxorubicin (Figure 2.6), a commonly used drug for TACE.     The main chemical property 
of interest is that the drug is positively charged allowing interaction with the negatively 
charged polymers during the encapsulation process.  This is believed to be of great 
significance so that small microparticles can bind to the drug molecule producing a system 
with high drug loadings and controlled release abilities.  Small microparticle hydrogel 
systems will exhibit a high surface area that can rapidly swell making them liable to rapid 
release rates which can makes this aim of controlled release for hydrophilic drugs particularly 
challenging.   
In an ideal world, doxorubicin would have been investigated however the anti-cancer drug is 
highly toxic and was too dangerous for the lab environment where the research was 
performed.  Also, the molecule was to expensive for this research.  Therefore verapamil, a 
safer cheaper compound was chosen for the investigation.  The properties of the verapamil 
and doxorubicin are detailed in Table 2.1.   
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Verapamil Hydrochloride Doxorubicin Hydrochloride 
Form White powder Red powder 
Molecular weight (g/mol) 491.06 543.5 
pKa 8.6 8.4 
pH 5.6 6.5 
Water solubility (25 °C) 83 mg/mL 10 mg/mL 
Table 2.1 – Chemical properties of Verapamil Hydrochloride and Doxorubicin Hydrochloride 
 
Figure 2.5 – Chemical structure of Verapamil hydrochloride (Sigma Aldrich) 
 
Figure 2.6 Chemical structure of doxorubicin hydrochloride (Sigma Aldrich) 
Verapamil is used to treat high blood pressure and heart disorders as a calcium channel 
blocker where it relaxes the muscles in the heart.  It has been investigated in several reviews 
based on microparticle drug carriers.  The first, which inspired the concept of polymer/drug 
interactions in this thesis, was by the work of Mahesh et al (2007) who encapsulated the drug 
into alginate/Aerosol OT nanoparticles by a double emulsion method, where the system gave 
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high loadings and controlled release rates.  Mahesh also investigated doxorubicin where the 
two drugs were released at similar rates.  Zhang et al (2014) produced an alginate-chitosan 
hybrid particle system by the solvent extrusion method.  Large microparticles 1 – 1.5 mm 
were produced where the particles displayed a release over 12 hours.  Pasparatis et al (2006) 
encapsulated verapamil hydrochloride into large alginate beads with chitosan coatings where 
the chitosan coating slightly sustained the release compared to the alginate beads.   
2.8 Conclusion 
 
This chapter detailed various water soluble polymers that display negative charges allowing 
them to interact with positively charged small molecular weight hydrophilic drugs.  These 
interactions can potentially allow small microparticle systems that display high surface areas 
to be capable of controlled release of a water loving molecule, an area that has seen limited 
attention in the literature.  These interactions will be of great significance since hydrogel 
based drug delivery systems are known to swell when exposed to water which can lead to 
rapid or instant drug release rates.  Therefore the ability for the gel to not only encapsulate 
but retain the drug effectively in the formulation is critical.  The reviewed materials are to be 
investigated for the ability to load and control the release of verapamil hydrochloride as the 
model drug.   
 
 
 
46 
 
CHAPTER 3 
MATERIAL SCREENING 
 
3.1 Introduction 
 
The initial experiments investigated in this chapter were to explore various negatively 
charged water soluble polymers for their drug loading and controlled release characteristics, 
of verapamil hydrochloride, a small molecular weight cationic hydrophilic drug.  
Development of drug delivery systems for hydrophilic drugs with high loadings and 
controlled release characteristics is challenging due to the hydrophilic nature of the drug.  
Large masses of the drug can be lost during the production process and the drug delivery 
systems containing hydrophilic compounds are often subject to the burst effect, where large 
masses of the drug are released in an uncontrolled manner.  Therefore, in order to fabricate a 
system capable of controlled release, materials that would allow interaction with the drug 
were of key interest.  Also, introduction of inorganic materials into the polymer gels to 
increase the gel strength in an attempt to slow down the drug release rates were also 
investigated.  Large gel beads were produced by the syringe droplet method.  This method 
allowed a fast hydrogel production method to allow screening of the effectiveness of the 
investigated polymers for their controlled release capabilities.   
The objectives of these initial experiments were to; 
 Investigate various water soluble polymers for their controlled release abilities where 
polymers that display a negative charge were of interest. 
 Investigate various mixtures of materials that can potentially prolong the drug release 
rate as opposed to single polymer systems.  
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 Characterise the materials for their drug loading, encapsulation and drug release 
capabilities of verapamil hydrochloride.  
3.2 Materials and Methods 
 
3.2.1 Materials  
 
Alginic acid sodium salt (ID # 180947, MW 120,000 – 190,000 g/mol, viscosity (1 %) 15-
20 cP, M/G 1.56), kappa carrageenan (ID # 22048, viscosity (0.3%) 5-25 mPa.s), iota 
carrageenan (ID # C1138) and sodium silicate were supplied by Sigma Aldrich UK.  Gellan 
(Gelzan MW 3 x 10
5
 Daltons) and low DE pectin (MW 60,000 – 130,000 g/mol) were 
supplied by CP Kelco.   Calcium chloride, potassium chloride and phosphate buffered saline 
(PBS) were supplied by Fisher Scientific UK.  Verapamil hydrochloride was supplied by 
Cambridge Bioscience.  All aqueous solutions were produced using double distilled water. 
3.2.2 Production of the alginate and pectin beads     
 
Alginate and pectin beads were produced by the syringe droplet method using a syringe fitted 
with a 14 G needle (Sugawara et al 1994).  Solutions and were produced as follows.  Polymer 
solutions at 6 % w/v were produced by mixing the materials in distilled water overnight at 50 
°C.  A 2 % w/v solution of verapamil hydrochloride was produced by dissolving the drug in 
distilled water with mild heating.  To produce the polymer-drug solution, equal volumes were 
well mixed with gentle heating producing a slightly cloudy solution with a final concentration 
of 3 % w/v polymer and 1 % w/v verapamil hydrochloride.  A 3 % w/v solution was chosen 
since higher polymer concentrations will give denser gels once crosslinked and can 
potentially display improved controlled release characteristics.  Also, the polymer 
concentrations investigated would be used to produce the small microparticle system in the 
next chapter.  Concentrations above 3 % would be too viscous to process into small 
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microparticles therefore 3 % was used as a standard concentration for all materials 
investigated.  A 1 M calcium chloride solution was chosen as the crosslinking solution by 
dissolving the calcium chloride dihydrate in distilled water.  Since verapamil belongs to the 
hydrophilic class of drugs, a strong crosslinking concentration was chosen to minimise the 
crosslinking period of the beads to reduce drug loss during the fabrication process.  To 
prepare the beads, 2 mL of the polymer-drug solution was added drop wise to 20 mL of the 1 
M calcium chloride solution and the beads were then left to crosslink for a 1 hour period in a 
fridge.  The beads were then filtered and dried overnight and stored in vials for analysis.   
3.2.3 Production of the Gellan and Carrageenan (kappa/iota) beads 
 
Gellan, kappa carrageenan and iota carrageenan beads were also produced by the syringe 
droplet method using a syringe and a 14 G needle. Solutions were produced as follows.  6 % 
w/v gellan and carrageenan were produced by adding the polymers to pre heated distilled 
water at 120 °C and mixed overnight.  The beads were then produced as with the alginate 
beads above.  Crosslinking solutions of 1 M potassium chloride for kappa carrageenan and 
1 M calcium chloride for gellan and iota carrageenan were produced by mixing the 
crosslinking agents in distilled water.  Beads were produced by adding 2 mL of the polymer-
drug solutions dropwise to 20 mL of the corresponding crosslinking solutions in an ice bath.  
All beads were left for 1 hour to harden in a fridge followed by filtration and oven drying 
overnight.  The beads where then stored in vials for analysis.  The polymer and drug solutions 
were mixed and added to the crosslinking agents quickly as the high polymer concentrations 
would causes the polymer solutions to gel quickly once removed from the heat source.     
3.2.4 Production of the alginate/sodium silicate  
 
Alginate/sodium silicate beads were also produced by the syringe droplet method.  Solutions 
were produced as follows.  A 6 % w/v alginate solution was produced by mixing the polymer 
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overnight.  Several concentrations of 4 %, 8 %, 12 %, 16% and 20 % w/v sodium silicate 
were produced by dissolving the powder in distilled water at 80 °C.  A 4 % w/v verapamil 
hydrochloride solution was produced by dissolving the drug in distilled water with mild 
heating.  To produce the polymer-ceramic-drug solution, 5 mL of the alginate and 2.5 mL of 
the verapamil hydrochloride solution were added and well mixed with mild heating.  This 
was followed by addition of 2.5 mL of the desired sodium silicate concentration.  The 
combination of materials was well mixed yielding a 10 mL solution composed of 3 % w/v 
alginate, 1% w/v verapamil hydrochloride along with 1 - 5% w/v sodium silicate.  A 1 M 
calcium chloride was prepared as the crosslinking agent.  To prepare the beads, 2 mL of the 
mixture was added though a syringe fitted with a 14 G needle to 20 mL of the calcium 
chloride solution and were crosslinked for a one hour period in a fridge.  Again, beads were 
filtered, oven dried and stored in vials for analysis.  
Blank beads in all of the above formulations were prepared and used as the blank sample in 
the drug loading and release studies for the drug content analysis with UV spectroscopy.        
3.2.5 Swelling of the polymer beads 
 
The polymer beads were analysed for their swell characteristics (Equation 3.1) (Nagasawa et 
al 2004).  1 gram of the beads was suspended in 10 mL of double distilled water and left to 
hydrate for 24 hours.  Excess water was removed by drying the beads on a paper towel and 
the hydrated mass was recorded.  The mean was determined from three independent studies 
and swelling (S) was determined by; 
S = W2 – W1 / W2  x 100  
Equation 3.1 – Hydrogel swelling 
 
Where W1 is the initial dry mass and W2 is the hydrated mass.   
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3.2.6 Drug loading and encapsulation efficiency  
 
The drug loading (DL) and encapsulation efficiency (EE) of the beads were determined by 
measuring the mass of drug lost to the crosslinking solutions (Equation 3.2a and b) (indirect 
DL method) (Mitra et al 2014).  A 1 mL sample was removed from the crosslinking solutions 
and spun down in eppendorf tubes to separate any solid polymer masses from the drug 
solution.  750 µL of the supernatant was removed and the verapamil hydrochloride content 
was assessed with UV spectroscopy (Jasco V-530) at 278 nm (Mahesh et al 2007) where a 
mass of drug was determined from a calibration curve of verapamil hydrochloride prepared 
by serial dilution.   
All drug samples were run against a blank sample obtained from the 1M crosslinking solution 
used to prepare the blank beads.   
DL and EE was determined by; 
DL = [(D1 – D2) / P] x 100 
Equation 3.2a – DL of the hydrogel beads 
 
EE = [(D1 – D2) / D1] x 100 
Equation 3.2b –EE of the hydrogel beads 
 
Where D1 is the initial mass of drug used in bead preparation, D2 is the mass of drug lost to 
the crosslinking solution and P is the mass of material used in bead preparation. All drug 
loading and encapsulation studies were performed three times where the mean average was 
determined ± standard deviation (SD).      
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3.2.7 Drug release  
The polymer beads were subject to in vitro release in PBS as the release media at 37 °C.  
50 mg of beads were suspended in 100 mL of PBS (pH 7.4) in 250 mL conical flasks plunged 
with polystyrene foam plugs and mixed in an incubator at 100 rpm.  1 mL samples were 
taken on an hourly basis over the first 12 hours of the drug release study followed by a daily 
basis.  For each 1 mL of release media removed, 1 mL of fresh PBS was replaced.  All 
samples were spun down in eppendorf tubes at 10,000 rpm for 1 minute using a centrifuge 
then 750 µL of the supernatant was analysed for verapamil content by UV spectroscopy at 
278 nm.  Blank beads were used as a control in all polymer formulations.  All drug release 
studies were performed three times where the mean average mass was determined ± SD.        
3.3 Results and Discussion 
3.3.1 Production of the Polymer beads  
The polymer beads were prepared by the syringe droplet method (Sugawara et al 1994), 
(Figure 3.1a, b and c).  All polymers, upon addition to the hardening bath form instant 
spherical gel beads though various gelling mechanisms.   The alginate, pectin and alginate-
sodium silicate beads form instant gels upon contact with the calcium chloride solution where 
the carboxyl groups (and oxygen atoms in sodium silicate complex) in the polymer backbone 
are externally crosslinked by divalent calcium ions though the egg box configuration.  When 
fabricating alginate and pectin into drug delivery systems, the degree of crosslinking within 
the beads can have a great influence on the gel strength.  Alginate with a high G/M ratio, high 
molecular weight and high concentration can produce strong beads with a high degree of 
crosslinking, however when too high, these solutions would become highly viscous making 
them difficult to process.  The 3 % solution was chosen since it was considered to be strong 
enough to produce strong hydrogels while still being processable into small microparticles to 
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be investigated in chapter 5.  As for the Gellan, Kappa and Iota carrageenan, the gel beads are 
formed though a sol-gel transition.  In their heated states, the polymer chains exist as a 
random entanglement of coils that upon cooling form double helical junctions forming the 
solid beads.  Addition of the relative ions, calcium for gellan and iota carrageenan and 
potassium for kappa carrageenan to the hardening solutions increases the gel strength by 
allowing the helical structures to pack tighter, forming stronger gels.  Kappa carrageenan has 
one sulfonate group in its structure and forms strong brittle gels whereas iota carrageenan has 
two sulfonate groups and forms weaker elastic gels.  The iota gels were of a more disordered 
structure than the spherical kappa carrageenan beads due to this weaker elastic gel structure.             
The polymers investigated in this study have been developed into a range of drug delivery 
hydrogels by the syringe droplet method for the encapsulation of many drugs, proteins and 
cells due to its mild and fast bead preparation procedure (Kim et al 2005, Xu et al 2007, 
Stabler et al 2001). Kishore et al (2012) produced an alginate hydrogel bead system for the 
encapsulation and controlled release of an antibiotic rifampicin where effective drug loadings 
and controlled release was achieved.  Pasparakis et al (2006) produced a verapamil 
hydrochloride loaded alginate/chitosan hydrogel system for controlled release applications 
where interactions between the negatively charged alginate and positively charged chitosan 
prolonged release from the beads.  Also, Mrunalini et al (2010) produced a gellan hydrogel 
system by ionotropic gelation for the controlled delivery of an acid soluble drug amoxicillin 
for delivery to the stomach.  Despite its fast and mild preparation procedure, the beads 
produced are too large for many drug delivery applications however the method provided a 
good procedure to assess the various materials abilities to load and release the encapsulated 
drugs.   
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Alginate Pectin 
  
Figure 3.1a – Alginate and Pectin beads formed by the syringe droplet method 
 
Gellan Kappa Carrageenan Iota Carrageenan 
   
Figure 3.1b – Gellan, kappa and iota carrageenan beads 
 
 
 
 
 
 
 
Figure 3.1c – Alginate/sodium silicate beads 
 
3.3.2 Swelling of the polymer beads 
 
The polymer beads were analysed for their swellability where the variation in the dry and 
hydrated masses were assessed (Table 3.1a and 1b).  Alginate, pectin and gellan all displayed 
Alginate Sodium Silicate 
 
5 mm 5 mm 
5 mm 5 mm 5 mm 
5 mm 
54 
 
similar swelling characteristics where the change in mass was approximately 50 % the initial 
weight of the dry beads.  Each of these polymers contains carboxyl groups in the backbone 
and gel though interactions between the carboxyl groups and calcium ions.  Since identical 
polymer and crosslinking concentrations were used to form the gels, it is believed that this 
similarity resulted in similar water uptakes of the alginate, gellan and pectin gel beads.    Iota 
and kappa carrageenan had slightly varied swelling characteristics where iota carrageenan 
took on a higher water mass than kappa carrageenan.  This is believed to be due to the fact 
that iota carrageenan forms a softer elastic gel with higher hydrophilic character since it 
contains two sulfonate groups, while kappa carrgeenan forms a stronger rigid gel with one 
sulfonate group, resulting in iota carrageenan taking on a higher mass of water.  
Swelling of hydrogel system is dependent on the density of the polymer network which is a 
result of a combination of the polymer concentration, cross linker concentration and 
crosslinking time used to produce the hydrogel. Surajit et al (2010) have investigated several 
formulation parameters in the production of calcium pectinate beads which included polymer 
concentration, crosslinking concentration and crosslinking time on the swelling rates where 
increasing these parameters generally decreases swelling due to the increased gel density.     
The addition of the sodium silicate into the alginate saw a fairly significant reduction of 
swelling in the hydrated mass compared to the alginate beads swelling of 54 %.  Upon 
increasing the silicate concentrations from 1 – 5 %, the beads saw a decrease in swelling from 
24 % <p 0.068> - 19 % <p 0.066> - 17 % <p 0.056> - 13 % <p 0.048) - 11 % <p 0.047> 
respectively.  Since this is the first swelling study on this organic-inorganic blend, the 
reduced water intake is believed to be due to several factors.  Firstly, it is seen from the image 
of the beads in figure 3.1c that the presence of the sodium silicate gives the beads a colour 
change from an off white in the alginate beads alone to an opaque white when the mineral is 
present.  The silicate is believed to interact with the alginate and calcium ions with a greater 
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degree of crosslinking increasing the gel strength, reducing the water intake compared to 
alginate alone.  Birdi et al (2012) discuss this interaction within the crosslinking mechanism 
producing stronger gels where the degradation rate was dramatically decreased and the colour 
change confirms some degree of interaction within the beads.  Also, silica has a nano-porous 
microstructure while alginate is highly porous.  Presence of the sodium silicate reduces the 
beads porosity, which can also reduce the water intake of the beads.  Finally it is known that 
inorganic materials do not swell to the degree that organic polymers do where the presence of 
the sodium silicate prevents the gel from swelling to the extent of the alginate beads.     
Polymer Alginate  Pectin Gellan Iota Cag Kappa Cag 
Swelling (%) 54  48  43  63  47  
St Dev 5.2 3.4 6.3 8.4 6.2 
RSD (%) 9.6 7.1 14.7 13.1 13.2 
Table 3.1a – Swelling of the polymer beads 
Na Silicate  1 % 2 %  3 % 4 %  5 %  
Swelling (%) 24  19  17  13  11  
St Dev 2.1 3.6 2.7 1.3 1.9 
RSD (%) 8.6 18.9 15.9 10 17.3 
Table 3.1b – Swelling of the alginate-sodium silicate beads 
3.3.3 Drug loading and Encapsulation efficiency of the polymer beads 
 
All polymer bead formulations were loaded with verapamil hydrochloride as a model drug.  
Verapamil hydrochloride was chosen as it is a small molecular weight hydrophilic drug with 
a positive charge like doxorubicin hydrochloride, a commonly used hydrophilic drug for 
TACE.    The DL and EE (Table 3.2a) of the polymer beads was determined by the indirect 
method where drug masses were determined from the drug lost to the crosslinking solutions 
by a calibration curve of verapamil hydrochloride (Figure 3.2).     From the polymer beads, 
DL of 9.7 %, 11.2 % and 8.7 % and EE of 29.2 %, 33.6 % and 26.1 % were determined for 
alginate, pectin and gellan respectively.  As for carrageenan, DL of 22 % and 17.5 % and EE 
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of 65.6 % and 52.7 % for kappa and iota carrageenan respectively were determined.  
Alginate, pectin and gellan are carboxylated polymers while carrageenan is a sulfonated 
polymer.  The DL (22 %) <p 0.025> and EE (65.6 %) <p 0.020> in kappa carrageenan was 
significantly higher compared to the carboxylated polymer alginate with a DL of 9.7 % and 
EE of 29.2 %.  The sulfonate groups give the polymer a stronger negative charger than the 
carboxylated polymers and they are stronger acidic functional groups that allow them to 
interact and bind strongly to positive basic drugs such as verapamil hydrochloride allowing 
higher drug retention.  As for the variations of DL and EE with kappa and iota carrageenan, 
higher DL and EE were determined for kappa carrageenan.   Kappa carrageenan forms strong 
gels while iota carrageenan forms gels that are soft and elastic, where the weaker gel can be 
less effective at retaining the drug during the production process.  Despite iota carrageenan 
having two sulfonate functional groups that potentially allows it to interact with higher 
masses of drug, kappa carrageenan’s stronger gel strength allowed it to retain larger masses 
of drug during the production process which makes it the favoured choice for drug delivery 
systems.    
The addition of the sodium silicate to the alginate saw some interesting trends (Table 3.2b).  
Firstly the DL compared to the 3 % alginate beads (DL 9.7 %), the presence of the sodium 
silicate in the hydrogel beads greatly increased DL at low concentrations, however this 
became less significant with increasing sodium silicate concentration within the 3 % alginate 
beads where a DL of 19.4 % <p 0.025>, 16.2 % <p 0.04>, 15.3 % <p 0.06>, 13 % <p 0.07> 
and 12.05 % <p 0.1> was determined for 1 – 5 % sodium silicate respectively. As for EE, the 
silicate significantly increased the efficiency as the silicate content increased where an EE of 
75.9 % <p 0.03>, 81.3 % <p 0.02>, 91.7 % <p 0.01>, 90 % <p 0.01> and 96.5 % <p 0.01> 
was determined for 1 – 5 % sodium silicate respectively.   
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For increasing silicate concentrations, decreasing drug loading and increasing encapsulation 
efficiencies were determined as detailed above.  The sodium silicate interacts with the 
crosslinking mechanism of the alginate and calcium ions producing a stronger gel with a 
higher degree of crosslinking.  Since the mass of drug within the varying material 
formulations stays constant while the mass of sodium silicate increases, the drug delivery 
system can see a general decrease in DL with the increasing material-drug ratio.  As for EE, 
the literature has reported that higher polymer concentrations prevents the internal drug from 
leaking out into the crosslinking bath during production due to the increased density and 
reduced porosity resulting in higher EE.  This is also seen with the alginate-sodium silicate 
beads where higher masses of silicate are believed to allow stronger crosslinks to be 
produced, preventing high masses of drug from diffusing out of the beads during production.  
Tavakol et al (2013) investigated the effects of polymer and crosslinking concentration on 
alginate-carboxylmethyl chitosan beads where higher concentrations displayed greater drug 
retention during the manufacturing process resulting in a greater EE.    
 
Figure 3.2 – Calibration curve of Verapamil Hydrochloride 
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Alginate  Pectin  Gellan  Cag (kappa) Cag (iota)  
DL (%) 9.7  11.2  8.7  22.0  17.5  
St Dev 0.6 0.7 0.5 0.6 0.6 
RSD (%) 6.2 6.3 4.5 2.7 3.4 
EE (%) 29.2  33.6  26.1  65.6  52.7  
St Dev 1.6 1.9 1.6 1.2 1.9 
RSD (%) 5.5 1.4 6.1 1.8 3.6 
Table 3.2a – DL and EE of the polymer beads 
1% Si 2% Si 3% Si 4% Si 5% Si 
DL (%) 19.4  16.2  15.3  13  12.0  
St Dev 0.3 0.5 0.7 0.3 0.2 
RSD (%) 1.5 3.1 4.6 2.3 1.6 
EE (%) 75.9  81.3  91.7  90.0  96.4  
St Dev 3.5 2.5 1.6 2.1 2.0 
RSD (%) 4.6 3.1 1.7 2.3 2.1 
 
Table 3.2b – DL and EE of the alginate/sodium silicate beads  
3.3.4 Drug release from the polymer beads  
The polymer beads were subject to in-vitro release in PBS where the percentage drug release 
is illustrated over an 8 hour period (Figure 3.3).    From the release studies, the polymer beads 
showed no sign of controlled release where the entire drug was released within the first hour.  
Particulate drug delivery systems produced from hydrogels are known to display rapid release 
rates due to their high porosity, fast swelling and degradation.  Also, due to their water loving 
characteristics, production of drug delivery systems for hydrophilic compounds that are 
capable of controlled release is known to be a challenging concept.  Drug delivery systems 
produced from these porous materials are often subject to the burst effect, where a 
formulation releases a large proportion of its cargo upon contact with the release media.  
Some studies such as the investigation by Mahesh et al (2007) have investigated methods to 
overcome this pitfall of hydrogel drug delivery systems by introducing stronger functional 
groups that have stronger interactions with the drug in an attempt to prolong the release rate. 
In this study, sulfonate groups were introduced to alginate nanoparticles to allow stronger 
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interactions with several positively charged drugs and release sustained over several weeks 
was achieved.  It was expected that the carrageenan beads would allow sustained release to be 
achieved since the molecules contain sulfonate groups in their backbones, however, although 
higher drug loadings were obtained, controlled release was not obtainable.   
 
Figure 3.3 – Drug release profile of the polymer beads in PBS illustrating percentage drug release.  Each point 
shows the mean average value taken from three independent studies ± SD. 
The alginate-sodium silicate blend saw an interesting trend in drug release rates compared to 
the single polymer counterpart where the percentage drug release over the first 12 hours and 
following 8 week period are illustrated (Figures 3.4a and Figure 3.4b).  By varying the 
concentration of sodium silicate from 1 % - 5 % w/v in 3 % w/v alginate the drug release rate 
was significantly decreased.  After 1 week of the release study, the 1 % w/v formulation 
released 100 % <p 0.98> of the drug whereas 90 % <p 0.36>, 43 % <p 0.03>, 28 % <p 0.02> 
and 25 % <p 0.02> for concentrations of 2 %, 3 %, 4 % and 5 % respectively, were released 
at the 1 week time point.  Over the first 12 hour period, the release rates vary for beads 
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containing 2 – 5 % sodium silicate opposed to the decreasing trend with increasing silicate 
content that is seen over the majority of the study.  This is believed to be due to varying 
masses of surface drug on the exterior of the beads resulting in the initial varied release 
patterns for the increasing sodium silicate concentrations, which can be a common 
observation in microencapsulation.   
The decrease in drug release rate is believed to be due to several factors.  Firstly, drug release 
of a hydrophilic drug is known to be mainly controlled by diffusion and addition of the 
sodium silicate into the hydrogel changes the gels microstructure reducing the beads porosity 
and increases the crosslinking density, making drug diffusion more challenging, thereby 
decreasing the drug release rate.  Also, both alginate and sodium silicate have negative 
charges allowing them to electrostatically interact with the positive charge of the drug, where 
the interaction is also believed to aid the decreased release rate.  Finally, inorganic materials 
are known to have slower swelling and degradation rates than organic polymers which are 
also believed to aid the decreased release rate.  By combining the polymer drug interaction 
with high crosslinking density and reduced porosity the alginate-sodium silicate blend 
provided an efficient material for the controlled release of the hydrophilic drug, which will be 
taken forward in the next chapter to be processed into a small microparticle carrier.  The idea 
of this material blend came from the work by Birdi et al (2012) where the alginate-sodium 
silicate beads were produced with the aim to reduce degradation rate of alginate hydrogels.  
With the addition of silicate, the beads were able to retain their shapes over a period of weeks 
where pure alginate beads degraded at a faster rate.  However, the blend has not been 
invested or produced into a microparticle based drug delivery system for controlled release 
applications.   
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Figure 3.4a – Percentage drug release profile of the alginate sodium silicate beads over the first 12 hours of the 
release study.  Sodium silicate concentrations of 1 – 5 % in 3 % alginate were investigated.  Each point shows 
the mean average value taken from three independent studies ± SD. 
 
Figure 3.4b – Percentage drug release profile of the alginate sodium silicate beads over the 8 week release 
period.  Each point shows the mean average value taken from three independent studies ± SD. 
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3.4 Conclusions  
 
This chapter reviewed various polymers that have seen extensive use in drug delivery where 
anionic polymers were investigated to encapsulate a small molecular weight hydrophilic 
drug.  Despite their frequent use as drug delivery matrices, the polymers where unable to 
offer any kind of controlled release characteristics.  Sulfonated polymers saw high drug 
loadings due to the stronger interactions between drug and polymer however these were not 
sufficient enough to give a sustained release rate.  A hybrid of the organic polymer alginate 
and inorganic sodium silicate was investigated.  This combination not only was able to yield 
high loadings and high entrapment efficiencies, but also allow the drug release rate to be 
varied from days to weeks by variation of the silica concentration.  The presence of the 
silicate allowed strong gel beads with reduced degradation, porosity and permeability 
resulting in controlled release of the small molecular weight hydrophilic drug. This material 
was therefore carried forward to produce into a microparticle delivery system to act as the 
drug delivery component of the PIP system for TACE.  Controlled release of hydrophilic 
compounds is an area that has seen limited success; therefore this organic-inorganic blend 
shows great potential for both this work and other drug delivery applications.        
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CHAPTER 4 
MICROPARTICLES FOR DRUG DELIVERY APPLICATIONS 
 
4.1 Introduction to Microparticle Drug Delivery Systems 
Following the advances in drug delivery technology, controlled delivery systems have seen 
extensive research to overcome pitfalls in traditional drug delivery methods.  Of such 
controlled release technologies, particulate based drug delivery systems offer an attractive 
administration method due to their spherical geometries and ability to tailor the drug release 
rate to a desired timeframe (Madhav et al 2011).  Particles also allow protection of drugs 
from environments such as those along the gastro intestinal tract, a concept that is vital in 
some oral dosage forms, where drugs can be rapidly degraded in the stomach acid or rapidly 
absorbed while in transit inside the small intestine.  They can also allow taste masking of foul 
tasting drugs, increasing patient compliance.  Controlled release also reduced the dosage of 
the drug which can result in a reduction of the number of side effects and reduce the 
frequency of treatments compared to traditional delivery.     
These drug delivery particles can range from tens of nanometres to large millimetre sized 
beads (Padalkar et al 2011) and are commonly in the form of solid spheres or capsules 
(Figure 4.1).  Spheres consist of a solid matrix type delivery system such as a crosslinked 
hydrogel network where drugs are distributed within the matrix core.  Capsules are systems 
composed of a liquid substance entrapped within a solid shell.  Oil soluble drugs are 
entrapped within a water soluble polymer shell and water based drugs are encapsulated 
within a hydrophobic polymer shell (Vauthier et al 2009).     
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Figure 4.1 – Commonly used particle systems in drug delivery.  Microspheres (left) which consist of a solid 
matrix and capsules (right) consisting of a liquid core encapsulated within a solid shell (Vauthier et al 2009).  
Spheres on the nano and microscale have seen extensive research in controlled release 
applications due to their solid structures allowing desirable release profiles of a variety of 
drugs to be achieved.   Cho et al (2014) encapsulated resveratrol, a poorly water soluble drug, 
into chitosan particles crosslinked with tripolyphosphate by a nozzle vibrating method.  
Particles produced were in the size range of 150 – 200 µm and controlled the release rate of 
the drug over 5 hours with encapsulation efficiencies up to 97%.  Soni et al (2010) 
encapsulated theophylline, a slightly water soluble drug into alginate particles by the water in 
oil external crosslinking method.  Depending on the formulation parameters, particles ranging 
from 10 – 20 µm where produced where the drug release was controlled over an 8 hour 
period with encapsulation efficiencies ranging from 70 – 90 %.  Dahtat et al (2013) produced 
insulin loaded alginate/chitosan beads crosslinked with calcium chloride followed by 
glutaraldehyde by the ionotropic gelation method where large beads, approximately 1.2 mm 
in diameter delivered insulin over an 8 hour period.   
Each drug has a minimum level where an effective therapeutic effect can be achieved along 
with a minimum toxicity point where unwanted side effects can arise (Figure 4.2).  The range 
in-between is known as the therapeutic window which can be narrow or wide depending on 
the drug (Padalkar et al 2011).  Pharmaceutical companies have taken to improve upon 
existing products by producing controlled release systems where the key aim is to control the 
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release of the drug within the therapeutic window for a desired period of time.  This is a 
region where the best effective therapeutic effect can be achieved.  Regions below this point 
(minimum therapeutic point) are non-effective where the region above this point (minimum 
toxic point) can result in toxic effects.  This method of drug delivery avoids overdosing, 
reduces the frequency of treatments, reduces the dose of drug required and avoids peaks in 
toxicity which can result in unwanted side effects.  This is particularly important for anti-
cancer drugs which can have high toxicities and narrow therapeutic windows.     
 
 
 
  
 
Figure 4.2 – The idealised controlled release profile.  In conventional methods, drugs can reach high toxicity 
levels resulting in unwanted side effects and has no control over release rate.   In controlled release 
formulations, the drug concentration can be controlled within the therapeutic window for a desired time period.   
Advantages of particulate based drug delivery include; tailoring size and surface 
characteristics, controlled release to increase efficiency and decrease side effects, site specific 
delivery, taste masking and drug protection and also increased patient compliance (Padalkar 
et al 2011).  Disadvantages include difficulty in producing uniform sized particles which can 
lead to irregular results in drug release.  Also, microparticles below 100 µm in diameter tend 
to display poor flow properties which can affect the dosage uniformity when producing a 
capsule or tablet.  Also small microparticles below 100 µm can be highly cohesive making 
THERAPEUTIC WINDOW 
Traditional  
delivery 
Controlled  
delivery 
Plasma 
conc 
Time 
Min toxic pt 
Min therapeutic pt 
  
TOXIC 
NO EFFECT 
66 
 
them liable to agglomeration and their high surface areas can result in rapid release rates of 
the encapsulated drug (Padalkar et al 2011).  
4.2 Particle production methods  
 
The choice of production method for micro/nanoparticles is highly dependent on the 
materials being processed and more importantly, the drug to be encapsulated.  For example, 
producing particles for water soluble drugs by the oil in water emulsion, a method that 
consists of a large volume of water can result in low entrapment efficiencies due to migration 
of the drug from the oil droplets to the continuous water phase.  Therefore the process 
method used requires some consideration.  Several methods that are suitable for 
encapsulation of hydrophilic compounds are discussed.   
4.2.1 Emulsions 
 
Emulsions have not only been used as an administration method for drugs but also as a 
particle production method (Figure 4.3).  Emulsions consist of three main ingredients, the 
dispersed phase, the continuous phase plus a surfactant/emulsifier.  The dispersed phase 
forms small droplets that are dispersed throughout a continuous phase when the emulsion is 
agitated by methods such as mixing or sonication.  Surfactants are dissolved within the 
continuous phase and stabilize the dispersion of droplets, allowing them to remain in a 
uniform state (Billany).  Depending on the ingredients used within the emulsion, several 
types can be produced.  Water-in-oil (w/o) emulsions consist of water droplets dispersed 
throughout an oil continuous phase while oil-in-water (o/w) emulsions are oil droplets 
dispersed throughout a water phase.  Multiple emulsions consist of primary emulsions within 
secondary emulsions and are classed as water-in-oil-in-water (w/o/w) or oil-in water-in oil 
(o/w/o).  For the former, a w/o is emulsified in a secondary water phase and for the latter, a 
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o/w emulsion is emulsified in a secondary oil phase.  For water soluble drugs, w/o and w/o/w 
emulsions have proven to produce particles with high drug loadings due to the drugs poor 
solubility in the continuous phase (Billany).  When using w/o/w emulsions to manufacture 
particle systems for hydrophilic drugs, the mixing speed is an important factor since if set to 
high, the high shear can force the water droplets in the primary w/o emulsion to the external 
water phase, resulting in low entrapment efficiencies.   
The general process of particle formation by the emulsion process involves dispersion of a 
polymer solution into to an appropriate continuous phase containing the surfactant under 
mixing or sonication.  Hydrophobic polymers such as PLGA are dissolved in 
dichloromethane and are commonly emulsified in a continuous phase of water containing 
PVA as a surfactant while hydrophilic polymers such as alginate are commonly emulsified in 
isooctane containing span 80 as the emulsifier.  The polymer is mixed at a set speed to obtain 
particles of a desired size where faster mixing speeds result in droplets of a smaller size.  The 
droplets are then formed into solid particles by a hardening process where for polymers such 
as PLGA, solid particles are formed by evaporation of the dichloromethane and for polymers 
such as alginate, the relevant chemical crosslinking agent is added to the emulsion inducing 
crosslinking.  The obtained solid particles are then separated from the emulsion by filtration 
or centrifugation followed by washing in an appropriate solvent. The obtained slurry is then 
dried under atmospheric conditions, by freeze drying or under vacuum.   
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Figure 4.3 - Formation of particles by the emulsion method.  Firstly, the polymer is dispersed into the 
continuous phase containing surfactant under mixing followed by addition of crosslinker (for polymers requiring 
crosslinking).  Then, droplets are left to harden followed by separation, washing and finally drying. 
As mentioned above, emulsions require addition of surfactants to stabilize the water and oil 
phases.  Without presence of surfactants, droplets would be attracted to one and other 
forming aggregates, a process known as coalescence (Billany 2007).  The primary job of 
surfactants is to avoid this by the application of a protective layer around the surface of the 
droplets that will cause approaching droplets to repel and therefore, remain uniformly 
distributed within the continuous phase (Billany 2007).  This also decreases the surface 
tension between the water and oil phases allows the breakdown of the dispersed phase into 
droplets to be an easier process, which can also result in the formation of smaller particles.  A 
wide variety of surfactants are available where the best choice can generally come from 
practical experience with emulsion science however, the type of emulsion used can eliminate 
many surfactants since they will not be soluble in the continuous phase.  The choice can be 
further narrowed by use of the hydrophilic lipophilic balance (HLB) (Figure 4.4).  The HLB 
is a measure of the hydrophilic and lipophilic groups in the surfactant and assigns each group 
a number where a lower numbers are oil soluble and higher numbers are water soluble 
(Billany 2007).  
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Figure 4.4 – HLB values for various emulsifying agents 
 
The formulation process of particles though emulsions has various processing parameters 
including polymer concentration, surfactant concentration, mixing speed, crosslinker 
concentration, crosslinking time and ratio of dispersed phase to continuous phase.  The 
general effect of these on particle size and formation is shown in Table 4.1.  
Parameter Effect on size Effect on morphology 
Polymer concentration Increasing increases particle 
size due to higher viscosity 
At high conc, clumpy 
particles can be formed 
Surfactant concentration Increasing decreases particle 
size due to reduced surface 
tension 
When inefficient 
agglomerated particles are 
formed 
Mixing speed Increasing decreases particle 
size due to increased shear 
Irregular sizes can be formed 
at low speeds 
Crosslinking concentration Increases slightly decreases 
particle size due to denser 
crosslinking 
When inefficient particles 
can lose their structure 
during separation process 
Crosslinking / hardening time As with crosslinking 
concentration 
As with crosslinking 
concentration 
Dispersed: Continuous Increasing increases particle 
size due to increased 
dispersion concentration 
When in too high  
agglomerated forms can be 
produced 
 
Table 4.1 – General effect of emulsion processing parameters on particle size and formation 
 
Hydrophilic  
Lipophilic  
Solubilizing agents (15 -18) 
Detergents (13 – 15) 
o/w emulsifiers (8 – 16) 
Wetting agents (7-9) 
w/o emulsifiers (3 – 6) 
Antifoaming agents (2 – 3) 
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The effect of the above parameters has seen extensive research in particle production.  Soni et 
al (2013) investigated the effects of polymer concentration on the formation of alginate 
microspheres by the w-o emulsion.  Increasing polymer concentrations from 2 %, 4 % and 
8 % saw an increase in particle size from 7.6, 8.2 and 12.5 µm.  A study by Jose et al (2011) 
investigated the effects of drug concentration, mixing speed and emulsifier concentration of 
the production of chitosan particles by the emulsion method.  Increasing the mixing speed 
from 1000, 1500 and 2000 rpm decreased the particle size from 12.7, 8.6 and 5.2 µm.  Also 
increasing the emulsifier (Span 80) concentration from 0.5 %, 1 % and 1.5 % w/v decreased 
particle size from 10.3, 8.6 and 7.2 µm.  The choice of oil used as the continuous phase can 
have a large effect on the size of particles produced even when identical parameters such as 
mixing speeds are used.  Particles produced using mineral oil as the continuous phase can 
give larger particles than those produced in isooctane due to the higher viscosity of the oil 
phase.   
4.2.2 Ionic gelation/polyelectrolyte formation 
 
One pitfall of the emulsion method is the requirement of organic solvents and high energy 
inputs making them undesirable for some drugs.  Ionic gelation, also known as 
polyelectrolyte formation is a mild particle formulation process where microparticles are 
formed in an aqueous environment with mild processing methods (Vauthier et al 2009).  A 
polymer is added to its corresponding gelling agent in dilute solutions under mixing.  This 
forms a pre-gel phase where the polymer chains react with the gelling agent forming small 
clusters.  By addition of a second polysaccharide of opposite charge to the initial polymer, the 
clusters are stabilised by formation of a complexation between the two oppositely charged 
polysaccharides (Vauthier et al 2009).  In the production of alginate particles, alginate is 
added to solutions of calcium chloride in dilute solutions forming the pre gel phase which is 
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then stabilised by addition of a cationic polymer such as chitosan (De et al 2003).  It is 
possible to form particles by simply mixing the two oppositely charged polymers in dilute 
solutions however, use of the pre gel phase is known to allow more compact gels to be 
obtained (Rajaonarivony et al 1993).  Although mild processing conditions can allow 
sensitive drugs to be encapsulated, particle size is difficult to control.  Also, the method is 
limited to dilute polymer solutions, which can give gels with limited crosslinking densities, 
therefore giving limitations to their controlled release applications.  Key process parameters 
are the concentrations of the oppositely charged polymers and if used, the crosslinking agent 
in the pre gel phase.  
This approach has also been used as a coating technique known as the layer-by-layer 
approach. Particles can be coated with alternating layers of oppositely charged polymers 
though electrostatic interactions with the goal of prolonging release rate and reducing the 
burst effect.  Several formulations consisting of coating particles with an oppositely charged 
polymer have known to reduce drug release rate.  Lui et al (2013) investigated this method to 
coat liposomes with alternating layers of alginate and chitosan that was attracted to the 
oppositely charged surfaces, where the drug release of vitamin E was sustained compared to 
un-coated liposomes.     
4.2.3 Spray Drying 
 
Spray drying (Figure 4.5), despite being a drying technology has been used for the 
encapsulation of drugs into polymeric microparticles.  The general process allows the 
formation of a liquids, emulsions, dispersions and gels into dry powders in a single step 
which is easier to scale up than emulsions and ionic gelation methods (Richardson et al 
2002).   
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Figure 4.5 – The Buchi B-290 mini spray dryer.  Particles are formed by pumping a solution to a nozzle where 
it is atomized into small droplets.  The droplets are then rapidly dried in a drying chamber where fine particle 
masses are removed by a cyclone and the product is collected.  Compressed nitrogen is frequently used as the 
drying gas (Buchi UK) 
The spray drying process involves three main stages.  Firstly the material to be spray dried is 
fed through to the spray drying unit to a nozzle of a desired size where the liquid is atomized.  
The atomization process is an important one since it determines the size of droplets produced 
and therefore the particle size.  Atomization occurs when a gas under high pressure travels 
through a tube with a reduced diameter causing the gas to increase in momentum.  This 
increase in momentum creates a pressure drop causing the feed to exit the atomizer as a spray 
of droplets which are rapidly dried in a drying chamber at a desired temperature where solid 
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particles are formed (Richardson et al 2002).  Fine particle masses are separated in a cyclone 
and the product is collected in a collection vessel at the end of the process.   
Several types of atomizers are available which are based on being a single fluid, twin flow or 
rotary disc atomizers (Figure 4.6).  Single fluid atomizers force the liquid out under high 
pressure though an orifice creating the fine spray.  They are the most energy efficient but can 
block easily due to the fast evaporation rate of the liquid (Billany 2007, Richardson et al 
2002).  Twin fluid nozzles involves flow of two fluids, the polymer to be spray dried in an 
interior nozzle and the drying gas though an exterior section where compressed air or 
nitrogen is frequently used (Billany 2007, Richardson et al 2002).  Rotary disk atomizers 
involve the liquid being fed to rotating discs under high speeds of 10,000 to 30,000 rpm.  The 
feed is fed from the disc to the exterior of the atomizer where it becomes thinner and is 
eventually ejected from the atomizer as a fine spray of droplets.  Rotary disks are commonly 
used on the industrial scale but require drying tanks with relatively large diameters (Billany 
2007 and Richardson et al 2002).   
 
 
 
 
 
 
Figure 4.6 – Atomizers used in spray drying.  Single flow (left), Twin flow (middle) and rotating disk (right) 
Gas 
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Feed Feed 
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Once atomized, the droplets are sprayed into a drying chamber where solid particles are 
formed by evaporation of the solvent which can take several to tens of seconds depending on 
the volatility of the solvent used to dissolve the material (Richardson et al 2002).  Initially the 
droplets velocity and direction of flow are that which is provided by the atomizer.  It is 
necessary for the gas to be well mixed with the droplets allowing evaporation to initiate and 
influence the movement of droplets in the drying process and preventing material sticking to 
the sides of the drying chamber (Richardson et al 2002).  The air flow within the drying 
chamber can operate in a co-current or counter-current flow pattern.  In co-current flow, the 
air flows in the same regime as the atomized liquid.  This flow regime has the benefit of low 
product temperatures which is useful for heat sensitive materials however they have relatively 
low efficiencies.  In counter-current flow regimes, the spray from the atomizer initially flows 
in the opposite direction to the flow of gas which then falls due to gravitational force causing 
the material to resume flow in the direction of the gas.  Co-current flow regimes have higher 
efficiencies however are limited due to degradation of heat sensitive products (Richardson et 
al 2002). 
Advantages of spray drying include a rapid production process in one step, ease to scale up, 
the process is less dependent on the hydrophilicity or hydrophobicity of the raw materials, 
high encapsulation efficiencies can be achieved, less residual solvent is left in the dried 
product and the process can operate under sterile conditions.  The main drawback of spray 
drying is the equipment is bulky and expensive and the process can be difficult for heat 
sensitive drugs such as proteins.    
Several of the critical processing parameters in spray drying that effect particle size and 
morphology are the polymer concentration, flow rate and inlet temperature (Estevinho et al 
2013).  Generally increasing each parameter increases the size of the microparticles produced 
(Bowey 2009).  For water soluble polymers concentrations are typically 2 – 3 % w/v.  On 
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increasing the concentration, the increase in polymer viscosity makes atomization a more 
challenging process resulting in larger particles of broader size distributions being produced 
(Lorenzo-Lamosa et al 1998).  Concentrations higher than 3 % can be too viscous to be fed 
and atomize resulting in inefficient production rates and uniform particle size and geometries.  
Also increasing polymer concentration is known to increase the overall production yield since 
larger particles are formed resulting in less product being lost to the cyclone.  Feed rates for 
water soluble polymers are dependent on the concentration to be spray dried where for 
alginate at 2 % w/v flow rates approximately 5 - 10 mL/min have been reported.  Like with 
increased polymer concentrations, increasing feed rate increases particle size.  However, 
when the feed rate is too high, atomization is an inefficient process resulting in large amounts 
of material sticking to the drying chamber where clumpy products are obtained in the 
collection vessel (Estevinho et al 2013).  Operating temperatures are dependent on the 
material and also, the drug to be spray dried.  For natural polymers, inlet temperatures of 
150 °C have been a frequently reported within the literature.  Despite high inlet temperatures 
being required, outlet temperatures (the temperature of the drying chamber) are lower than 
that of the inlet temperature. Also, the air-water interface is only exposed to this temperature 
for a fraction of a second since evaporation begins the instant the droplets are atomized which 
is a rapid process, resulting in fast cooling of the droplet. Therefore, drugs at the interior of 
the droplets are not exposed to the high tempratures (Desai et al 2005).    
A study by Roberto et al (2013) investigated the encapsulation of mangiferin into pectin and 
chitosan particles using the Buchi B-290 mini spray dryer.  Polymer concentrations of 1 % 
w/v, an inlet temperature of 160 °C and flow rate of 6 mL/min were the operating conditions 
used to produce the particles.  Bowey (2009) investigated encapsulation of insulin into 
alginate particles with the Buchi B-290 mini spray dryer.  Polymer concentrations of 1 – 2 % 
w/v, inlet temperature of 150 °C and a flow rate of 5 mL/min were the investigated 
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parameters.  Particle sizes of 1.2 and 1.6 µm were found for 1 and 2 % alginate respectively 
and yields of 15 and 30 % were obtained for 1 and 2 % respectively.  Another study by 
Mobus et al (2012) produced alginate particles at 1 % w/v with several other polymers 
blended in at operating conditions of 145 °C and flow rate of  7 mL/min using a Buchi B-190 
mini spray dryer.  Spherical particles were formed ranging from 2.9 – 5 µm depending on the 
polymers blended with the 1 % alginate.   
4.3 Particle Characterization methods 
4.3.1 Imaging 
 
Imaging methods provide information about a particulate systems size and morphology.  
Light microscopy is a quick effective imaging method that allows a population of 
microparticles from several microns in size to be viewed.  In the case of hydrogel based 
microparticles, the dry particles are best viewed when suspended in water where they swell 
allowing a clear image to be viewed. Detailed characteristics such as the size and shape of 
particles from 5 – 10 µm in diameter can be easily viewed and images can be captured with 
an attached digital camera.  Fluorescent microscopes are useful tools in analysing particles 
containing dyes such as coated particles.  Also, when formulating emulsion systems light 
microscopes can be useful in overcoming issues in stability such as insufficient surfactant 
concentrations.   
When formulating sub-micron sized particles, light microscopy is not sufficient enough to 
provide a detailed image.  SEM produces images by a source of electrons being accelerated 
down a column though a number of lenses and apertures to produce a focused beam that is 
used to scan a specimen.  As the electrons scan the specimen, secondary electrons are 
produced which are collected by a detector to produce an image of the sample at a higher 
resolution than that of light microscopes.  Care must be taken when imaging with SEM as 
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some polymers used to fabricate microparticles can be ruptured by the electron source during 
imaging.  SEM is particularly useful for sub-micron size particles and allows a detailed view 
of the particles microstructure.  However they are large and costly to operate and samples 
must be placed on adhesive discs and coated with gold or platinum prior to viewing. 
4.3.2 Particle sizing  
 
Particle size is an important physical characteristic of a microparticle system.  Size is a factor 
that governs the drug release rate where small particles release drugs faster than larger 
particles due to their increased surface area.  Many applications will require a particular size 
with narrow size distributions.  Drugs for pulmonary delivery require particles of 1 - 5 µm in 
diameter to allow drugs to be delivered deep to the alveoli region of the lung which contains 
a high surface area for the drugs to enter the system circulation.  Also, in the case of this 
work microparticles of a size calibrated to a patient’s blood vessels are needed to effectively 
target and embolize the tumour.   
One common method of obtaining this information is though laser diffraction.  This 
technique measures how a particle scatters light as a laser beam is passed through a 
particulate dispersion.  Large particles will scatter the light at small angles and smaller 
particles will scatter light at larger ones.  Data is then collected where the average size and 
size distribution of the particles are determined by Mie’s theory of scattering light.   Optical 
properties such as refractive index are required in this theory in order to produce accurate 
data.  Other theories such as the Fraunhofer approximation assume particles to be completely 
opaque and allow a simpler method that does not require optical properties.  It can give 
accurate size data on large particles that are opaque however can lead to inaccurate results for 
particles below 10 µm or that are transparent.  Particle size by laser diffraction is commonly 
reported as a volume distribution by a plot of particle size and % volume that details the 
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distribution of a particulate population.  Particle sizes typically reported are the mean particle 
size (D50), the size below 10 % of the population (D10) and the size greater than 90 % of the 
population (D90) (Figure 4.7).  
 
 
 
 
 
Figure 4.7 – A typical laser diffraction particle size plot showing the volume distribution of a particle 
population.  The positions of the D10, 50 and 90 are illustrated.  
4.3.3 Drug loading, Encapsulation and Drug release 
 
DL and EE are determined by treating a known mass of particles suspended in water or an 
appropriate solvent though methods such as sonication to remove the encapsulated drug 
contents.  The solution is analysed with methods such as UV spectroscopy to determine the 
mass of drug within the particles by use of a calibration curve of the encapsulated compound.   
DL is the ratio of drug released from a unit mass of particles, for example if 100 mg of 
particle release 10 mg of drug, the DL is 10 %.  EE is the amount of drug encapsulated into a 
unit of particles over the initial loading of drug, for example if 100 mg of drug is used to 
produce a batch of particles and 50 mg is encapsulated, the EE is 50 %.  Ideally DL and EE 
are required to be as high as possible to lower the mass of material used in a dosage form, and 
to reduce loss of drug during the production process.  Drug release is termed as being in-vitro 
or in-vivo where the former is performed in chemicals simulating a particular environment 
and the latter in a live specimen.  Samples are taken on a regular basis to monitor the rate at 
Volume 
distribution 
(%) 
Size (µm) 
D90 
D10 
D50 
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which a drug diffuses out of a polymer matrix allowing a release profile to be plotted 
showing how the drug is released.  Spectroscopy techniques such as UV spectroscopy are 
useful tools for analysing the absorbance of a drug solution where a mass of drug can be 
determined from a calibration curve prepared by serial dilution.       
4.3.4 Swelling  
 
Swelling of polymer materials, particularly hydrogels is an important factor which 
contributes to the drug release rate.  This can be a measurement of change in diameter or 
mass of the particles.   Swelling is determined by a known mass of dry particles being added 
to water for a set period of time to induce swelling.  The gels are then removed where excess 
water is removed and the hydrated masses are then recorded from which a swelling ratio, or 
intake of water can be determined.  Swelling rates can vary from hydrogels of varying density 
caused by variations in process conditions such as polymer concentration, crosslinking 
concentration, molecular weight and crosslinking time.   
4.3.5 Zeta potential  
 
When a particle system is dispersed in a liquid medium, two layers of ions can exist 
surrounding the solid particles.  These are made up of an inner layer (stern layer) and an outer 
layer (diffuse layer).  Ions in the stern layer are held tightly by the solid particle whereas the 
ions in the outer layer are less associated with the particle.  The potential at the boundary of 
these layers is known as the zeta potential which can have a large effect on how a particulate 
system behaves and is frequently used to assess the stability of a particulate system.  A 
typical zeta potential value for microparticle drug carriers can range from - 100 mV to + 100 
mV where zeta potential values below – 30 mV and above + 30 mV will generally display a 
stable dispersed particle system where the particles will give a uniformly dispersed 
population.  When a particulate dispersion has a low zeta potential, there will be less charges 
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to repel adjacent particles causing the particles to aggregate forming large clusters.  The pH 
of a solution will have a large effect of the zeta potential of a particle suspension.  Particles 
that display a strong negative charge suspended in a solution with a high alkali content can 
acquire a higher negative charge, likewise for particles with a positive chare in a highly acidic 
medium the system will display a higher positive charge.  An unstable aggregated particle 
system is undesirable in drug delivery applications since the irregular sized clusters will have 
various drug release properties due to the variance in cluster/particle size and surface area.   
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CHAPTER 5 
PRODUCTION OF THE DRUG DELIVERY PARTICLES 
5.1 Introduction 
In this chapter, the alginate-sodium silicate blend previously investigated was developed into 
a microparticulate drug delivery system where verapamil hydrochloride was encapsulated.  
Microparticles offer an attractive method of delivering drugs to the body due to their small 
spherical geometries, allowing uniform and reproducible release patterns to be achieved.  
Their small size also allows administration by the parental route, allowing controlled release 
of an encapsulated drug.  Particles can also allow protection of encapsulated compounds 
along with controlled release by diffusion of the drug though a polymer matrix.  Two 
production methods were investigated, the water in oil emulsion and spray drying.  Critical 
process parameters for each method were investigated where the parameter’s effects on 
particle size and form were analysed with light microscopy, Scanning Electron Microscopy 
(SEM) and laser diffraction.  Along with the morphologies of the particles, the DL, EE and 
drug release characteristics were analysed by UV spectroscopy.   More specifically, the 
objectives of this section were to; 
 Investigate production processes for the development of crosslinked alginate particles 
suitable for the encapsulation of hydrophilic drugs.   
 Explore the effects of the critical processing parameters on particle formation for the 
chosen methods.  
 Characterize the developed particle systems for their size, shape, DL/EE and drug 
release properties.   
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5.2 Materials 
  
Alginate sodium salt (ID # 180947, MW 120,000 – 190,000 g/mol, viscosity (1 %) 15-20 cP, 
M/G 1.56), sodium silicate, Span 85 and Tween 85 were supplied by Sigma Aldrich UK.  
Calcium chloride dihydrate, isooctane, hexane and phosphate buffered saline (PBS) was 
supplied by Fisher Scientific UK. Verapamil hydrochloride was supplied by Cambridge 
Bioscience.  All aqueous solutions were produced with distilled water.   
5.3 Methods  
5.3.1 Water in oil emulsion method  
Alginate particles were produced by the w-o emulsion method similar to the method 
investigated by Soni et al (2010).  The formulations produced are listed in Table 5.1 where 
effects of alginate concentration (formulations A1 – A3), mixing speed (formulations M1 – 
M3), calcium chloride concentration (formulations C1 – C3), surfactant concentration 
(formulations S1 – S3) and sodium silicate concentration (formulations Si1 – Si3) were 
investigated.   
The dispersed phase was prepared by producing various alginate concentrations by dissolving 
the polymer in distilled water over night.  A continuous phase was produced by mixing 
various concentrations of Span 85 and Tween 85 in a ratio of 0.8: 0.2 into 100 mL isooctane 
in a 200 mL beaker.  10 mL of the alginate solution was added to the continuous phase under 
homogenization (IKAT25 Fisher Scientific) at various speeds and mixed for 30 seconds 
where the speed was then reduced to 3000 rpm.   2 mL calcium chloride at various 
concentrations were then added and mixed for an additional 5 minutes.  The emulsions were 
left at 4 °C for 20 minutes to allow the particles time to crosslink.  Emulsions were then spun 
in a centrifuge at 10,000 rpm for 5 minutes, washed with hexane and re-spun twice.  Finally, 
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a third washing was performed using distilled water and the particles were collected by 
suction filtration then dried in an oven and stored for analyses.   
For the alginate-sodium silicate particles, equal volumes 6 % w/v alginate and various 
sodium silicate concentrations were mixed then processed as above.   
Alginate                
(% w/w) 
Mixing 
speed (rpm) 
CaCl2                          
(M) 
Surfactants   
(% w/w) 
Na Silicate 
(% w/w) 
A1 1 15000 1 5 - 
A2 2 15000 1 5 - 
A3 3 15000 1 5 - 
M1 2 5000 1 5 - 
M2 2 15000 1 5 - 
M3 2 25000 1 5 - 
C1 2 15000 0.25 5 - 
C2 2 15000 0.5 5 - 
C3 2 15000 1 5 - 
S1 2 15000 1 1 - 
S2 2 15000 1 3 - 
S3 2 15000 1 5 - 
Si1 2 15000 1 5 1 
Si2 2 15000 1 5 2 
Si3 2 15000 1 5 3 
Table 5.1 – Investigated processing parameters in the w-o emulsion for microparticle formation. 
5.3.2 Spray Drying 
 
A spray drying method was also investigated for production of alginate particles using a 
Buchi B-290 mini spray dryer fitted with a twin fluid nozzle operating with a co-current flow.  
A method was produced based on the training provided by the equipment supplier (Buchi 
UK).  The processing parameters investigated in the study are listed in Table 5.2.  The effects 
of alginate concentration (A1 – A3), inlet temperature (T1 – T3), flow rate (F1 – F3), sodium 
silicate concentration (Si1 – Si3), verapamil hydrochloride concentration in alginate  (V1 – 
V3) and verapamil hydrochloride concentration in alginate-sodium silicate (VSi1 – VSi3) on 
particle formation were investigated.   
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Various alginate solutions were prepared by dissolving the polymer in distilled water.  The 
desired inlet temperature and flow rate was set and the aspirator was set at 100 % for all runs. 
Compressed nitrogen was used as the drying gas and was supplied at 5 bar for all runs.  The 
gas supply was activated followed by activation of the aspirator.  The inlet temperature was 
activated and allowed to reach the set temperature.  Once the temperature was reached, the 
alginate solution was fed to the dryer unit at the set flow rate initiating particle production.  
Once all the processing material had been spray dried, the tubing and nozzle was cleaned by 
pumping distilled water for 10 seconds.  The pump was switched off followed by 
deactivation of the inlet temperature, then the compressed nitrogen gas and finally the 
aspirator.  The equipment was allowed to cool until an inlet temperature setting gave a 
reading of 90 ºC before being dismantled for particle collection, since some particle of the 
equipment would be too hot to handle immediately after drying.  The spray dried particles 
were then crosslinked by mixing a 10 % w/v mass of particles in 1 M calcium chloride for 10 
seconds and leaving to crosslink at 4 °C for 20 minutes.  The resulting particles were then 
collected by suction filtration and washed with distilled water.  The alginate-sodium silicate 
particles were produced by mixing equal volumes of 6 % alginate with various silicate 
concentrations and processing as above. 
Drug loaded alginate particles were produced by mixing equal volumes of alginate and 
verapamil hydrochloride which was processed as above.  As for the alginate-sodium silicate 
particles, alginate and verapamil hydrochloride were well mixed with mild heating in a ratio 
of 1: 0.5 which was then followed by addition of the sodium silicate in a ratio of 1: 0.5 to the 
volume of alginate used.  The mixture was well mixed and processed as above. 
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Alginate                
(% w/w) 
Inlet Temp 
(°C) 
Flow rate 
(mL/min) 
Na silicate 
(%/w/w) 
VHCL       
(% w/w) 
A1 2 150 10 - - 
A2 3 150 10 - - 
A3 4 150 10 - - 
T1 3 120 10 - - 
T2 3 150 10 - - 
T3 3 180 10 - - 
F1 3 150 5 - - 
F2 3 150 10 - - 
F3 3 150 20 - - 
Si3 3 150 10 1.5 - 
Si1 3 150 10 3 - 
Si2 3 150 10 4.5 - 
VA1 3 150 10 - 0.5 
VA2 3 150 10 - 1 
VA3 3 150 10 - 2 
VSi1 3 150 10 1.5 0.5 
VSi2 3 150 10 1.5 1 
VSi3 3 150 10 1.5 2 
Table 5.2 – Parameters investigated for the spray dried particles.   
5.3.3 Particle Characterization  
 
5.3.3.1 Light microscopy 
 
Particles characterised by light microscopy (Olympus BH2) were suspended in water then 
several drops of the dispersion were placed on a microscope slide then covered with a cover 
slip.  The particles were viewed at X 20 magnification where images were taken with an 
attached digital camera.    
5.3.3.2  SEM 
 
Particles analysed with SEM (JEOL 6060) were mounted on an aluminium SEM stub and 
subsequently coated with platinum using a sputter coater. The samples were coated for 2 
minutes with a deposition pressure of 20 bar depositing a layer of platinum equivalent to 150 
Angstrom.    
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5.3.3.3 Particle sizing 
 
The particle size and size distribution were analysed by laser diffraction using wet dispersion 
on the Malvern Mastersizer 2000.  A solution of 0.1 % Tween 85 was used as the dispensing 
media with a particle concentration of 10 % w/v which was added to the sample dispersion 
unit under mixing at 2000 rpm using a plastic pipette.  Five measurements were preformed 
per formulation where each measurement was subject to a run time of 10 seconds.  The D10, 50 
and 90 particle sizes along with the particle size distribution curves were reported.     
5.3.3.4 Drug loading and Encapsulation efficiency  
 
To determine the drug loading and encapsulation efficiencies, 50 mg of particles were 
suspended in 50 mL PBS and sonicated for 4 hours.  1 mL was removed and analysed as 
detailed in chapter 3.   
5.3.3.5 Drug release  
 
The particles were subject to in-vitro release.  100 mg of particles were suspended in 100 mL 
PBS in 250 mL conical flasks plugged with polystyrene foam plugs and mixed at 100 rpm at 
37 °C in an orbital shaker.  Samples were taken as in discussed in the chapter 3.   
5.4 Results and Discussion  
 
5.4.1 Water in oil emulsion method  
 
The w-o emulsion was investigated as a microparticle production method for the alginate-
sodium silicate blend.  Critical processing parameters of alginate concentration, mixing 
speed, crosslinking concentration, surfactant concentration and the ratio of alginate: sodium 
silicate were investigated and analysed by light microscopy, laser diffraction along with the 
DL/EE and drug release by UV spectroscopy.    
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5.4.1.1 Effect of alginate concentration on particle size and formation 
 
The effect of alginate concentration on the particle size and form was investigated and 
analysed with light microscopy and laser diffraction where concentrations of 1 %, 3 % and 
5 % w/v were explored.  Increasing the polymer concentration from 1 % to 5 % had several 
effects on the particle’s size and morphology as illustrated in the light microscopy images 
(Figure 5.1) and particle sizing data (Figure 5.2 and Table 5.3).  Firstly, upon increasing 
polymer concentration, larger particles with increased size distributions were obtained where 
average sizes of 4.5, 9.7 and 55.8 µm were determined from 1 %, 3 % and 5 % alginate 
respectively.    Also, particles produced with 1 % alginate appeared to be in a clustered order 
compared to those prepared with 3 % and 5 % alginate solution.      
During the emulsification process, the dispersed phase is broken down into droplets which 
form the templates for the produced particles.  Increasing polymer concentration results in a 
larger particle size due to the increase in polymer viscosity.  This is due to the increased 
viscosities of the dispersed phase being a more challenging process to be broken down into 
the droplets that form the solid microparticles.  In some cases, increases in mixing speed will 
be required to provide adequate shear to form spherical particles of a desired size.     This was 
particularly true for particles produced with 5 % alginate where the average size and size 
distribution was much larger than particles produced with 1 % and 3 % alginate solutions due 
to the higher viscosity.  To allow a more uniform size range to be produced with 5 % 
alginate, the homogenization speed or time could be increased to allow further breakdown the 
droplets, although the homogenization time was deliberately kept short in order to minimise 
drug loss.  As for the clustered particles produced with 1 % alginate, reduction in polymer 
concentration results in smaller particles being produced due since the polymer is easier to 
break down during the mixing process.  Small particles are known to aggregate, as seen with 
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the 1 % alginate particles.  It would have been worth assessing the zeta potential of the 
particles produced with the varying alginate concentrations to assess effect of alginate 
concentration on particle stability.  The alginate particles are likely to display a negative 
charge which could increase with increasing alginate concentration.  This increased charge 
could attract more ions lowering the zeta potential (below – 30mV) producing a system with 
greater stability, where the 1 % alginate particles could possibly not be attracting a sufficient 
concentration of ions to allow the particles to stay uniformly distributed.  Since imaging was 
conducted in distilled water, effects in acidic and alkali conditions would need to be 
addressed to assess the effect of pH on the stability of the system. 
Very few studies tend to investigate production of small microparticles using water soluble 
polymers by the emulsion method with concentrations greater than 2 % w/v due to the high 
viscosity resulting in large particle formation.  A study by Varma et al (2014) investigated 
production of chitosan particles by the w-o emulsion.  Increasing the polymer concentration 
from 1 – 2 % w/v gave a small increase in particle size of 10.2 – 11.6 µm.  The study by Soni 
et al (2010) investigated production of alginate particles by the w-o emulsion method 
investigating concentrations from 2 – 8 % w/v.  Increasing the polymer concentration saw a 
general increase in particle size from 7.6 – 22.5 µm, however mixing speeds were also 
increased for increased polymer concentrations.  All formulations gave spherical 
morphologies apart from 8 % alginate which gave irregular geometries (Soni et al 2010).   
Alnaief et al (2011) also investigated effects of alginate concentration on particle formation.  
Varying the concentration from 1.5 – 3 % w/v resulted in a particle size increase from 318 – 
608 µm.  These particles were relatively large compared to others reported in the literature 
and in this work which was possibly due to vegetable oil being used as the continuous phase 
which has a relatively high viscosity compared to isooctane, the continuous phase used in this 
emulsion.  Also, the surfactants and mixing speed used was 1 % and 400 rpm respectively 
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while in this system 3 % and 15,000 rpm were used which gave lower surface tensions and 
higher shear rates, resulting in generation of smaller microparticles.  As well as polymer 
concentration, the mixing speed and surfactant concentration can have significant effects on 
particle size which are discussed below.      
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Figure 5.1 – Light microscope images of the alginate microparticles produced with (A) 1 %, (B) 3 % and (C) 
5 % w/v alginate.  The effect on particle form is illustrated.  The surfactant concentration, mixing speed and 
calcium chloride concentration used in all alginate formulations were 5 %, 15000 rpm and 1M respectively.  `   
Figure 5.2 – Size distribution of the alginate microparticles produced with 1 %, 3 % and 5 % alginate.  The 
effect of alginate concentration on the particle size and size distribution is illustrated.  The surfactant 
concentration, mixing speed and calcium chloride concentration were 5 %, 15000 rpm and 1M respectively. 
 
 
C 20 µm 
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D10 (µm) D50 (µm) D90 (µm) 
1% Alginate 2.4  4.5  8.9  
ST Dev 0.4 0.6 0.8 
RSD (%) 16.7 13.3 89 
3% Alginate 4.5  9.7  20.3  
ST Dev 0.8 0.6 1.3 
RSD (%) 17.8 6.2 6.4 
5% Alginate 13.5  55.8  135.1  
ST Dev 1.7 3.6 11.7 
RSD (%) 12.6 6.5 8.7 
Table 5.3 – Sizing data for the alginate particles produced with 1 %, 3 % and 5 % alginate showing the D10, D50 
and D90 sizes.  Each value shows the mean average of three independent studies ± SD 
5.4.1.2 Effect of mixing speed on particle production  
 
The effect of the emulsion mixing speed on particle size and form was investigated by light 
microscopy (Figure 5.3) and laser diffraction (Figure 5.4 and Table 5.4).  Agitation methods 
used in emulsions are dependent on the desired size of the particles where for this process, a 
high speed homogenizer was used since the high shear was capable of breaking the polymer 
down into small droplets allowing particles 1 – 5 µm to be produced.    Mixing speeds of 
5000, 15000 and 25000 rpm were investigated that was shown to strongly influence particle 
diameter.  Firstly, by increasing the mixing speed, smaller particles with narrower size 
distributions were obtained.  Also, like in the case with decreasing polymer concentration the 
higher mixing speeds produced particles that displayed signs of aggregation.  Small particles 
are known to aggregate due to an increase in adhesive and cohesive forces caused between 
adjacent particles and surfaces that are known to give them poor flow properties.   
The mixing process creates shearing within the emulsion resulting in breakdown of the 
dispersed droplets.  Increasing the mixing speed increases the shear created in the emulsion 
easing droplet breakup allowing smaller droplets to be produced.  For polymers that require 
chemical crosslinking, a sufficient level of shearing to produce turbulent flow of the 
continuous phase is required to allow the polymer and crosslinker droplets to collide, in order 
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for the polymer droplets to form solid particles.  Also, emulsions can tend to result in large 
size distributions due to the shear variation within the mixing vessel.  Forces around the 
agitator will be high while those at the outskirts of the vessel will be low.  Due to the 
decreased levels of shear at the outskirts of the vessel, droplets in this region are liable to 
agglomeration resulting in an increase in the average size and size distribution.  This was 
particularly true for particles produced at 5000 rpm since this speed gave the lowest level of 
agitation.  This can be resolved by increasing the mixing time however as discussed, the 
mixing time was kept short to avoid high levels of drug loss.   
The effects of mixing speed have been detailed in various studies in the literature.  A study by 
Alnaief et al (2011) investigated mixing speeds of 200 – 1400 rpm in the w-o emulsion to 
produce alginate particles where increasing the mixing speed decreased particle size from 
from 547 – 75 µm.  Alnaief also discuss that effects of viscosity of the continuous phase can 
also affect particle size.  Since vegetable oil which has a higher viscosity than isooctane was 
used as the continuous phase, their particles were considerably larger than the particles 
produced in this chapter.  Vaidya et al (2009) produced pectin particles using isooctane as the 
continuous phase with mixing speeds of 500 – 2000 rpm, where the same decreasing trend 
was seen where the size decreased from 13.9 to 9.8 µm.  The slowest mixing speed 
investigated in this work was 5000 rpm which produced large particles of 34.5 µm.  Vaidya’s 
fastest investigated mixing speed was 2000 rpm which produced smaller particles (2.9 µm) 
than the 5000 rpm mixing speed investigated in this work, where the general trend for 
increasing mixing speeds has shown to decrease particle size, which was the opposite in this 
case.  The type of mixing equipment (magnetic/overhead etc) can have a large influence on 
the particle size even when operating at the same speed since different shear intensities and 
flow patterns can be produced with various types of impellers/flees etc.  Also, particle size 
can be greatly affected by the ingredients used in the emulsion such as polymer 
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concentration, polymer molecular weight and surfactant concentration, which all vary from 
different studies.    
 
 
 
Figure 5.3 – Light microscope images of the alginate microparticles produced at (A) 5000, (B) 15000 and (C) 
25000 rpm.  The effect on particle size and form is illustrated.  The alginate concentration, calcium chloride 
concentration and surfactant concentrations were 3 %, 1M and 5 % respectively.  
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Figure 5.4 – Particle size distribution curves for alginate microparticles produced at 5000, 15000 and 25000 
rpm.  The effect on the size distribution is shown.  The alginate concentration, calcium chloride concentration 
and surfactant concentrations were 3 %, 1M and 5 % respectively.  
 
Table 5.4 – Sizing data for the alginate particles produces at 5000, 15000 and 25000 rpm showing the effect of 
mixing speed on the D10, D50 and D90.  Each size is the mean average of three independent studies ± SD.   
5.4.1.3 Effect of surfactant concentration on particle production   
The effect of surfactant concentration on the particle size and form was investigated.  Span 85 
and Tween 85 in a ratio of 0.8: 0.2 at concentrations of 1 %, 3 % and 5 % v/v were explored.  
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25000 rpm 
D10 (µm) D50 (µm) D90 (µm) 
5000 rpm  16.3 34.5  61.6  
St Dev 2.4 5.8 14.7 
RSD (%) 14.7 16.8 23.8 
15000 rpm  4.7  9.5  22.9  
St Dev  0.3 2.4 9.3 
RSD (%) 6.3 25.6 40.6 
25000 rpm 2.8 µ  4.3  80.8  
St Dev 0.7 0.2 19.9 
RSD (%) 25 4.6 24.6 
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By varying the surfactant concentrations, two key characteristic were found.  Firstly, upon 
increasing the surfactant concentration, the particle size decreases where average sizes of 
24.5, 12.3 and 7.3 µm were determined for 1 %, 3 % and 5 % respectively as shown in the 
sizing data (Table 5.5).  Also, upon increasing the surfactant concentration, particles 
produced were less aggregated and more uniformly dispersed with narrower size distributions 
as illustrated in the light microscopy images and particle size graphs (Figure 5.5 and 5.6).      
Emulsions require the addition of surfactants in order to increase the stability of the system 
allowing droplets to stay dispersed.  Without stabilisation, the two phases will aggregate until 
the water and oil phases revert back to their separate individual states.  Emulsion stability is 
based on the interfacial film theory.  Addition of surfactants to an emulsion system adds an 
interfacial layer around the dispersed droplets.  Since surfactants are amphiphilic materials, 
the hydrophilic and hydrophobic portions will arrange into the relevant areas of the emulsions 
(i.e. hydrophilic portions at the water droplets surface and hydrophobic portions in the 
continuous phase). With the surfactants covering the surface of the water droplets, adjacent 
droplets will repel preventing coalescence and allowing them to stay uniformly dispersed 
allowing fine particulate powders to be formed.  The concentration of surfactants in the 
emulsion must be sufficient enough to give an effective level of stabilization keeping the 
droplets dispersed.  When low levels are present, agglomerated products are formed as with 
particles produced with 1 % surfactants.  Another effect of surfactant concentration is their 
effect on particle size.  As well as increasing stability, they also reduce the surface tension 
between the water and oil interface and therefore, ease the process of droplet breakdown 
producing smaller particles as shown in the sizing data.  Combination of surfactants with 
different Hydrophilic Lipophilic Balance (HLB) values (i.e. one hydrophilic and one 
hydrophobic) has been reported to give increased stability by introducing more 
hydrophilic/lipophilic groups into the emulsion system.  Span 85 is a commonly used 
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lipophilic surfactant in w-o emulsions where several reviews have also used it along with 
Tween 85 (a hydrophilic surfactant) to increase stability, such as a study by Wong et al 
(2002) who used the two surfactants to produced pectin microspheres.  When developing 
emulsions containing various surfactants with different HLB values, the HLB provides a 
good idea of the ratios of surfactants required to produce a stable emulsion however 
experimentation in recommended to ensure the best stability can be obtained.   
The pectin particles produced by Vaidya et al (2009) investigated various surfactant (Span 
80) concentrations ranging from 0.75 – 1.5 % where particle size decreased from 10.8 – 8.7 
µm.  Like the study by Vaidya, many other reviews discuss use of surfactant concentrations 
below 2 % and where spherical particles with a uniform size and size distribution are 
obtained however, with this study, surfactant concentrations at 1 % were not sufficient 
enough to stabilise the emulsion.  It is unknown why surfactant concentrations required to 
stabilise the emulsion in this work had to be significantly higher than those recorded within 
the literature.  If experimental conditions such as reducing the dispersed phase were to be 
investigated, the reduction of water surfaces in need of stabilisation could overcome the 
stabilization issue.    
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Figure 5.5 – Light microscope images of the alginate microparticles produced with (A) 1%, (B) 3% and (C) 5% 
surfactants.  The effect of surfactant concentration on particle size and form is illustrated.  The alginate 
concentration, mixing speed and calcium chloride concentration was 3%, 15000 rpm and 1M respectively.   
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Figure 5.6 – Size distribution curves for the alginate microspheres produce with 1%, 3% and 5% surfactants. 
The size distribution and average particle size is illustrated.  The alginate concentration, mixing speed and 
calcium chloride concentration was 3%, 15000 rpm and 1M respectively.   
D10 (µm) D50(µm)  D90 (µm) 
1% surfactants  6.3  24.5 114.9 
St Dev 1.3 6.9 24.6 
RSD (%) 20.6 28.2 21.5 
3% surfactants 6.7  12.3  52.5  
St Dev 1.7 4.6 18.3 
RSD (%) 25.4 36.5 34.8 
5% surfactants 3.2  7.3 28.1  
St Dev 0.8 3.6 6.2 
RSD (%) 25 4.9 22.1 
Table 5.5 – Sizing data for the alginate particles produced with 1 %, 3 % and 5 % surfactants showing their 
effects on the D10, D50 and D90 sizes.  Each size is the mean average of three independent studies ± SD. 
5.4.1.4 Effect of calcium chloride concentration on particle production 
 
The effect of calcium chloride concentration as the chemical crosslinking agent was explored 
where concentrations of 0.25, 0.5 and 1 M were investigated.  The light microscopy images 
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illustrate the effects of varying concentration on particle formation (5.7).  Particles produced 
with 0.25 M calcium chloride gave agglomerated forms that were in a poor lumpy formation 
while those produced with 1 M gave spherical spheres where the particulate product was in a 
fine powdered form.   
Increasing the crosslinking concentration provides a higher concentration of calcium ions to 
interact with the alginates carboxyl groups.  When insufficient concentrations are available, 
weak gels are formed producing the poor clumpy products.  The exterior of the spheres are 
hardened however, the interiors remain weak which causes them to deform during the 
separation process such as filtration and centrifugal force.  This could be overcome by 
increasing crosslinking time however, long periods would be required which could lead to 
high drug loss in the production process.  Since these particles would have to undergo a 
secondary encapsulation process to produce the Particle-in-Particle system, drug loss at this 
stage must be kept to a minimum.  Also, increasing crosslinking concentrations is known to 
decrease particle size due to tighter, denser gels being produced however, the particles 
produced with 0.25 and 0.5 M calcium chloride concentrations failed to produce a uniform 
population of spherical particles.     
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Figure 5.7 – Light microscope images of the alginate microspheres produced with (A) 0.25M, (B) 0.5M and (C) 
1M calcium chloride solution showing its effect on particle formation.  Alginate concentration, mixing speed 
and surfactant concentration was 3%, 15000 rpm and 5% respectively.   
5.4.1.5 Effect of sodium silicate concentration on particle production 
 
Sodium silicate concentrations of 0.75 %, 1.5 % and 3 % was incorporated into 3 % alginate 
yielding a 0.5: 1, 1: 1 and 1: 1.5 ratio of alginate: silicate and the particles were analysed with 
light microscopy and laser diffraction (Figures 5.8 and 5.9 and Table 5.6).  Compared to the 
pure alginate particles, the organic-inorganic hybrid was highly aggregated with irregular 
morphologies and large size distributions.  0.75 % silicate produced the most uniform 
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particles however, 1.5 % and 3 % produced highly aggregated forms with no uniform 
particulate products.   
Since this combination of materials has not been explored within the literature, it is believed 
that crosslinking the droplets with calcium chloride cause them to rupture since they 
displayed spherical geometries prior to the crosslinker addition.  After crosslinking, they take 
on the aggregated forms as shown in the microscopy images.  As previously discussed, it is 
known that the sodium silicate interacts with the crosslinking mechanism of the alginate and 
calcium ions.  When the sodium silicate to alginate ratio is high (1:1.5), it is believed that the 
strong interaction between the sodium silicate and calcium ions causes the organic-inorganic 
droplets to rupture into aggregated masses of material preventing spherical particles from 
being produced as shown in the light microscopy images. Perhaps by varying the process 
conditions by reducing the ratio of dispersed phase could allow more uniform products to be 
formed.   
 
A 20 µm 
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Figure 5.8– Light microscope images of the Alginate/Sodium silicate particles produced with 3 % alginate and 
(A) 0.75 %, (B) 1.5 % and (C) 3 % sodium silicate showing the effect of sodium silicate on particle formation.  
The mixing speed, surfactant concentration and calcium chloride concentration was 15000, 5 % and 1M 
respectively. 
B 
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Figure 5.9 – Particle size distribution curves for the alginate sodium silicate particles produced with 3% alginate 
and 0.75 %, 1.5 % and 3 % sodium silicate showing its effect on particle size and size distribution. The mixing 
speed, surfactant concentration and calcium chloride concentration was 15000, 5% and 1M respectively.  
D10 (µm) D50 (µm) D90 (µm) 
0.75 % Si   8.5  32.1  64.8  
St Dev 3.5 11.4 24.1 
RSD (%) 41.2 35.5 37.2 
1.5 % Si 14.3  67.6  143.1  
St Dev 7.3 21.4 49.4 
RSD (%) 51 31.7 34.5 
3 % Si 13.4  97.5  243.1  
St Dev 4.6 22.3 53.6 
RSD (%) 34.3 22.9 22.1 
Table 5.6 – sizing data for the alginate sodium silicate particles produced with 0.75%. 1% and 3% sodium 
silicate showing their effects on the D10, D50 and D90 particle sizes.  Each size is the mean average of three 
independent studies ± SD. 
5.4.1.6 Drug loading 
 
Despite fine particles being produced by the w-o emulsion method, it was not possible to 
obtain any drug loaded particles.  Polymer: Drug ratios up to 1: 2 were investigated however 
a 0 % drug loading was obtained in all cases.  Other parameters known to increase 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0 100 200 300 400 500 
V
o
lu
m
e
 (
%
) 
Particle Size (µm) 
3% Si 
1% Si 
0.75% Si 
104 
 
encapsulation such as increased dispersed phase, shorter mixing times, increased surfactant 
concentrations, high polymer concentration and no washing stages were investigated 
however, these also failed to produce any drug loaded particles.   
The w-o emulsion required high speed homogenization resulting in high shearing on the 
alginate droplets.  Also, extensive washing stages are required in order to remove the excess 
oil from the particles resulting in increased drug loss.  Encapsulation of hydrophilic drugs by 
the emulsion method is known to be a challenging process since the drug can migrate from 
the droplets to the continuous phase, resulting in low encapsulation efficiencies.  Despite the 
drug being a hydrophilic one, with low solubility in the isooctane used as the continuous 
phase, it is believed that the porous nature of the alginate along with the high energy created 
by the high speed homogenization resulted in the drug migrating into the oil phase.  A sample 
of the oil was analysed by UV spectroscopy for verapamil hydrochloride content however, a 
reading could not be obtained where the UV absorbance reading rapidly fluctuated.   
5.4.2 Spray drying method  
 
Spray drying was a second method investigated for the production of the microparticles.  The 
method is known to be ideal as a particle production process due to its one step process, ease 
to scale up and has potential to achieve high drug loading and encapsulation efficiencies.  The 
critical process parameters investigated were polymer concentration, flow rate, inlet 
temperature, flow rate, polymer: silicate ratio and polymer: drug ratio.  Nozzle size also 
effects particle size however, as only one was available this parameter was not explored.        
5.4.2.1 Effect of alginate concentration on particle production  
 
The effect of alginate concentration on the particle size and morphology was investigated and 
analysed with SEM (Figure 5.10) and laser diffraction (Figure 5.11 and Table 5.7) where 
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concentrations of 1 %, 2 % and 4 % w/v were investigated.  With increasing polymer 
concentration the particle size increased as illustrated in the SEM images and sizing data.  
Average sizes of 2.9, 4.7 and 5.3 µm were produced with 1 %, 2 % and 4 % respectively.  
Also upon increasing the alginate concentration, the particle size distribution increased as 
shown in the size distribution curves.    
During the spray drying process, a spray of droplets are produced by atomization of the 
polymer solution fed to the nozzle.  Increases in polymer viscosity make it more difficult for 
the polymer mass to pass though the nozzle,  making atomization a difficult process that will 
result in larger particles with wider size distributions being produced.  Microparticles 
produced with water soluble polymers by spray drying are rarely used with solutions greater 
than 2 – 3 % w/v due to the high viscosity of the solution.  However, 4 % alginate was 
explored since the increased density could potentially prolong the release rate.   
Various polymer concentrations have been investigated for the production of microparticles 
by spray drying using natural polymers.  2 % w/v alginate is a common concentration 
investigated where Benchabane et al (2007) produced BSA loaded alginate particles with a 
uniform size distribution that displayed an average size of approximately 2.5 µm. The 
alginate particles produced by Benchabane displayed a similar particle size to the particles 
produced in this work where Benchabane used a flow rate of 7 mL/min and inlet temperature 
of 150 °C as the operating conditions to produce their microparticles.  Mladenovska et al 
(2007) produced alginate microspheres where a concentration of 3.5 % alginate produced 
particles with an average size of 6.2 µm.  No size distribution curves were reported however 
the SEM gave an image of a single particle showing a spherical geometry.   
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Figure 5.10 – SEM images of the alginate particles produced with (A) 2 %, (B) 3 % and (C) 4 % alginate 
showing its effect on particle size and form.  The inlet temperature and pumping rate was 150 °C and 
10 mL/min respectively.    
A 
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Figure 5.11 – Particle size distribution curves of the alginate particles produced with 2 %, 3 % and 4 % alginate 
showing its effect on the average size and size distribution.  The inlet temperature and pumping rate was 150 °C 
and 10 mL/min respectively.   
D10 (µm) D50 (µm) D90 (µm) 
2% Alginate 1.8  2.9  122.5  
St Dev 0.2 0.4 27.3 
RSD (%) 11.1 13.7 22.3 
3% Alginate 2.4  4.7  110.1  
St Dev 0.4 0.2 32.4 
RSD (%) 16.7 4.3 29.1 
4% Alginate 2.3  5.3  35.8  
St Dev 0.2 0.6 4.7 
RSD (%) 8.9 11.3 13.1 
Table 5.7 – Particle sizing data of the alginate particles showing the D10, D50 and D90 particle sizes.  Each value 
is the mean average of three independent studies ± SD. 
One of the benefits that make spray drying attractive is its one step process, where methods 
such as emulsions require additional washing and drying stages.  However the microparticles 
produced in this spray drying method were not crosslinked.  Without chemical crosslinking, 
the particles would dissolve resulting in rapid release of the drug which is not ideal since 
controlled release of the active is required.  Therefore, the particles were crosslinked post-
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production where some degrees of aggregation occurred.  When crosslinked, it is believed 
that the high surface area of the particles causes the particles to highly aggregate since the un-
crosslinked particles were more uniformly dispersed when viewed by SEM (Figure 5.11).  
The zeta potential of the particles in the calcium chloride solution would also be worth 
investigating as the pH of the solution could be reducing the stability of the particle system 
causing the particles to aggregate to a higher degree where particles are then crosslinked to 
adjacent particles forming the larger aggregates.  Preforming the crosslinking in calcium 
chloride solutions with modified pH levels could possibly allow a more uniform distribution 
of particles to be produced, however this method would have to ensure the calcium ions do 
not interact with the added pH modifiers allowing them to crosslink the alginate chains.   
Various methods have produced particles that are crosslinked in the drying process, allowing 
particles to be produced in the one step procedure.  Erdinc et al (2011) produced a 
polyelectrolyte complex composed of alginate and chitosan where the lightly crosslinked gel 
was spray dried into microparticles.  Alginate concentrations of 0.2 – 2 % w/v were 
investigated where particles became highly clustered at higher concentrations.  The average 
size also increased from 2.2 to 4.9 µm with increasing polymer concentration.  Also, Mobus 
et al (2012) added a solution of Zn(NH3)SO4 to alginate solutions where during the drying 
process, water and ammonia are expelled from the alginate droplets, leaving zinc to crosslink 
the polymer chains producing the crosslinked particles.   
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Figure 5.12 – SEM of the un-crosslinked alginate particles produced with (A) 2 %, (B) 3 % and (C) 4 % 
alginate particles showing the effect on particle size and form.  The inlet temperature and pumping rate was 150 
°C and 10 mL/min respectively. 
A 
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5.4.2.2 Effect of inlet temperature on particle production  
 
The effect of the inlet temperature on particle size and form were analysed with SEM (Figure 
5.12) and particle sizing (Figure 5.13 and Table 5.8).  Upon increasing the inlet temperature, 
no noticeable changes in particle size was seen where the average sizes produced were 5.7, 
5.4 and 5.8 µm for inlet temperatures of 120, 150 and 180 °C respectively.  However, 
particles produced at 120 °C saw a slightly more aggregated product compared to the higher 
inlet temperatures.   
Upon atomization of a polymer solution, the liquid spray is rapidly dried which can take 
several seconds to approximately 10 seconds depending on volatility the material being spray 
dried.  When drying temperatures are not sufficient, water can be retained in the collected 
particles leading to aggregated formations being produced.  Particles produced at 120 °C are 
believed to retain water after drying resulting in these aggregated particles being formed.   
This can be overcome by increasing the inlet temperature or by use of a different flow pattern 
that gives the droplets a longer drying time in the drying chamber which would be better 
suited to drugs that are heat sensitive.    
The effect of varying inlet temperatures are not often reviewed in spray drying where 
temperatures of 150 °C ± 10 °C are often used for water soluble polymers.  Results vary 
within the literature where increasing inlet temperatures have seen the change in particle size 
increase, decrease or show no effect.  Benchabane et al (2007) varied inlet temperatures from 
150 – 200  C and no variation in particle size was seen whereas Marshall (1954) commented 
on an increase in particle size with increasing inlet temperature.  This could also be down to 
the sizing method used and the chemical properties of the materials being used (molecular 
weight/concentration etc).  Particles produced from polymers on high concentration and 
molecular weight will have a reduced swellability, and when sizing methods such as laser 
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diffraction are used, the particles can swell in while suspended in the dispersant, where these 
varying concentrations and molecular weights can result in different particle sizes being 
measured.    
 
 
 
Figure 5.13 – SEM images of the alginate particles produced at temperatures of (A) 120 (B) 150 and (C) 180 °C 
showing their effects on particle size and form.  The alginate concentration and pumping rate was 3 % and 
10 mL/min respectively.  
A 
B 
C 
112 
 
 
Figure 5.14 – Particle size curves of the alginate particles produced at temperatures of 120 150 and 180 °C 
showing its effect on the average particle size and size distribution.  The alginate concentration and pumping 
rate was 3 % and 10 mL/min respectively. 
D10 (µm) D50 (µm) D90 (µm)  
120 °C 1.8  5.7  201 
St Dev 0.3 1.4 52.7 
RSD (%) 16.7 24.6 26.2 
150 °C 2.5  5.4  236  
St Dev 1.2 2.4 93.6 
RSD (%) 48 44.4 39.7 
180 °C 2.7  5.8  221  
St Dev 0.9 1.7 74.7 
RSD (%) 33.3 29.3 33.8 
Table 5.8 – Sizing data of the alginate particles produced at 120, 150 and 180 °C showing its effect on the D10, 
D50 and D90 particle sizes.  Each value is the mean average of three independent studies ± SD. 
5.4.2.3 Effect of alginate flow rate on microparticle production 
 
The effect of polymer flow rate on particle size and form was investigated and analysed with 
SEM (Figure 5.14) and laser diffraction (Figure 5.15 and Table 5.9).  By increasing the flow 
rate from 5, 10 and 20 mL/min, average particle sizes of 3.9, 5.7 and 8.9 µm were determined 
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for the increasing flow rates.  Flow rates of 20 mL/min were too fast for the atomization 
process resulting in highly aggregated particles being formed.         
Like with increasing polymer concentration, increasing the polymer flow rates makes the 
atomization process more difficult resulting in increased particle size and increased size 
distribution.  At exceptionally high flow rates (greater than 20 mL/min), large amounts of 
material can be deposited on the sides of the drying chamber which increases when larger 
volumes of material are spray dried.  This can result in low production yields since a large 
proportion of the material is lost in the drying chamber and the particles that are collected 
show signs of aggregation perhaps due to inadequate drying like in the case with insufficient 
inlet temperatures.  This effect could possibly be overcome by use of higher drying 
temperatures or use of counter current flow patterns to dry the droplets faster and allow 
longer contact times during drying.  Also, increasing the nozzle size can allow increased flow 
rates (and also polymer concentrations) to be used allowing higher production rates, which 
would then also increase particle size.        
Benchabane et al (2007) processed alginate solutions at 12 and 24 mL/min and saw the same 
increasing trend in particle size increase from 2.7 to 3.2 µm.  Coppi et al (2001) produced 
alginate particles at a flow rate of 5 mL/min where an average size of 2.1 µm was produced, 
similar to those produced in this work.   
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Figure 5.15 – SEM images of the alginate particles produced at flow rates of (A) 5, (B) 10 and (C) 20 mL/min 
where the effect on particle size and form are shown.  The alginate concentration and in let temperature were 
3 % and 150 °C.   
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Figure 5.16 – Particle size curves for the particles produced at flow rates of 5, 10 and 20 mL/min showing the 
effect on the average particle size and size distribution.  The alginate concentration and inlet temperature were 
3 % and 150 °C respectively.   
D10 D50 D90 
5 mL/min 2.1  3.9  183  
St Dev 0.3 0.3 28.8 
RSD (%) 14.2 7.7 15.7 
10 mL/min 2.5  5.7  273  
St Dev 0.3 0.6 89.9 
RSD (%) 12 10.5 32.9 
20 mL/min 2.9  8.9  417  
St Dev 0.2 1.3 101.4 
RSD (%) 6.9 14.6 24.3 
 
Table 5.9 - Particle sizing data for the alginate particles produced at 5, 10 and 20 mL/min showing the effect on 
the D10, D50 and D90 particle sizes.  Each value shows the mean average of three independent studies ± SD.  
5.4.2.4 Drug loading and encapsulation efficiency of the alginate microparticles 
 
The alginate particles were loaded with 1 % w/v verapamil hydrochloride and the effects of 
alginate concentration on DL and EE were investigated (Table 5.10).  On increasing polymer 
concentration from 2 % - 4 % w/v the DL decreased from 18.7 % to 12.2 % and EE increased 
from 37.4 % to 48.8 %.  
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The particles were produced with constant drug concentrations while the mass of polymer 
was increased.  Since DL is a measure of the ratio of polymer to drug, keeping the mass of 
drug constant is likely to see a general decrease in DL as the polymer concentration increases.  
EE will tend to increase with increased polymer concentration since higher crosslinking 
densities are capable of retaining higher masses of drug due to the decrease in particle 
porosity.  
Mobus et al (2012) produced alginate particles with 1 % alginate by the spray drying method 
encapsulating the protein bovine serum albumin (BSA) with encapsulation efficiencies as 
high as 96.5 %.  BSA is a large molecular weight protein and the particles were crosslinked 
in the drying chamber, whereas particles in this process were crosslinked post production, 
where some drug was lost to the crosslinking solution.  Drugs with larger molecular weights 
can also result in higher EE since the increase in the size of the molecule makes it more 
difficult to diffuse out of the microparticle.  As previously disused reviews for alginate 
particles encapsulating hydrophilic drugs are limited, where many spray drying methods have 
been emphasized towards proteins and large molecular weight compounds.    
2% Alginate 3% Alginate 4% Alginate 
DL (%) 18.7  15.3  12.2  
St Dev 1.2 0.9 1.3 
RSD (%) 6.4 5.9 10.7 
EE (%) 37.4  46.2  48.8  
St Dev 2.5 3.5 5.2 
RSD (%) 6.7 7.6 10.7 
 
Table 5.10 – Drug loading and encapsulation efficiency of the alginate particles produced with 2%, 3% and 4% 
alginate loaded with 1% verapamil hydrochloride.  Each value shows the mean average of three independent 
studies ± SD.   
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5.4.2.5 Drug release from the alginate microparticles 
  
The alginate particles produced with varying alginate concentrations of 1 %, 2 % and 4 % 
were subject to in-vitro release in PBS (Figure 5.16).  Like with the alginate beads discussed 
in the previous chapter, all formulations released the entire mass of drug within the first hour.  
It was hypothesized that increased polymer concentrations could potentially result in 
controlled release due to increased crosslinking density however, all formulations resulted in 
rapid release rates due to the high porosity of the alginate and rapid diffusion of the small 
molecular weight hydrophilic drug into the PBS release media.   
The majority of alginate microparticle based drug delivery systems have been applied to the 
encapsulation of large molecular weight compounds, where the larger size of the molecule 
can potentially allow the diffusion process to be reduced resulting in slower release rates.  
The alginate particles produced by Mobus et al (2012) allowed sustained release of BSA 
from alginate particles within 48 hours with an initial burst release of 60 % within the first 8 
hours.   
 
Figure 5.17 – Drug release profile for the verapamil hydrochloride loaded alginate particles produced with 2 %, 
3 % and 4 % alginate.  Each point shows the mean average of three independent studies.   
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5.4.2.6 Effect of alginate: sodium silicate ratio on particle production  
 
The effect of alginate: sodium silicate ratio on microparticle formation was analysed with 
SEM and laser sizing where concentrations of 1.5 %, 3 % and 4.5 % in 3 % alginate were 
investigated (Figures 5.17 and 5.18 and Table 5.11).  By increasing the sodium silicate ratio, 
the aggregation of the particles greatly increased resulting in large particle clusters displaying 
wide size distributions.   
Like with the investigated polymer concentrations in pure alginate particles, the aggregation 
was mainly believed to be due to the particles high surface area.  With increasing the silicate 
concentration, alginate becomes the less dominant material within the particle which can 
possibly result in the silicate dissolving out of the smaller mass of alginate resulting in a 
aggregated irregular structure being formed.   
This formation could possibly be overcome by crosslinking the particles during the drying 
process by the release of the crosslinker ions as to the method by Mobus et al (2012) to allow 
alginate particles with higher degrees of sphericity and containing higher silicate masses to be 
produced.   
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Figure 5.18 – SEM of the alginate/sodium silicate particles produced with sodium silicate concentrations of 
1.5 %, 3 % and 4.5 %.  The effect on particle form is shown.  The alginate concentration, inlet temperature and 
pumping rate were 3%, 150 °C and 10 mL/min respectively. 
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Figure 5.19 – Particle size distributions of the alginate sodium silicate particles produced with sodium silicate 
concentrations of 1.5 %, 3 % and 4.5 % sodium silicate.  The effect of silicate concentration on the size 
distribution is shown.   
D10 D50 D90 
1.5% Si 3.7  9.3  21.1  
St Dev 0.7 2.7 4.9 
RSD (%) 18.9 29 23.2 
3% Si 12.5  18.4  83.5  
St Dev 4.1 3.7 22.2 
RSD (%) 32.8 20.1 26.6 
4.5% Si 17.4  27.7  115.5  
St Dev 4.6 6.2 44.8 
RSD (%) 26.4 22.4 38.8 
Table 5.11 – Particle size data of the alginate particle produced with sodium silicate concentrations of 1.5 %, 
3 % and 4.5 %.  Each value is the mean average of three independent studies ± SD. 
Like with the alginate particles, un-crosslinked alginate sodium silicate particles were also 
analysed with SEM (Figure 5.19).  The particles were more spherically uniform compared to 
the crosslinked product indicating that the aggregated formation occurs during the 
crosslinking process.  Like with the other aggregated particle issues, this could also be down 
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to particle instability in the calcium chloride solution which could be addressed by 
determination of the zeta potential.   
 
 
 
Figure 5.20 – SEM images of the un-crosslinked alginate sodium silicate particles produced with 1.5, 3 and 
4.5 % sodium silicate.  The alginate concentration used was 3 % w/v.   
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5.4.2.7 Drug loading and encapsulation efficiency of the alginate sodium silicate 
microparticles 
 
The effect of alginate concentration on the DL and EE of the alginate sodium silicate 
particles was investigated where a 1 : 1.5 ratio of alginate and silicate was investigated (Table 
5.12).  With increasing alginate concentration, the drug loadings decreased from 15.2 % to 
9.3 % in 2 % to 4 % alginate due to the concentration of drug staying constant while the 
material mass increases.  As for the EE, with increasing polymer concentration, the EE 
increases from 60.8 % to 75 % due to the increased gel density.     
2% alginate 3% alginate 4% alginate 
DL (%) 15.2  10.7  9.3  
St Dev 1.6 1.5 1.3 
RSD (%) 10.5 23.3 14 
EE (%) 60.8 65.1  75  
St Dev  6.6 9.7 9.6 
RSD (%) 10.9 14.9 12.8 
 
Table 5.12 – Effect of alginate concentration on drug loading and encapsulation efficiency of the alginate 
sodium silicate microparticles.  Concentrations of 2 %, 3 % and 4 % were investigated.  Each value is the mean 
average of three independent studies ± SD.   
The effect of sodium silicate concentration on DL and EE were also investigated (Table 
5.13).  By increasing the silicate concentration from 1.5 to 4.5 % w/v in the 3 % alginate 
particles, DL again decreased from 11.1 % to 8.5 % when EE increased from 49.9 % to 
64.3 % due to the increased gel density retaining higher masses of drug.    
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1.5 % Na silicate 3 % Na silicate 4.5 % Na silicate 
DL (%) 11.1  9.6  8.5  
St Dev 1.6 1.5 1.2 
RSD (%) 14.4 15.6 14.1 
EE (%) 49.9 58.2  64.3  
St Dev 6.6 9.7 8.9 
RSD (%) 13.2 16.7 13.8 
 
Table 5.13 – Effect of alginate: sodium silicate ratio on drug loading and encapsulation efficiency of the 
alginate sodium silicate microparticles.  Concentrations of 1.5, 3 and 4.5 % w/v in 3 % alginate were 
investigated.  Each value is the mean average of three independent studies ± SD.  
The effect of drug concentration was also investigated (Table 5.14).  By increasing the drug 
concentration from 0.5 % to 2 %, the DL increases from 5.5 to 20.1 %.  As expected, by 
increasing the initial loading of drug, higher DL can be obtained.  Particles produced with 
2 % verapamil hydrochloride were however highly aggregated.  When the polymer and drug 
are mixed the interaction between the drug and polymer can potentially increase the viscosity 
of the solution making the atomization process more challenging resulting in the aggregated 
particles.  The EE however decreased with increasing drug concentration.  This is believed to 
be due to the limited number of carboxyl groups available for interaction with the drug 
resulting in a decrease in EE.  A similar effect was observed by Maesh et al (2007) where 
methylene blue was encapsulated within alginate nanospheres where the methylene blue 
concentration ranged from 5 – 15 mg per mL of alginate (1%).  The EE saw a decrease from 
99.8% to 74.1 % by increasing the drug concentration from 5 – 15 mg/mL where they 
concluded the decrease was due to limited carboxyl groups available to interact with the drug. 
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0.5% VHCl 1% VHCl 2% VHCl 
DL (%) 5.5  10.7  20.1  
St Dev 0.6 1.5 1.6 
RSD (%) 10.9 14 8 
EE (%) 67  64.6  60.4  
St Dev 10.9 9 4.8 
RSD (%) 16.3 13.9 7.9 
 
Table 5.14 – Effect of verapamil hydrochloride concentration on drug loading and encapsulation efficiency of 
the alginate sodium silicate microparticles.  Concentrations of 0.5%, 1% and 2% were investigated.  Each value 
is the mean average of three independent studies ± SD.   
5.4.2.8 Drug release from the alginate sodium silicate microparticles 
 
The alginate sodium silicate particles were subject to in-vitro release in PBS where effects of 
alginate concentration, silicate concentration and drug concentration were investigated 
(Figures 5.20, 5.21 and 5.22 respectively).  By increasing the alginate and silicate 
concentrations slight decreases in drug release were observed as shown by the cumulative 
release and percentage release profiles.  However, due to the short release period of 4 hours 
and when experimental error is taken into account, these variations of the process parameters 
could be having no real effect on drug release rate since the particles high surface area along 
with the water loving nature of the drug result in fast release rates.  The particles do however 
see an improvement on the single alginate microparticle systems where the drug is instantly 
released due to the reduced porosity/increased material interaction and reduced degradation 
as discussed in the previous chapter.   
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Figure 5.21 – Percentage drug release of the alginate sodium silicate particles illustrating the effect of alginate 
concentration on drug release rate.   Concentrations of 2%, 3% and 4% were investigated.  Each point is the 
mean average of three independent studies ± SD.  
 
Figure 5.22 – Percentage drug release of the alginate sodium silicate particles illustrating the effect of silicate 
concentration on drug release rate.  Concentrations of 1.5%, 3% and 4.5% were investigated.  Each point is the 
mean average of three independent studies ±SD.  
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Figure 5.23 – Percentage drug release of the alginate sodium silicate particles illustrating the effect of drug 
concentration on drug release rate.  Concentrations of 0.5%, 1% and 2% were investigated.  Each point is the 
mean average of three independent studies ± SD.  
 
5.5 Conclusion 
 
In this section, microparticle production methods for the alginate sodium silicate blend were 
investigated.  The w-o emulsion and spray drying methods were chosen due to their ability to 
produce particles as carriers for hydrophilic drugs.  In the w-o emulsion, effects of polymer 
concentration, mixing speed, crosslinking concentration and surfactant concentration were 
explored illustrating their effects on particle formation.  Successful formation of the particles 
was highly dependent on sufficient stabilization in the emulsion along with adequate 
crosslinking concentrations.  Also, the desired size of particles was found to be highly 
dependent on choice of the appropriate polymer concentration and mixing speeds.    Although 
uniformly distributed spherical particles were produced, the method failed to allow drug 
loaded particles to be produced which was believed to be due to the transfer of the drug into 
the oil phase.  Spray drying was investigated since it is known to produce particles with high 
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EE in a single step.  Parameters investigated where the polymer/silicate concentration, inlet 
temperature, polymer flow rate and drug concentration where the effects on the particle 
formation were analysed.  Again, choice of the appropriate processing parameters allowed 
various particle sizes to be obtained.  The particles produced displayed spherical geometries 
that were uniformly distributed and displayed high loadings and controlled release of the 
encapsulated compound.  These microparticles did not significantly increase the release rate 
compared to the alginate counterpart since was over a 5 hour period with a burst of 
approximately 60 % within the first hour.  However it offered an improvement over the 
alginate particles where the drug was instantly released.  The 3 % alginate / 1.5 % sodium 
silicate containing 1 % verapamil hydrochloride is the formulation to be carried forward for 
encapsulation into the larger embolic particles producing the PIP system for TACE.  This 
formulation displayed the highest uniformity with high drug loadings where other 
investigated parameters failed to display significant variations in drug release rate.    
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CHAPTER 6 
PRODUCTION OF THE EMBOLIC PARTICLES AND 
ENCAPSUALTION OF THE DRUG DELIVERY PARTICLES 
 
6.1 Introduction  
 
In this chapter, microspheres were produced as embolizing particles where the 3 % alginate / 
1.5 % sodium silicate / 1 % verapamil hydrochloride formulation produced in chapter 5 was 
encapsulated into the optimized embolic particles, producing the PIP system.  Two methods 
for production of the embolic particles were investigated, the w-o emulsion and the nozzle 
vibrating method.   Parameters effecting particle size and form were investigated.  Once 
optimum production procedures were obtained, the drug delivery particles were encapsulated 
yielding the PIP system.  The morphology of the embolic particles were analysed with 
microscopy and laser diffraction along with the DL/EE and drug release rates which were 
determined by in-vitro analysis with UV spectroscopy.  The aims of this chapter were to; 
 Investigate methods for producing large microparticles in the TACE size range (100 – 
1000 µm) with narrow size distributions. 
 Investigate the effects of processing parameters on embolic particle size and form for 
the chosen methods. 
 Investigate drug delivery particle loading, ensuring the drug delivery particles are 
uniformly dispersed within the embolizing particles.   
 Ensure the microstructure of the embolizing particles allow the effect of particle size 
on drug release rate to be decoupled.  
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6.2 Particle-in-Particle systems for drug delivery applications  
 
The concept of a PIP system is one that has been explored to overcome several obstacles 
within drug delivery.  Such obstacles include; protection of oral dosage forms along the 
gastrointestinal tract, prolonged drug release rates and delivery by the pulmonary route.  
Production methods for PIP systems are similar to those used to produce single particle 
systems where the particles to be encapsulated are dispersed into the matrix material where 
methods such as spray drying, emulsions and ionotropic gelation have been frequently 
explored.   It is to the best of this author’s knowledge that no other researcher has attempted 
to develop a PIP system that decouples drug release rate from particle size while also 
allowing encapsulation of a range of drugs not only for TACE, but for drug delivery in 
general.  Therefore, this concept is one that has potential for a variety of drug delivery 
applications.     
Firstly, for TACE specifically, only one other PIP system has been found within the 
literature.  The work of Pouponneau et al (2011) investigated the production of a doxorubicin 
loaded particle system where the anti-cancer drug was loaded into PLGA microparticles 
along with iron cobalt nanoparticles (Figure 6.1).  The PLGA particles controlled the release 
of the drug over several days and the magnetic iron cobalt nanoparticles acted as a steering 
mechanism so that when magnetic fields were introduced, the PLGA particles could be 
directed to the tumour site.  A similar PIP system was used as a delivery system for inhalation 
in the treatment of lung cancer.  Here, McBride et al (2013) produced a system composed of 
spray dried lactose microparticles loaded with doxorubicin and iron oxide nanoparticles 
where once again, the magnetic field could guide the particles to the relevant site of the lung 
tumour.   
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Figure 6.1 – The only other known PIP system used for TACE.  The system is composed of magnetic 
nanoparticles and doxorubicin encapsulated within PLGA microparticles (Pouponneau et al 2011).  
When alteration of release rates have been an aim, PIP systems reported within the literature 
have aimed to extend the release rate rather than decouple it from the particle size.  Hassan et 
al (2009) composed a system of ibuprofen loaded PCL nanoparticles entrapped within PLGA 
microparticles with the intent to reduce the burst effect and sustain release rate.  The PCL 
nanoparticles released the majority of the drug instantly, whereas the PIP system displayed an 
initial burst release of 21 % in the first 15 minutes followed by a sustained release rate over 
an 8 hour period.  The work by Lee et al (2008) produced a catechin loaded liposome system 
in calcium pectinate beads by the ionotropic gelation method.  Calcium pectinate makes an 
attractive material for oral delivery however suffers from rapid release of small molecular 
weight drugs.  Liposomes were designed to control release of catechin, where the liposomes 
were then loaded into calcium pectinate beads, where the system saw a controlled release rate 
over 4 hours.    
Many PIP systems have been developed with the intent of protecting the encapsulated drug 
loaded particles after oral administration from the conditions of the gastro intestinal tract.  
The environment in the stomach is highly acidic where fast degradation can occur, 
particularly for protein based compounds.  Also, the small intestine has a high surface area 
PLGA 
Particle 
Iron 
nanoparticles 
Doxorubicin 
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where high absorption rates occur.  The colon makes an attractive site for drug delivery due 
to its neutral pH and long transit time however, drugs or drug loaded particles require 
protection whilst traveling along the upper gastro intestinal tract.  Alginate makes an 
attractive material to protect against conditions of the stomach acid since it contracts in acidic 
media.  Garrait et al (2014) produced a microparticle system composed of alginate 
microparticles containing amaranath red loaded chitosan nanoparticles.  The alginate particles 
had an average diameter of 285 µm and the nanoparticles a diameter of 690 nm. In-vitro 
studies in conditions simulating the stomach saw a release of less than 5 % and conditions 
simulating the small intestine saw a rapid release of the drug.  The work by Barea et al (2012) 
produced 5-ASA loaded chitosan coated liposomes within Eudrajit S100 microspheres for 
oral delivery to the colon.  The Eudragit S100 protected the drug loaded liposomes in the 
acidic conditions of the stomach and small intestine until the colon site was reached.  Once at 
the colon, the Eudragit S100 degraded and allowed controlled release of the 5-ASA from the 
liposome system.     
PIP systems have seen increasing interest for delivery of proteins and insulin by the 
pulmonary (lung) route.  The work of Kaye et al (2009) produced a PIP system where 
antibodies were encapsulated into PLGA particles.  These particles were then formulated into 
a PIP system by entrapment into lactose microspheres in a one-step spray drying method.  
The lactose particles were designed so that their size (1-5 µm) would allow deep penetration 
into the airways and then dissolve upon contact with the aqueous environment.  The PLGA 
particles would then adhere to the lining of the lung, allowing controlled release of the 
encapsulated compound.     
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6.3 Production of the embolizing particles by Nozzle Vibrating technology 
 
One method that has seen limited attention for particle production is based upon a theory 
investigated by Lord Rayleigh in the late 19
th
 century (Figure 6.2).  He found that when 
liquid jets fall under gravity, they will break up into droplets caused by disturbances along the 
length of the falling liquid jet.  When the jet length exceeds its diameter by a factor of 3.13, 
instability along the jet increases, resulting in rupturing of the falling jet generating droplets 
(Brandenberger et al 1998).  Application of a disturbance such as a vibration to a liquid jet 
flowing in a laminar fashion causes the jet to be broken down into uniformly sized droplets 
which can be processed into particles of a uniform size range.  For optimum droplet 
formation, Rayleigh defined the optimum wavelength of a falling liquid jet for droplet 
formation in Equation 6.1 (Brandenberger et al 1998).   
 
 
 
 
   
 Figure 6.2 – Break-up of a falling liquid jet caused by growing disturbances along the jet length.  As the length 
increases, disturbances also increase generating droplets.  
    λOPT = π x √ (2d) 
Equation 6.1 – The optimum wavelength defined by Rayleigh 
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Rayleigh’s theory applied to Newtonian fluids such as water however, the work by Weber 
extended this principle for Non-Newtonian fluids such as alginate by adding the effects of 
viscosity, density and surface tension to Rayleigh’s theory.  Weber’s optimum wave length 
definition is given in Equation 6.2 (Brandenberger et al 1998).   
λOPT = π √ (2d) x √ 1 + [( 3η) / √ (ρσd)] 
Equation 6.2 – The optimum wavelength taking effects of density, viscosity and surface tension into account 
defined by Weber.  
By knowing the optimum wavelength, an approximate vibrating frequency for optimum 
droplet formation can be determined by Equation 6.3.  The diameter of the droplet can also be 
determined by Equation 6.4 (Brandenberger et al 1998).   
f = v / λ 
Equation 6.3 – Optimum operating frequency for droplet formation.  
d = 
3
 √ (1.5 x d2 x λ OPT) 
Equation 6.4 – Diameter of the produced droplets. 
Where; 
 λ – wavelength (m) 
 d – nozzle diameter (m) 
 η – viscosity (Pa s) 
 σ – surface tension (N m-1) 
 ρ – density (Kg m3) 
 v – velocity (m s-1) 
 f – frequency (Hz) 
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Several pieces of apparatus have been developed based on this principle to form 
microspheres of a uniform size.  Gaudio et al (2005) used a nozzle vibrating unit to produce 
large alginate beads whilst investigating the effects of polymer concentration on bead 
formation using a vibrating frequency of 250 Hz and nozzle of 400 µm.  The diameter of the 
beads ranged from 0.5 – 3.5 mm when increasing the alginate concentration from 0.5 % - 
2.5 % w/v.  Lee et al (1996) used a sound induced vibrating method to produce uniform 
alginate beads where the size of the beads ranged from 1.5 – 3.5 mm depending on the flow 
rate, frequency and nozzle size used.   
The nozzle vibrating encapsulator used in the work also applies an electrostatic charge to the 
surface of the falling droplets causing them to repel into a fine spray, which prevents 
aggregation allowing particles with narrower size ranges and highly spherical geometries to 
be produced with adjustable sizes.  Particle formation by nozzle vibrating technology has 
been a limited area of study when compared to methods such as emulsions and spray drying.  
The nozzle vibration method provides a good alternate to the ionotropic gelation method, one 
that has the benefit of mild preparation but suffers from production of relatively large beads.  
Benefits of the method are faster production rates and access to a wide range of particle sizes 
from 150 – 2000 µm, whilst still allowing mild processing conditions.  Particles produced 
with this method also fit the embolizing particle specifications of TACE such as uniform size, 
calibrated sizes and smooth hydrophilic surface with spherical geometries.  The method 
however is limited to polymer concentrations that are able to flow though the nozzles.   When 
particles less than 300 µm are required, alginate concentrations are limited up to ~ 1.5 % w/v.   
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6.4 Materials  
 
Alginate (ID # 180947, MW 120,000 – 190,000 g/mol, viscosity (1 %) 15-20 cP, M/G 1.56) 
kappa carrageenan (ID # 22048, 0.3 % solution viscosity 5 – 25 mPa.s), mineral oil and 
sodium silicate were supplied by Sigma Aldrich UK.  Calcium chloride dihydrate, hexane 
and phosphate buffered saline (PBS) were supplied by Fisher Scientific UK.  Verapamil 
hydrochloride was supplied by Cambridge Bioscience.  Food grade vegetable oil was used.  
Distilled water was used to produce all aqueous solutions.   
6.5 Methods  
 
6.5.1 Production of the embolic particles by the w-o emulsion 
 
The embolizing microparticles were produced by the w-o emulsion method.  A solution of 
6 % w/v kappa carrageenan was produced by dissolving the polymer in distilled water at 
90 °C for 8 hours.  The drug loaded particles were dispersed into water at 50 °C where equal 
volumes of the dispersion and hot carrageenan were mixed, yielding a dispersion of 3 % 
carrageenan containing 2 % or 5 % w/v drug loaded particles.  5 mL of the dispersion was 
then added rapidly through a syringe to 50 mL of vegetable oil at 50 °C under mixing at 400, 
600 or 800 rpm by use of an overhead stirrer (IKARW 20 Fisher Scientific).  Mixing speeds 
of 400, 600 and 800 rpm would produce small, medium and large micron sized embolic 
particles in the TACE size range respectively.  The emulsion was mixed for 5 minutes with 
no heating and then left at 4 °C for 10 minutes to allow the carrageenan particles to harden.  
The particles were then collected though particle sieves (120 µm) and washed in three 50 mL 
portions of hexane followed by one 50 mL portion of water and then finally oven dried.    
Blank carrageenan particles were also produced as a control.   
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6.5.2 Production of embolic particles by nozzle vibrating technology  
 
Alginate microspheres were produced using a Buchi B-395 Pro Microencapsulator unit by a 
method that was developed based on the standard operating procedure provided by Buchi 
(Figures 6.3 and 6.4).  The effects of alginate flowrate (A1 – A3), vibrating frequency (V1 – 
V3), electrode strength (E1 – E3) and nozzle size (N1 – N3) were investigated (Table 6.1).  
1.5 % alginate and 1M calcium chloride was used to produce and crosslink all formulations.  
The desired parameters were set and the alginate was added to a 50 mL syringe then fixed to 
the encapsulation unit.  The frequency was activated followed by initiation of the polymer 
flow rate, where a steady stream of alginate left the nozzle.  The electrode was then activated 
producing the spray of droplets which were collected in a bath of the 1M calcium chloride 
solution under mixing at 100 rpm.  10 mL of alginate was collected in microsphere formation 
per 100 mL of calcium chloride solution.  The particles were collected by filtration though 
particle sieves (120 µm), and stored in air tight vials for analysis.     
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Figure 6.3 – Production of microparticles using the B-395 Microencapsulator (Buchi) 
 
 
 
 
 
 
 
 
Figure 6.4 – Droplet formation in microspheres (left) and microcapsules (right) 
Alginate Alginate 
Oil 
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Alginate flow 
rate (mL/min) 
Vibrating 
frequency (Hz) 
Electrode 
strength (V) 
Nozzle size  
(µm) 
A1 5 1500 2000 300 
A2 10 1500 2000 300 
A3 15 1500 2000 300 
V1 10 1000 2000 300 
V2 10 1500 2000 300 
V3 10 2000 2000 300 
E1 10 1500 1500 300 
E2 10 1500 2000 300 
E3 10 1500 2500 300 
N1 5 2000 1000 150 
N2 10 1500 2000 300 
N3 20 800 2500 450 
Table 6.1 – Process parameters investigated for microsphere formation. 
Microcapsules were also produced using the same encapsulation unit where mineral oil was 
encapsulated into the alginate shells.  The nozzle component of the encapsulation has a 
specific nozzle for microcapsule production where microcapsules of a desired shell and core 
size can be produced.  The smallest core nozzle that allowed the mineral oil to freely flow 
though was the 200 µm nozzle, therefore this was used in all formulations.  Shell nozzles of 
300, 400 and 500 µm where the investigated shell nozzles as these fall into the range for 
TACE.   
Again, 1.5 % alginate was crosslinked into 1 M calcium chloride baths in all formulations.  
The process parameters investigated were the alginate flowrate (Al1 – Al3), oil flowrate (O1 
– O3), and shell nozzle size (Sh1 – Sh3) (Table 6.2).  The alginate flowrate was controlled by 
use of a pressure bottle and the mineral oil flow rate by the microencapsulator’s attached 
syringe pump.  The choice of vibration frequency and electrode strength was dependant on 
the shell nozzle being used for capsule formation, where vibration frequencies of 1500, 800 
and 600 Hz and electrode strengths of 1500, 2000 and 2500 V were used for the investigated 
for the shell nozzles of 300, 400 and 500 µm respectively.    
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Before capsule production, the desired nozzles were fitted and the vibration and electrode 
settings were set.  The pressure bottle was activated initiating the flow of alginate until the 
desired pressure (mbar) was reached.  This was then followed by activation of the oil flow 
rate, where a stream of alginate containing the oil was produced.  The vibration and electrode 
were then activated producing the droplet spray where the capsules were collected and 
crosslinked in the calcium chloride solution under mixing at 100 rpm.  Again, 100 mL of 
calcium chloride was used per 10 mL of alginate processed.  At the end of the production all 
settings were deactivated and the capsules were filtered by use of particle sieves and stored in 
air tight vials for analysis.   
Alginate flow rate 
(mbar) 
Oil flow rate 
(mL/min) 
Shell nozzle  
(µm) 
Al1 150 10 400 
Al2 175 10 400 
Al3 200 10 400 
O1 175 5 400 
O2 175 10 400 
O3 175 20 400 
Sh1 175 10 300 
Sh2 175 10 400 
Sh3 175 10 500 
Table 6.2 – Process parameters investigated for microcapsule formation.  Nozzle vibrations were 1500, 1000 
800 Hz for shell nozzles of 300, 400 and 500 µm respectively.  Electrode strengths were 2000, 2500 and 2500 V 
for shell nozzles of 300, 400 and 500 µm respectively. 
The microencapsulation unit was also used to produce verapamil hydrochloride loaded 
alginate-sodium silicate microspheres where 1 % w/v verapamil hydrochloride was loaded 
into the particles.  Investigated parameters were alginate concentration (Alg1 - Alg3), sodium 
silicate concentration (Si1 – Si3) and nozzle size (No1 – No3) (Table 6.3) which were 
processed as detailed above.    
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Alginate Conc        
(w/v) 
Na Silicate Conc 
(w/v) 
Nozzle size           
(µm) 
Alg1 1 1.5 300 
Alg2 2 3 300 
Alg3 3 4.5 300 
Si1 2 1 300 
Si2 2 2 300 
Si3 2 3 300 
No1 2 3 150 
No2 2 3 300 
No3 2 3 450 
 
Table 6.3 – Process parameters investigated for verapamil hydrochloride loaded alginate/sodium silicate 
microspheres.   The nozzle vibration used was 1000, 1500 and 2000 Hz for nozzles sizes of 150, 300 and 450 
µm respectively.  The electrode strength for nozzles of 150, 300 and 450 µm was 1500, 2000 and 2500 V 
respectively.  Alginate flowrates of 5, 10 and 20 mL/min were used for nozzle sizes of 150, 300 and 450 µm 
respectively.   
6.5.3 Particle characterization  
 
Particles were characterised for their size and morphology by light microscopy and laser 
diffraction along with the DL/EE and drug release rate by UV spectroscopy using the 
methods previously discussed.  
6.6 Results and Discussion 
 6.6.1 Emulsion method  
The w-o emulsion method for production of the PIP system was investigated where the drug 
delivery particles were encapsulated into kappa carrageenan embolizing particles and the 
effect of mixing speed and drug particle loading was investigated.    
6.6.1.1 Particle production  
The embolic particles were produced by the w-o emulsion method where the effect of mixing 
speed on particle size was investigated by light microscopy and laser diffraction (Figure 6.5 
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and 6.6 and Table 6.4).  By increasing the mixing speed, decreasing particle sizes of 1294, 
736 and 378 µm for speeds of 400, 600 and 800 rpm were resulted as a consequence of the 
increase in shear.  Particles are formed by a sol-gel formation as the carrageenan undergoes 
cooling by formation of double helical junction zones.  The temperature of the oil phase was 
an important factor since if too low, the polymer gels instantly preventing droplet breakdown 
and resulting in large beads like those produced in the ionotropic gelation method.  When the 
oil is too hot, the polymer is broken down into droplets smaller than 50 µm in diameter even 
at the slowest mixing speed, which would not allow particles to be produced in the size range 
suitable for TACE.  By heating the oil to 40 °C and rapidly adding the polymer/particle 
dispersion at 90 °C, the exterior of the particles cool rapidly where a specific particle size 
range can be obtained by adjustment of the mixing speed.  The produced microparticles 
displayed relatively large size distributions however, this could be overcome by passing 
through a particle sieve to obtain a desired size. This system also did not use a surfactant in 
the continuous phase since its addition results in formation of droplets too small for the 
desired TACE size range in this work.  Since the polymer droplets harden within seconds of 
being added to the oil, aggregation of the particles in the emulsion was not an issue.   
 
A 500 µm 
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Figure 6.5 – Light microscope images of the 3 % carrageenan microspheres produced at (A) 400, (B) 600 and 
(C) 800 rpm illustrating the effect of mixing speed on particle size. 
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Figure 6.6 – Particle size distribution of the carrageenan particles produced at 400, 600 and 800 rpm illustrating 
the effect of mixing speed on particle size distribution.  
 D10 (µm) D50 (µm) D90 (µm) 
400 rpm 951  1294  1642  
St Dev 105 125 189 
RSD (%) 11.0 9.7 11.5 
600 rpm 488  736  1062  
St Dev 66 80 96 
RSD (%) 13.5 10.9 9.0 
800 rpm 181  378  602  
St Dev 22 50.0 54 
RSD (%) 12.1 13.2 8.9 
Table 6.4 – Particle size data of the carrageenan particles produced at 400, 600 and 800 rpm showing the effect 
of mixing speed on the D10, D50 and D90 particle sizes.  Each value is the mean average of three independent 
studies ± SD. 
6.6.1.2 Drug loading and encapsulation efficiency  
 
The loading of the drug delivery particles into the carrageenan spheres was investigated by 
light microscopy (Figures 6.7 and 6.8) and the DL and EE of the PIP system was determined 
by UV spectroscopy (Tables 6.5 and 6.6).  From the light microscope images, it was seen that 
the drug delivery particles were uniformly distributed within the embolic carrageenan 
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particles.  They did however appear to be encapsulated in a clustered fashion which was due 
to the initial clustered morphology of the drug delivery particles caused during their 
production.  Carrageenan made an attractive choice as the embolic agent since the drug 
delivery particles can be effectively encapsulated uniformly throughout the spheres due to the 
fast gelation process.  Also since the particles are transparent, the uniformity of the 
encapsulated particles is easily viewed under a standard light microscope.     
 
 
A 
B 500 µm 
500 µm 
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Figure 6.7 – Light microscope images of the carrageenan PIP system produced at (A) 400, (B) 600 and (C) 
800 rpm.  All embolic particles were loaded with 2% w/v drug delivery particles. 
 
Figure 6.8 – The embolic carrageenan particles produced at 800 rpm under a higher magnification. 
 
An important feature of the PIPs for TACE is for the particles of each size to have identical 
drug loadings, allowing the same dose of drug to be administrated to patients with various 
blood vessel widths.  For the Drug delivery particle loadings of 2 %, similar DLs of 3.2 % 
C 500 µm 
300 µm 
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<p 0.88>, 3.3 % <p 0.74> and 2.7 % <p 0.60> were obtained for PIPs produced at 400, 60 
and 800 rpm respectively.  Likewise for 5 % drug delivery particle loadings, similar DLs of 
5.4 % <p 0.75>, 5.1 % <p 0.73> and 4.8 % <p 0.70> were determined for mixing speeds of 
400, 600 and 800 rpm respectively.  Since the production method is quick with a rapid 
gelation process, this allows the drug loss to be kept to a minimum where particles produced 
at 800 rpm has a slightly lower DL due to the faster mixing speed, and possible higher masses 
of drug loss during the washing process. 
The EE value is less significant in producing a suitable system for TACE however the EE 
saw a slight decreases with increasing mixing speeds.  EEs for 2 % drug delivery particles 
were 77.7 %, 77.7 % and 67.1 % where the 5 % drug delivery particles gave EEs of 82.3 %, 
78.2 % and 72.1 %.  This general decrease was believed to be due to the increased in shear 
created with higher mixing speeds resulting in small masses of particles being lost to the 
continuous phase of the emulsion before the gelation of carrageenan occurs.  Also, the o-w 
emulsion is known to generally suffer the disadvantage of requiring multiple washing stages 
to ensure all surface oil is removed which can result in a higher drug loss.   
 400 rpm 600 rpm 800 rpm 
DL (%) 3.2  3.3 2.7  
St Dev 0.7 0.5 0.7 
RSD (%) 21.9 15.6 33.3 
EE (%) 77.7  77.7  67.1  
St Dev 18.5 12.9 17.6 
RSD (%) 24.1 16.6 26.2 
Table 6.5 – Drug loading and encapsulation efficiency of the PIP system produced at 400, 600 and 800 rpm.  
2 % w/v of the drug delivery particles was loaded.  Each value shows the mean average of three independent 
studies ± SD. 
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 400 rpm 600 rpm 800 rpm 
DL (%) 5.4  5.1 4.8  
St Dev 1.0 0.8 0.7 
RSD (%) 18.5 15.7 14.6 
EE (%) 82.3  78.2  73.1  
St Dev 15.1 12.8 11.7 
RSD (%) 18.3 16.4 16.0 
 
Table 6.6 – Drug loading and encapsulation efficiency of the PIP system produced at 400, 600 and 800 rpm.  
5% particle loadings were used.  Each value shows the mean average of three independent studies ± SD. 
6.6.1.3 Drug release from PIP system 
 
The PIP systems were subject to in-vitro release in PBS where the effects of particle size and 
particle loading were investigated (Figures 6.10 and 6.11).  By increasing the particle 
loading, a higher mass of drug was released due to the higher initial loading of drug particles 
into the embolizing spheres.  A fundamental property of the PIPs is for the effect of particle 
size to be decoupled from the drug release rate, allowing PIPs of different sizes to display the 
same release pattern.  No real significant changes in drug release were observed in particles 
produced at mixing speeds of 400, 600 and 800 rpm, indicating that PIP size had no 
significant effect on the drug release pattern, allowing the effect to be decoupled.  PIPs 
loaded with 2 % particles saw release of 64 % <p 0.43>, 73 % <0.61> and 72 % <p 0.62> of 
the drug within the first two hours, then 95 % <p 0.89>, 92 % <p 0.85> and 96 % <p 0.82> 
after 4 hours for mixing speeds of 400, 600 and 800 respectively. Also, PIPs loaded with 5 % 
particles saw release of 45 % <p 0.45>, 59 % <p 0.63> and 62 % <p 0.53>  in the first two 
hours followed by release of 85 % <p 0.52 >, 94 % <p 0.62 > and 96 % <p 0.65> after 4 
hours for mixing speeds of 400, 600 and 800 rpm respectively showing similar release 
patterns for the various sized PIPs.    
Carrageenan was chosen since it is a thermoresponsive polymer that forms strong gels even 
without addition of potassium ions to reinforce the double helical junction zones formed 
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during the crosslinking, which can potentially allow the particles to be more permeable than 
chemically crosslinked gels.  Also, since the large beads investigated in the initial material 
screening experiments in chapter 3 released the encapsulated drugs instantly, it was 
hypothesized that they would make ideal embolizing materials since their porous 
microstructures could have the potential to allow the production of PIPs that allow the effect 
of particle size on drug release rate to be decupled.  However, despite the similar release rates 
being achieved, the release profile was fairly short and the PIPs may not display similar 
release profiles for drugs that have a release period of 1-2 weeks.  It would therefore be 
worthwhile investigating if similar results can be obtained from PIPs containing a 
hydrophobic drug, since their poor water solubility can potentially allow a 1 – 2 week release 
period to be achieved.  
 
 
Figure 6.9 –Percentage drug release profiles of the PIP system produced at 400, 600 and 800 rpm.  A 2 % drug 
delivery particle loading was used.  Each data point shows the mean average of three independent studies ± SD.  
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Figure 6.10 – Percentage drug release profiles of the PIP system produced at 400, 600 and 800 rpm.  A 5% drug 
delivery particle loading was used.  Each data point shows the mean average of three independent studies ± SD.  
6.6.2 Production of the embolic particles by a nozzle vibration method 
 
A second method for producing the embolizing particles was also investigated based on the 
principle of nozzle vibrating.  This method allows particles with a uniform size to be 
produced by applying a superimposed vibration to a flowing polymer jet, and passing through 
a nozzle of a desired size.  An electrostatic charge is then applied, causing the droplets to 
repel where they are then collected in a hardening bath.   
6.6.2.1 Effect of vibration frequency on microsphere production 
 
The effect of vibration frequency on the microspheres was investigated by light microscopy 
and particle sizing (Figures 6.12 and 6.13 and Table 6.7).  By increasing the vibration 
frequency, smaller particles were obtained where average sizes of 576, 496 and 435 µm were 
determined for vibration frequencies of 1000, 1500 and 2000 Hz respectively.  By increasing 
the frequency, a higher vibration is applied to the flowing polymer jet, breaking it down in to 
more droplets resulting in a decrease in the particle size and also allows more droplets to be 
produced per second.  With the increasing nozzle sizes, lower vibration frequencies were 
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chosen.  Lower frequencies are required to allow optimum droplet formation for spheres 
produced with larger nozzles where Weber added effects of nozzle diameter into his 
equations for optimum droplet formation since less agitation is required to form the larger 
droplets (Equation 6.2).     
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Figure 6.11 – Light microscope images of the alginate microspheres illustrating the effect of vibrating 
frequency on particle form.  The investigated frequencies were (A) 1000, (B) 1500 and (C) 2000 Hz.  The 
operating flow rate, electrode strength and nozzle size were 10 mL/min, 1500 V and 300 µm respectively.  
 
Figure 6.12 – Particle size distribution of the alginate microspheres illustrating the effect of the vibrating 
frequency on the size distribution. The investigated frequencies were 1000, 1500 and 2000 Hz.  The flow rate, 
electrode strength and nozzle size were 10 mL/min, 1500 V and 300 µm respectively.   
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 D10 (µm) D50 (µm)  D90 (µm) 
1000 Hz 373  576  834  
ST Dev 25.2 33.5 38.4 
RSD (%) 6.8 5.8 4.6 
1500 Hz 303 496  684  
St Dev 12.4 22,9 33.1 
RSD (%) 4.1 4.6 4.8 
2000 Hz  285  435  643  
St Dev 13.4 20.5 34.7 
RSD (%) 4.7 4.7 5.4 
Table 6.7 – Particle size data for the alginate particles produced at vibrating frequencies of 1000, 1500 and 
2000 Hz showing its effect on the D10, D50 and D90 particle sizes.  Each value is the average of three independent 
studies ± SD. 
6.6.2.2 Effect of electrode voltage on particle production 
  
The effect of the electrode voltage was investigated by light microscopy and laser sizing 
(Figures 6.14 and 6.15 and Table 6.8).  By increasing the voltage applied to the electrode, the 
particle size decreases and the size distribution narrows where particle sizes of 776.8, 506 and 
436 µm were determined from voltages of 1000, 1500 and 2000 V respectively.   
The application of the electrode on the nozzle vibrating device applies a charge to the surface 
of the droplets to prevent droplets aggregating allowing beads with high degrees of sphericity 
and narrow size distributions to be produced.  By increasing the voltage applied to the 
electrode, higher charges are applied to the surface of the droplets allowing them to be 
repelled a greater distance.  This increase in the distance between droplets prevents 
aggregation, resulting in a decrease in particle size where the population has a narrower size 
range.  Higher voltages are required for particles produced with larger nozzles due to the 
increased weight of the droplet and act of gravitational forces so that the droplet stream can 
be effectively repelled and avoiding aggregation upon crosslinking.   
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Figure 6.13 – Light microscope images of the microspheres illustrating the effect of electrode voltage on 
particle form.  The investigated voltages were (A) 1000, (B) 1500 and (C) 2000 V.  The vibrating frequency, 
flow rate and particle size were 1500 Hz, 10 mL/min and 300 µm respectively. 
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Figure 6.14 – Particle size distribution of the microspheres illustrating the effect of electrode voltage on the size 
distribution.  The investigated voltages were 1000, 1500 and 2000 V.  The vibrating frequency, flow rate and 
particle size were 1500 Hz, 10 mL/min and 300 µm respectively. 
 D10 (µm) D50 (µm)  D90 (µm) 
1000 V 387  776  1398  
St Dev 18.4 39.5 78.9 
RSD (%) 4.8 5.1 5.6 
1500 V 302  506  815  
St Dev 13.9 27.3 40.8 
RSD (%) 4.6 5.4 5.0 
2000 V 285  435  643  
St Dev 16.1 23.5 34.8 
RSD (%) 5.6 5.4 5.4 
Table 6.8 – Particle size data for the microspheres produced at electrode voltages of 1000, 1500 and 2000 V 
showing their effects on the D10, D50 and D90 particle sizes.  Each value is the average of three independent 
studies ± SD. 
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6.6.2.3 Effect of nozzle size on particle production 
The effect of the nozzle size on particle formation was investigated by light microscopy and 
laser diffraction (Figures 6.16 and 6.17 and Table 6.9).  By increasing the nozzle size the 
particle size also increased where average sizes of 251, 496 and 836 µm were determined for 
nozzles of 150, 300 and 450 µm respectively.  As expected the size of the particles increases 
due to the increased nozzle diameter.  The diameters of the particles produced with a 
particular nozzle size are approximately twice that of the nozzle where the size can vary 
depending on the alginate flow rate, vibration frequency and electrode strength used during 
production allowing microspheres on a wide size scale to be produced.   
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Figure 6.15 – Light microscope images of the microspheres showing the effect of nozzle size on particle size.  
The investigated nozzle sizes were (A) 150, (B) 300 and (B) 450 µm.  The electrode voltage, vibrating 
frequency and flow rate were 1500 V, 1500 Hz and 10mL/min respectively. 
 
Figure 6.16 – Particle distribution of the microspheres showing the effect of nozzle size on the particle size 
distribution.  The investigated nozzle sizes were 150, 300 and 450 µm.  The electrode voltage, vibrating 
frequency and flow rate were 1500 V, 1500 Hz and 10 mL/min respectively. 
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 D10 (µm) D50 (µm)  D90 (µm) 
150 µm 133  251  417  
St Dev 6.3 10.4 19.3 
RSD (%) 4.7 4.1 4.6 
300 µm 303  496  648  
St Dev 17.8 23.5 33.2 
RSD (%) 5.9 4.7 5.1 
450 µm 521  836  1339  
St Dev 53.9 44.4 88.6 
RSD (%) 10.3 5.3 6.6 
Table 6.9 – Particle size data for the alginate particles produced with the various nozzle sizes showing their 
effect on the D10, D50 and D90 particle sizes.  Each value is the mean average of three independent studies ± SD. 
6.6.2.4 Drug loading and encapsulation  
 
Loading of the drug delivery particles into the microspheres was investigated however, due to 
their clustered and aggregated morphology, their encapsulation was not possible, even with 
the largest nozzle with a 1 mm diameter.  For successful encapsulation by nozzle vibrating, it 
is believed particles of a smaller size preferably, on the nanoscale, or a semisold system such 
as a liposomal based system would be required in order for the dispersion to flow freely 
though the nozzles.  However, in order to make use of this process for a potential drug 
delivery system, the alginate-sodium silicate mixture was formed into a microparticle system.  
The effects of alginate concentration, sodium silicate concentration and nozzle size on DL 
and EE were investigated where 1 % verapamil hydrochloride was loaded into all 
formulations (Tables 6.10 – 6.12).   
A decrease in DL of 14.2 %, 11.5 % and 9.3 % and increase in EE of 42.8 %, 57.5 % and 
71 % was determined by increasing the alginate concentration from 1 – 3 % w/v due increase 
in material mass previously discussed.  Similar effects on increasing sodium silicate 
concentration on the DL and EE were seen as to those reported in the previous chapters.  The 
effect of nozzle size saw an increase for both DL and EE on increasing nozzle diameter, 
where DL of 8.3 %, 10.1 % and 13.6 % and EE of 41.8 %, 50.6 % and 67.1 % were 
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determined for nozzles of 150, 300 and 450 µm respectively.   This was due to the effect of 
particle size on drug diffusion/loss during the crosslinking period.  Due to their higher surface 
area, smaller particles will tend to lose higher masses of drug during production resulting in 
lower loadings and encapsulation rates.   
 1 % Alginate 2 % Alginate 3 % Alginate 
DL (%) 14.2  11.5  9.3  
St Dev 0.5 0.2 0.2 
RSD (%) 3.5 1.7 2.2 
EE (%) 42.8  57.5  71  
St Dev 1.4 1.3 1.8 
RSD (%) 3.3 2.3 2.5 
Table 6.10 – The DL and EE of the alginate-sodium silicate microspheres showing the effect of alginate 
concentration on DL and EE.  The sodium silicate and nozzle size were 3 % and 300 µm respectively.  Each 
value is the mean average of three independent studies ± SD 
 1 % Silicate  2 % Silicate 3 % Silicate 
DL (%) 13.3  11.8  10.5  
St Dev 0.8 0.6 1.2 
RSD (%) 6.0 5.1 1.1 
EE (%) 40  47.3  52.6  
St Dev 2.5 2.6 3.7 
RSD (%) 6.3 5.5 7.0 
Table 6.11 – The DL and EE of the alginate-sodium silicate microspheres showing the effect of silicate 
concentration on DL and EE.  The alginate concentration and nozzle size were 2 % and 300 µm respectively.  
Each value is the mean average of three independent studies ± SD 
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 150 µm 300 µm 450 µm 
DL (%) 8.3  10.1  13.6  
St Dev 0.4 0.4 1.4 
RSD (%) 4.8 3.9 10.3 
EE (%) 41.8  50.6  67.1  
St Dev 1.4 1.6 5.2 
RSD (%) 3.3 3.2 7.7 
Table 6.12 – The DL and EE of the alginate-sodium silicate microspheres showing the effect of nozzle size on 
DL and EE.  The alginate concentration and sodium silicate concentration were 2 % and 3 % respectively.   
Each value is the mean average of three independent studies ± SD 
6.6.2.5 Drug release  
The microspheres were subject to in-vitro release in PBS.  The effects of alginate 
concentration, sodium silicate concentration and particle size on drug release rate were 
investigated (Figures 6.18 – 6.20).  By increasing the alginate concentration, the release rate 
of the beads decreased.  The initial burst in the first 2 hours saw a release of 80 % <p 0.06>, 
40 % <p 0.04> and 35 % <p 0.02> of the drug in alginate concentrations of 1 %, 2 % and 3 % 
respectively, followed by a steady release rate over the rest of the study.  The effect of 
sodium silicate concentration once again had a large effect on the drug release rate.  
Concentrations of 1 % resulted with a rapid release rate with the majority of the drug being 
fully released in the first 2 hours while the 3 % sodium silicate released approximately 45 % 
<p 0.03> of the drug in the first two hours followed by a steady release rate over the rest of 
the study.   
Increasing nozzle size, as expected increased the particle size.  This study also shows how 
particles of varying diameters can display various release rates.  Particles produced with the 
150 µm nozzle released 85 % of the drug within the first 5 hours of the study.  The 300, and 
450 µm nozzles produced larger particles which has a significant effect on the drug release 
rate, where only 55 % <p 0.03> and 15 % <p 0.02> of the drug was released within the first 5 
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hours.   Smaller particles are liable to faster release rates than larger particles due to their 
higher surface areas and lower distance for water molecules to penetrate in and drug 
molecules to diffuse out of the microparticle.  Although the particles produced with the 
microencapsulator do not meet the aim of this project by decoupling particle size on drug 
release rate, it did however provide a good alternate to producing spherical embolization 
spheres that can encapsulate a range of drugs, making it an attractive application for TACE.    
 
Figure 6.17 – Percentage drug release of the microspheres illustrating the effect of alginate concentration on 
drug release rate.  Each point is the mean average of three independent studies ± SD. 
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Figure 6.18 – Percentage drug release of the microspheres illustrating the effect of sodium silicate concentration 
on drug release rate.  Each point is the mean average of three independent studies ± SD.  
 
Figure 6.19 – Percentage drug release of the microspheres illustrating the effect of nozzle size on drug release 
rate.  Each point is the mean average of three independent studies ± SD. 
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6.6.2.6 Microcapsule formation    
 
The microencapsulation unit also allowed production of microcapsules, where oils could be 
encapsulated within an alginate shell.  Formation of alginate capsules containing mineral oil 
where the effect of the alginate and mineral oil flow rate on capsule formation was 
investigated by light microscopy (Figures 6.21 and 6.22).  The effect of shell nozzle size was 
also investigated by light microscopy and laser diffraction (Figures 6.23 and 6.24 and Table 
6.13).    
By increasing the oil flow rate from 5, 10 and 20 mL/min the morphology of the oil cores 
drastically changed.  An optimum flow rate of 10 mL/min yielded spherical cores 
encapsulated inside the alginate shells.  The flow rate of 5 mL/min was not sufficient enough 
to pump the oil though in a continuous motion resulting in the oil trickling throughout the 
alginate solution where alginate shells containing multiple cores were produced.  On the other 
hand, the flow rate of 20 mL/min gave flow rates that were too rapid for the alginate to 
effectively encapsulate to oil flow where large multiple cores were encapsulated within 
disordered alginate shells.   
 
A 500 µm 
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Figure 6.20 - Light microscope images of the microcapsules produced showing the effect of the oil flow rate on 
particle formation.  Oil flow rates of (A) 5, (B) 10 and (C) 20 mL/min were investigated.  The shell flow rate, 
vibrating frequency, electrode voltage, shell nozzle and core nozzle were 175 mbar, 800 Hz, 2500 V, 400 µm 
and 200 µm respectively.  
The alginate flow rate, controlled by a pressure bottle, was investigated where pressures of 
150, 175 and 200 mbar gave various results.  The operating pressure of 175 mbar gave an 
optimum production process where spherical alginate shells with a single oil core were 
obtained.  A pressure of 150 mbar gave an ineffective alginate flow rate to encapsulate the oil 
where disordered formations were produced with some empty shells due to the high oil flow 
rate causing the alginate droplets to rupture.  The flow rate of 200 mbar was too rapid for 
capsule formation since large aggregated alginate forms with multiple oil cores were 
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produced.  Also the higher flow rate prevented the droplet spray from being produced 
yielding aggregated products.     
Along with the correct vibration and electrode conditions, the oil and water flow rates must 
be carefully controlled so that the oil can be effectively encapsulated, with single spherical 
cores held inside spherical shells.  A general principle, according to the manufacturer is the 
core flow rate should be approximately 20 % of the shell flow rate.    
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Figure 6.21 - Light microscope images of the microcapsules showing the effect of the shell pressure on particle 
formation.  Pressures of (A) 150, (B) 175 and (C) 200 mbar were investigated.  The oil flow rate, vibrating 
frequency, electrode voltage, shell nozzle and core nozzle were 10 mL/min, 800 Hz, 2500 V, 400 µm and 
200 µm respectively.  
Microcapsules produced with shell nozzles of 300, 200 and 500 µm were produced where all 
shell nozzles were fitted with a core nozzle of 200 µm under the optimum operating 
conditions for the selected shell nozzle size.  With increasing shell size, the capsule size 
increased as expected, where the oil cores saw a slight variation in their size distribution.  The 
microcapsules made an interesting choice for the embolizing device since if the drug loaded 
particles could be encapsulated into the oil cores, this could potentially allow minimal loss of 
drug during storage and possibly extend the drug release rate of the hydrophilic compound 
due to the drugs poor solubility in lipophilic media.  However, since the drug delivery 
particles could not be encapsulated by this method this investigation was not possible to 
pursue.   
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Figure 6.22 - Light microscope images of the microcapsules showing the effect of shell nozzle size on particle 
formation.  Nozzles of (A) 300, (B) 400 and (C) 500 µm were investigated.  The shell flow rate, core flow rate, 
vibrating frequency and electrode voltage and core nozzle were 175 mbar, 10 mL/min, 800 Hz, 2500 V and 
200 µm respectively.  
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Figure 6.23 – Particle size distribution of the microcapsules produced showing the effect of shell nozzle size on 
the size distribution.  Nozzles of 300, 400 and 500 µm were investigated.  The shell flow rate, core flow rate, 
vibrating frequency and electrode voltage and core nozzle were 175 mbar, 10 mL/min, 800 Hz, 2500 V and 200 
µm respectively.  
 D10 (µm) D50 (µm)  D90 (µm) 
300 µm 438  682  1155  
St Dev 50.2 62.5 130 
RSD (%) 11.5 9.2 11.3 
400 µm 589  876  1352  
St Dev 67.3 97.3 173.0 
RSD (%) 11.4 11.1 12.9 
500 µm 710  1005  1431  
St Dev 59.7 115.0 115.1 
RSD (%) 8.4 11.4 8.4 
 
Table 6.13 – Particle size data for the microcapsules produced at the various nozzle sizes showing their effects 
on the D10, D50 and D90 particle sizes.  Each value is the mean average of three independent studies ± SD.    
 
 
0 500 1000 1500 2000 2500 
0 
5 
10 
15 
20 
25 
Particle size (µm) 
V
o
lu
m
e
 (
%
) 
300 micron 
400 micron 
500 micron 
168 
 
6.7 Conclusion 
 
This section investigated production of the embolic particles and incorporation of the drug 
delivery particles producing the PIP system for TACE.  PIP systems by the w-o emulsion 
gave particles of a broad size range within the TACE range, where the drug delivery particles 
were successfully encapsulated uniformly thought out the spheres.  Also, the PIP system 
produced allowed the aim of decoupling the effect of particle size on release rate to be 
achieved due to the high porosity of the carrageenan spheres.  However, due to the short 
release period and un-even drug loadings caused by the clustery drug delivery particles, 
further investigation is required to drawn stronger conclusions.   
A new microencapsulation device yet to be explored within the literature was also explored 
for embolic particle production.  Critical process parameters of vibrating frequency, electrode 
strength and nozzle size were investigated where particle formation was seen to be dependent 
on selection of an adequate electrode voltage to effectively repel the spray so that droplets 
avoided aggregation upon crosslinking.  Particle size could be controlled by choice of the 
desired nozzle and adjustment of the vibrating frequency.  Microcapsules were also formed 
where formation of capsules containing single oil cores in spherical spheres were dependent 
on selection of appropriate processing parameters.  Despite being an ideal method for 
embolic sphere production, the drug delivery particles could not be encapsulated due to their 
clustery morphology.  The method was however investigated to produce microspheres for the 
alginate-sodium silicate complex.  By variation of the alginate, silicate and nozzle size 
parameters, release rates from instant release to over 48 hours were achieved.   This method 
allowed production of particles under mild operating conditions where a range of 
microparticle sizes displaying controlled release could be produced.  Combining this new 
method with the alginate-sodium silicate blend studied though out this thesis, this single 
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technique allows great possibility not only for TACE but also other controlled drug delivery 
applications.  
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CHAPTER 7 
CONCLUDING REMARKS AND FUTURE WORK 
 
This thesis investigated the development of a new drug delivery system for the treatment of 
intermediate staged HCC.  A frequently used treatment for this condition is TACE, a non-
surgical method where DEBs have proven to show increased survival and improve patient 
well-being for those suffering with this non-curable disease.  Of the current DEBs, the DC 
Bead has been a popular choice due to its ability to load and control the release of 
doxorubicin, where the particles show smooth hydrophilic surfaces with spherical geometries 
that can be calibrated to a particular blood vessel size.  Despite their advantages, DEBs are 
limited to drugs that can bind to their functional groups, where in the DC bead, doxorubicin is 
held tightly by sulfonate groups.  Also, since the particles are to be calibrated to a specific 
blood vessel size, patients with small blood vessels will require smaller particles to those with 
larger blood vessels.  This variation will result in varying release rates where smaller particles 
will release their contents faster due to their increased surface area where some patients can 
potentially be exposed to peaks in the drugs toxicity.      
The drug delivery system designed in this thesis seeked to overcome these issues by use of a 
PIP system.  Small drug delivery particles were designed to load and release a desired drug, 
where they would then be encapsulated into larger particles to act as an embolization device.  
By using this PIP system, a drug delivery system that is more versatile to a wider range of 
drugs can be produced.  Also, the effect of particle size on drug release rate can then be 
decoupled by encapsulating the particles into larger embolizing particles that possess porous 
microstructures, allowing the release characteristics of the drug delivery particles to be 
retained.   
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The initial experiments investigated various polymer based materials and their capability to 
control the release of small molecular weight hydrophilic drugs, where verapamil 
hydrochloride was used as a model compound, since it displayed similar chemistry to 
doxorubicin. Polymers that displayed negative charges allowing interaction with the positive 
charge of the drug were of interest.  Carboxylated polymers such as alginate, pectin and 
gellan showed effective DL and EE however, were ineffective as controlled release materials.  
By introducing stronger polymer-drug interactions by use of the sulfonated polymer 
carrageenan, higher DL and EE were achieved however, the gels still resulted in an instant 
release of the drug.  A system composed of alginate and sodium silicate, a water soluble 
inorganic compound, allowed strong gels to be produced by the silica’s interaction with the 
alginate crosslinking mechanism.  This allowed strong gels where the silica reduced the 
degradation and porosity of the gel beads, enabling the release rate of the drug to be 
controlled.  By varying the concentration of silica incorporated into the gel beads, release 
rates from hours to several weeks could be produced, making this blend of materials an 
attractive choice for encapsulation of water soluble drugs.      
The alginate-sodium silicate blend was developed into a microparticulate drug delivery 
system where two methods were investigated, the w-o emulsion and spray drying.  In the w-o 
emulsion method, effects of polymer concentration, mixing speed, surfactant concentration 
and alginate: sodium silicate on particle size and formation were investigated by microscopy 
and particle sizing.  By increasing the polymer concentration, the particle size increased due 
to the increase in polymer viscosity.  Also, with increasing surfactant concentration and 
mixing speed, both of these parameters saw the particle size decreased due to the decreased 
surface tension and increased shear respectively.  Also, by increasing the crosslinking 
concentration, higher calcium ion concentrations were available to crosslink the polymer 
chains, enabling fine particulate powders which spherical geometries to be produced.  Despite 
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fine particles being produced, no drug loaded particles could be produced due to the 
migration of drug into the oil phase during the manufacturing process.     
The spray drying method was investigated due its ability to produce particles with high DL 
and EE.  Processing parameters of polymer concentration, inlet temperature, polymer flow 
rate and alginate: silicate and their effects on particle formation were once again investigated.  
Along with these, effects of alginate concentration, drug concentration and alginate: silicate 
on DL/EE and drug release rate of the particles was also investigated.  With increasing 
alginate concentration and flow rate, the particle size increased due to increasing in viscosity 
and flow rate making atomization less efficient.  Varying the inlet temperature had no effect 
on the size of the particles however particles produced at low temperatures resulting in 
aggregated products due to inefficient drying.  Particles produced by this method required 
crosslinking post-production where the particles took on aggregated formations due to their 
high surface areas which increased when the ratio of silicate: alginate increased.  As for the 
DL/EE and drug release, all formulations gave controlled release over a 4 hour period where 
little effect of varying the process parameters was seen due to the particles small size and 
high surface area.  Despite this, the particles produced did offer an attractive improvement 
over pure alginate particles that suffer limited loaded and instant release rates.     
Once an optimum drug loaded microparticulate system was obtained, production of the PIP 
system was explored.  Initially, methods for production of large particles in the TACE size 
range was investigated were the w-o emulsion and nozzle vibrating methods were chosen.  In 
the w-o emulsion, embolizing spheres were produced from kappa carrageenan were effects of 
the mixing speed on particle size were investigated where increased mixing speed resulting in 
smaller particles.  Also, the temperature of the oil was an important factor in order to obtain 
particles of a desired size specific to TACE.  These particles displayed spherical geometries 
however suffered from wide size distributions which could be overcome by sieving for a 
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desired particle size. Various concentrations of drug loaded particles were loaded into the 
embolic spheres where they were uniformly distributed with high loadings and entrapment 
efficiencies.  The spheres also displayed similar release rates to that of the drug delivery 
particles indicating that the effect of particle size on release rate was decoupled due to the 
porous nature of the carrageenan spheres.  Despite this conclusion, further investigation 
would be required since the release period was rather short and the clustery nature of the drug 
delivery particles resulting in larger standard deviations.    
The nozzle vibration method was also investigated to produce the embolizing spheres since it 
is a method that is yet to be explored in the literature and also allows ideal embolizing 
particles to be produced under mild processing conditions.  Effects of nozzle size, vibrating 
frequency and electrode voltage on particle formation were investigated.  By increasing the 
vibration frequency and electrode voltage particle size decreased due to the polymer being 
broken down into smaller droplets and decreased aggregation of the gelling polymer droplets.  
By increasing nozzle size, the particle size as expected increases.  As well as producing 
spheres, the encapsulation unit also allowed capsules to be produced where mineral oil was 
entrapped within alginate shells.  Effects of polymer and oil flow rates along with shell 
nozzle size were investigated.  The alginate and oil flow rates had to be carefully controlled 
to allow spherical capsules with a single oil core to be produced.  When flow rates were to 
high/low, aggregated capsules with multiple/no cores were the result.  Due to the clustery 
nature of the drug delivery particles, they could not be encapsulated into the spheres or 
capsules.  Therefore, to make use of this method for a drug delivery application, the alginate-
silicate blend was processed into microspheres.  Effects of polymer concentration, alginate: 
silicate ration and nozzle size on DL/EE and drug release were investigated upon increasing 
each parameter, various loadings and release rates up to 48 hours were obtained.   
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Despite the range of concepts covered in this thesis, there are still many other questions to be 
answered and areas to left to investigate.  Firstly, this system still falls short of the drug 
release rates when compared to the DC bead where delivery times up to 2 weeks can be 
achieved.  By incorporation of polymers containing sulfonate groups (the functional group 
used in the DC bead) or perhaps sulfonating a hydroxyl/carbonyl group into the alginate 
backbone, this could possibly allow longer release rates of the verapamil hydrochloride in the 
alginate-sodium silicate blend to be achieved. Investigation into alginate with higher G 
content to increase the gel strength could result in improved controlled release from the large 
hydrogel beads and the particles produced with the microencapsulator.  However this 
increase in gel strength from higher G content alginate may not be sufficient enough to 
significantly increase the release from the small drug delivery particles due to their high 
surface area.   
Release of doxorubicin hydrochloride would also have to be investigated.  The drug has a 
higher molecular weight and lower water solubility than verapamil hydrochloride where these 
chemical properties could result in slower release rates than verapamil in this thesis.   
The in-vitro drug release method used also needs to be addressed.  In this thesis the PIPs were 
simply mixed in a solution of PBS which is different to the conditions the PIPs will be 
exposed too once they have embolized the tumour.  Blood will flow with a pulsating rate 
which has a higher viscosity than a PBS solution.  Preforming the in-vitro release in 
conditions that simulate the PIPS blocking the blood vessels surrounding the tumour would 
allow more accurate drug delivery profiles to be obtained, perhaps by injecting the PIPs into 
silica tubing and constantly pumping a volume of media with the viscosity increased with a 
polymer.   
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Also investigation into other materials that could potentially prolong release rate would make 
an interesting study.  It would be worth researching materials that can interact with the amine 
groups in chitosan, a positively charged polymer, allowing encapsulation and controlled 
release of negatively charged small molecular weight hydrophilic drugs.   
Further work could have been performed to improve the morphology of the spray dried 
alginate-sodium silicate microparticles which were aggregated to a high degree, making their 
encapsulation in the microencapsulator not possible.  This was believed to be due to their 
high surface area and cohesive forces causing them to aggregate and cluster in the 
crosslinking process.  Assessment of their stability by assessment of their zeta potential could 
allow this issue to be addressed with stronger conclusions.  Microparticle systems with low 
zeta potentials (between -30 and +30) do not have ions that allow the particles to repel and 
stay uniformly distributed resulting in aggregated particulate systems.  When these unstable 
aggregated systems are crosslinked post production, the particles can bind with adjacent 
particles giving the highly aggregated crosslinked product opposed to a more favoured 
uniformly distributed population of particles.  The pH of the crosslinking solution can also be 
having a strong influence on the particle formation where the pH of the calcium chloride 
solution could be decreasing the stability of the particulate dispersion even further.  If the 
drug delivery particles were in an unstable range, addition of agents to adjust the charge of 
the particle could be explored.  A method that has frequently been explored to adjust the 
charge in the bilayers in liposome drug delivery systems which could adjust the charge of the 
particles to produce a more stable system.   
The ionic gelation method may also allow production of a more uniformly dispersed 
particulate system produced from the alginate-sodium silicate blend which could be 
reinforced with chitosan, however since dilute concentrations of polymers are needed, this 
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system may be incapable of controlled release, however may be an attractive method for 
obtaining high drug loadings.   
Also, since the system is designed to be more versatile to a wider variety of drugs, other 
active agents such as negatively charged/no charge, hydrophobic, large molecular weight and 
multiple drug molecules would need to be addressed.  For these other classes of drugs, it is 
more than likely that investigation into other materials/material blends that allow controlled 
release would be necessary as the alginate-silicate blend may not work as well with these 
other classes.  Liposomes may make attractive delivery systems for multiple rugs since both 
hydrophilic and hydrophobic can be encapsulated in the lipid core and lipid bilayers 
respectively, however they tend to have issues in stability and can be inefficient for high drug 
loading and controlled release of hydrophilic molecules.   
Finally, once produced, the PIPs would require a serialization procedure since it is to be 
delivered by the parental route.  Therefore sterilization methods such as treatment in alcohol 
or radiation and their effects on the drug delivery vehicle and drug molecule insuring its 
activity is not altered is of great significance.  However the spray drying method and 
microencapsulation units used in this work allows sterile production therefore can potentially 
allow for this step to be avoided.   
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